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ABSTRACT 
Since its discovery in the 1980’s, HIV has affected the lives of millions of individuals around the 
globe. Despite obvious need and an enormous amount of research a cure has remained elusive 
due to the rapid onset of mutated forms of the virus. However, there has been considerable 
success in reducing viral levels of infected individuals through the use of highly active 
antiretroviral therapy (HAART). The first-line regimen HAART mainly targets reverse 
transcriptase (RT) through the employment of two nucleoside RT inhibitors (NRTIs) and a non-
nucleoside RT inhibitor (NNRTI). NNRTIs target an allosteric pocket situated about 10 Å from 
the catalytic site and cause a conformational change in the enzyme upon binding, leading to the 
inhibition of viral replication. There are currently 5 FDA approved NNRTIs on the market which 
successfully inhibit viral replication, but the use of these drugs is becoming limited due to the 
onset of drug resistant strains of the virus. 
In light of this need for the development of novel NNRTIs, we set out to explore new territory in 
NNRTI drug design with a goal of maintaining efficacy in the presence of both wild-type and 
mutated forms of HIV-1. To this end we designed three different NNRTI scaffolds along three 
different research thrusts. 
The first of these focused on the synthesis of 15 novel flexible triazole containing compounds. 
With these compounds we sought to achieve π-π stacking interactions with conserved amino 
acid residue Trp229 in the hope that we would be able to maintain efficacy in the presence of 
mutated forms of the virus. An additional feature included hydrogen bonding interactions to the 
backbone of Lys103. However, despite having thoroughly explored the triazole ring with 
multiple substitution arrangements, these compounds had very poor to no activity against 
whole cell HIV-1. 
Secondly we focused on the synthesis of a 4-hydroxyindole scaffold as a potential NNRTI. The 
focus here was to achieve interactions to Trp229 and simultaneously achieve hydrogen bonding 
interactions to the backbone of Lys101 at the entrance of the pocket. This was a novel concept 
in this class of compounds. We were able to successfully synthesize the indole core as a proof-
of-concept using the Knoevenagel-Hemetsberger method however; this compound had no 
activity against HIV-1. 
Lastly, in our quest to synthesize a novel NNRTI that could maintain efficacy against HIV-1 we 
decided to attempt to improve upon the stability of a lead indole-based compound synthesized 
previously within our research group. The lead compound was found to be potent with an IC50 of 
1 nM but was unstable in acidic media due to the presence of a methoxy functionality situated at 
the 3-position on the indole. We sought to overcome this issue by introducing a substituted aryl 
amine functionality at this position. We were successful in synthesizing our desired compound 
but unfortunately it was significantly less active against whole cell HIV-1 than the lead 
compound. However, we were not completely deterred as there are a number of unexplored 
bioiososteres as possibilities to improve upon the stability of the lead compound while 
maintaining its excellent activity profile. 
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UITREKSEL 
Sedert die ontdekking van die menslike immuniteitsvirus (MIV) in die 1980’s, het die virus al 
die lewens van miljoene mense wêreldwyd geaffekteer. Ten spyte van die ooglopende behoefte 
aan ‘n geneesmiddel sowel as meer navorsing, bly ‘n keermiddel sover onbekombaar as gevolg 
van die verskillende mutasies wat binne die virus gebeur. Ten spyte hiervan, was daar al 
heelwat sukses in terme van ‘n verlaging van die virale vlakke in besmette individue deur die 
gebruik van hoogsaktiewe antiretrovirale terapie (HAART). As ‘n eerste behandeling, teiken 
HAART meestal trutranskriptase (RT) deur die inspanning van twee nukleosied 
trutranskriptase inhibeerders (NRTIs) en ‘n nie-nukleosied trutranskriptase inhibeerder 
(NNRTI). NNRTIs teiken ‘n allosteriese leemte wat ongeveer 10 Å weg van die katalitiese posisie 
is en veroorsaak dan ‘n konformasie verandering in die ensiem tydens die bindingsproses, wat 
dan lei tot die inhibisie van die virus se replikasie. Daar is tans 5 FDA goedgekeurde NNRTIs op 
die mark wat virale replikasie inhibeer, maar die gebruik van hierdie middels word alhoemeer 
belemmer as gevolg van die onwikkeling van weerstandige stamme van die virus. 
Met die oog op hierdie nood aan die ontwikkeling van nuwe NNRTIs, het ons gepoog om new 
gebiede te ondersoek in terme van die ontwerp van NNRTIs, met die doel om die effektiwiteit 
teen beide die wilde-tipe sowel as die gemuteerde vorme van HIV-1 te behou. Vir hierdie 
doeleindes het ons drie verskillende NNRTI steiers ontwerp, wat drie navorsingsdoeleindes na 
streef. 
Die eerste van hierdie doeleindes was die sintese van 15 nuwe buigsame triasool-bevattende 
middels. Met hierdie middels het on gepoog om π-π pakkingsinteraksies te behaal met 
aminosuur residu, Trp229, en sodoende die effektiwiteit van die NNRTIs in die gemuteerde 
vorm van die virus te behou. ‘n Additionele eienskap wat bygevoeg is, is ‘n waterstof-
bindingsinteraksie met die ruggraat van Lys103. Ten spyte van pogings om verskeie substitusie 
patrone om die triasool-ring te ondersoek, het hierdie middels baie swak tot geen aktiwiteit 
teen heel sel HIV-1 getoon nie. 
Tweedens, was die fokus op die sintese van ‘n 4-hidroksieindool steier as ‘n potensiele NNRTI. 
Die fokus hier was om ‘n interaksie met Trp229 te kry terselfdetyd as ‘n waterstof-
bindingsinteraksie met die ruggraat van Lys101, wat by die opening van die bindingssak is. 
Hierdie was ‘n nuwe konsep vir hierdie klas van middele. Ons het die indool-kern van hierdie 
molekules suksesvol gesintetiseer deur middel van ‘n Knoevenagel-Hemetsberger metode, maar 
ongelukkig het hulle geen aktiwiteit teen HIV-1 getoon nie. 
Laastens het ons gepoog om ‘n nuwe NNRTI te sintetiseer wat effiktiwiteit teen HIV-1 behou, 
deur te probeer om vorderings te maak op die stabiliteit van ‘n indool-gebaseerde hoof-middel 
wat al voorheen deur ons navorsingsgroep geraporteer is. Hierdie hoof-middel het ‘n IC50 
waarde van 1 nM gelewer, maar was onstabiel in suur medium as gevolg van die 
teenwoordigheid van ‘n metoksie-groep in die 3-posisie van die indool. Ons het gepoog om 
hierdie probleem te oorkom deur ‘n gesubtitueerde arielamien in hierdie posisie te plaas. Ons 
was suksesvol hierin, maar ongelukkig was die middel heelwat minder aktief teen die heel sel 
HIV-1 as die metoksie-weergawe. Ten spyte hiervan, is ons optimisties dat ons hierdie probleem 
kan oorkom, aangesien daar verskeie bioisostere is wat die stabilitiet van middel kan verbeter 
terwyl dit moontlik die effektiwiteit kan behou. 
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1.1. Introduction to HIV 
It was in the early 1980’s that researchers discovered that a retrovirus was responsible for the 
onset of the acquired immuno-deficiency syndrome (AIDS). This retrovirus, believed to 
originate from a subspecies of Central West African chimpanzee Pan troglodytes troglodytes, 
was first isolated from a patient with lymphadenopathy suspected to have AIDS.1 As a result, 
this retrovirus was originally called the lymphadenopathy-associated virus (LAV) but soon after 
came to be known as the human immunodeficiency virus (HIV) due to the fact that the presence 
of HIV went hand in hand with a notable decline in CD4 T-cells which play an important role in 
the adaptive immune response.2-4  
This discovery of HIV as the cause of AIDS came unexpectedly during a time when many people 
thought that epidemic diseases did not afflict first world countries. Moreover, it was believed 
that AIDS was perhaps caused by autoimmunity to white blood cells, funghi or even chemicals.3, 
5The discovery of HIV as the cause of AIDS was made possible due to the earlier discovery of the 
human T-cell leukemia virus (HTLV) types 1 and 2. The techniques for the identification and 
characterization of these retroviruses were made available with the discovery of reverse 
transcriptase by Temin and Baltimore almost ten years earlier in 1970. This led researchers to 
believe that AIDS would be caused by a retrovirus within the HTLV family. Although this theory 
was not entirely correct it did point researchers in the right direction for the discovery of HIV.3, 5 
Since this discovery HIV has earned the reputation as the most formidable pandemic affecting 
millions around the globe. The impact of HIV on society extends further than public health as it 
affects the economic growth, poverty, politics and society on a social level.6, 7 According to the 
World Health Organization (WHO) and UNAIDs 2013 global report there were in 2012 an 
estimated 35 million people living with HIV worldwide, with 70% of that population inhabiting 
Sub-Saharan Africa. They also reported an estimated 2.3 million new infections and 1.6 million 
AIDS related deaths in the same year.8 In Sub-Saharan Africa, South Africa has the highest 
reported incidence of HIV in the world, with an estimated 6.1 million individuals infected with 
HIV.8 The worst afflicted province is Kwazulu-Natal (KZN), which is probably linked to the high 
rate of unemployment, poverty and the social stigma often associated with infection.9 HIV-
related stigma and discrimination significantly hinders preventative measures as it often leads 
to the refusal of infected individuals to seek treatment, to adhere to the prescribed treatment 
and to disclose their HIV status to respective partners.6 Of concern is that these statistics are 
conservative and it is estimated that in Sub-Saharan Africa more than half of the population 
living with HIV are unaware of their HIV status. 10 
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1.2. Mode of Infection  
Although it is possible to acquire HIV through several accidental modes of contact such as blood 
transfusion, sexual transmission still accounts for almost 80% of HIV infection.11 One of the 
biggest travesties is mother-to-child transmission where during birth, blood contact with the 
infected mother may well lead to an infected infant. 
For viral infection to occur the HI virus, which is enveloped in a viral envelope protein, targets 
the CD4 receptor molecule found primarily on T-lymphocytes, macrophages and dendritic 
cells.12 The HI virus is then able to bind to the CD4 receptor with the aid of the viral envelope 
cell surface attachment glycoprotein gp120, which protrudes out from the viral envelope 
(Figure 1). The initial formation of the CD4/gp120 complex then allows for gp120 to associate 
with chemokine co-receptors, CCR5 or CXCR4, located on the host cell lipid membrane. The 
binding of gp120 with CD4 and the coreceptor triggers a conformational change in gp120 which 
exposes the viral transmembrane glycoprotein, gp41, which initiates the fusion of the viral 
envelope membrane with the plasma membrane of the host cell.12 The fusion of viral and host 
cell membranes leads to the release of the viral nucleocapsid, which contains the viral RNA and 
enzymes, into the cytoplasm of the host cell.13 After entry into the cytoplasm the viral capsid is 
removed and the viral core is released. At this point the enzyme reverse transcriptase 
transcribes the viral RNA into the complementary double-stranded viral DNA.13 
The newly transcribed DNA is then transported into the nucleus of the host cell where the viral 
integrase catalyzes the incorporation of the viral DNA into the host cell genome.13 The 
integrated viral DNA is now referred to as the “provirus” and can behave as a cellular gene and 
serve as a template for the transcription of new viral RNAs and mRNAs that are responsible for 
the translation of the structural, regulatory and accessory proteins needed for viral replicaton.13, 
14 The newly synthesized mRNA leaves the host nucleus and uses host ribosomes for the 
translation of non-functional precursor polyproteins Gag and Gagpol. The Gag precursor protein 
codes for all the structural viral proteins and the Gagpol precursor protein codes for the viral 
enzymes reverse transcriptase, integrase and protease.15 
The Gag precursor polyproteins along with the newly transcribed viral RNA then target the host 
cell plasma membrane promoting encapsulation of the viral RNA and polyprotein precursors. 
This leads to the formation of new immature virus particles using the host cell plasma 
membrane to form the viral envelope. These immature progeny virions are then released from 
the host cell. During or after the budding of the progeny virion from the host plasma membrane, 
cleavage of the Gag and Gagpol polyprotein precursors by HIV protease generates the mature 
Gag and Gagpol proteins. This ultimately leads to virion maturation and the spread of infection 
to other host cells.13, 16  
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Figure 1 HIV mode of infection and replication from Reynolds et al.14 
With primary infection, viral replication occurs rapidly which results in a high incidence of 
viraemia. As the levels of HIV in the bloodstream increase, the number of CD4+ T-cells 
decreases. At this point the majority of infected individuals show influenza-like symptoms. This 
is known as the acute stage of infection. Following this stage is the phase known as clinical 
latency, where viral levels in the bloodstream suddenly drop and CD4+ T-cell levels rise. This is 
due to the fact that the immune system responds using CD8+ T-cells and antibodies. Although 
viral levels drop at this stage, replication continues in viral reservoirs such as lymphoid organs. 
At the end of the clinical latency period, CD4+ levels once again drop as the viral levels increase. 
The clinical latency period in the absence of treatment can last as long as 4 to 10 years. After the 
latency period, viral replication accelerates and a gradual decrease in the efficacy of the immune 
system is observed, resulting in the onset of opportunistic infections and it is at this point that 
the disease is regarded as having progressed to AIDS. 
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1.3. Antiretroviral Treatments 
Although HIV has been fully characterized and its mode of infection and replication has been 
thoroughly studied, researchers have still not succeeded in creating a viable cure or vaccine 
against HIV. This can be attributed to the fact that HIV possesses a high mutation rate which 
makes it increasingly difficult to keep up with ever-changing therapeutic targets.17 Despite this, 
researchers have had considerable success in reducing the viral load in infected individuals, 
thereby improving quality of life and preventing the onset of co-infections leading to the 
development of AIDS. This has been achieved through the use of highly active antiretroviral 
therapy (HAART), also known as triple therapy. As the latter suggests, this treatment makes use 
of a combination of three drugs, covering at least two classes of antiviral agents, to inhibit viral 
replication in infected individuals. The different classes are categorized according to their target 
for inhibition in the HIV replication cycle. Typically HAART consists of two nucleoside reverse 
transcriptase inhibitors (NRTIs) or nucleotide reverse transcriptase inhibitors (NtRTIs) in 
combination with either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease 
inhibitor (PI).18  
The current first-line regimen recommended by the WHO in 2013 is to use the nucleotide 
reverse transcriptase inhibitor tenofovir disproxil fumarate in combination with nucleoside 
reverse transcriptase inhibitor lamivudine and non-nucleoside reverse transcriptase inhibitor 
efavirenz.18 The success of using HAART in the treatment of infected individuals has led to a 
decline of AIDS related deaths. The WHO has reported that AIDS related deaths are 2.3 million 
down from the number of deaths reported in 2005. Furthermore, the use of HAART has also led 
to a decline in the number of new infections to arise annually. In 2012 the number of new 
infections declined by 33% compared to the number of new infections in 2001.8 
In the past, HAART was usually introduced for HIV infected individuals in the period between 
clinical latency and the development of AIDS.14 In 2012, 9.7 million people were reported to be 
undergoing HAART which is an estimated 61% of those eligible for treatment. However, with 
the revision of the WHO guidelines this number dropped to only 34% of the population eligible 
for antiretroviral (ARV) treatment. This is due to the fact that the WHO has revised the 
recommended CD4 count for people living with HIV to be able to receive treatment. The new 
guidelines suggest that an infected individual with a CD4 count of ≤ 500 CD4 cells/mm3 can 
initiate ARV treatment whereas previously only patients with a CD4 count ≤ 350 cells/mm3 
were eligible for ARV treatment.10 Also, irrespective of the CD4 count, it has been ruled that 
HAART is to be initiated immediately for couples where the one partner is HIV positive, 
pregnant woman with HIV, individuals who also present coinfections such as tubercolosis and 
children under the age of 5 years.10  
Currently 25 antiretroviral drugs have been approved by the Food and Drug Administration 
(FDA) for the use in the treatment of HIV infected individuals. These drugs fall into six 
categories and cover five therapeutic targets.19  
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1.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
The oldest class of antiretrovirals are nucleoside reverse transcriptase inhibitors (NRTIs) which 
target the polymerase active site of reverse transcriptase (RT). These molecules are analogues 
of naturally occurring nucleosides but they lack the 3’ hydroxyl group required for the 
incorporation of nucleosides onto a growing DNA strand.20 These NRTIs act as chain 
terminators and directly inhibit the transcription of viral RNA into the dsDNA required for HIV 
replication. However, NRTIs are regarded as prodrugs. This means that in order for these 
nucleoside analogues to be recognized by the DNA polymerase of RT and incorporated onto the 
propagating DNA chain, they have to first be activated to their triphosphate form by cellular 
kinases (Figure 2).20 This requires three phosphorylation steps. Only once activated, can these 
analogues then compete with the naturally occurring nucleotides for incorporation onto the 
DNA strand. 
 
Figure 2 Activation of nucleoside thymidine and an NRTI to the triphosphate form 
3’-Azido-3’-deoxythiymidine (AZT) or zidovudine (Retrovir®, Figure 3) which acts as a mimic of 
thymidine was the first drug to be approved by the FDA for the treatment of HIV in 1987. This 
discovery of AZT as a potent inhibitor of HIV, however, was a serendipitous one. AZT was 
originally synthesized in 1964 by Dr Jerome P. Horwitz as an anti-cancer agent but when tested 
in leukemic mice AZT was found to have no activity. As a result, AZT was for a while shelved and 
forgotten.21 It was not until 1984 that AZT was rediscovered during a screening of a number 
compounds against the Friend Leukemia Virus (FLV) and the Harvey Sarcoma Virus (HaSV), 
thought to be highly comparable to HIV. The results of this screening were exceptional as AZT 
was found to completely inhibit viral replication in both retroviruses and was soon after tested 
against HIV to give the same promising results. This chance discovery led to considerable 
expectation among researchers that this drug would allow for the eradication of HIV. This belief 
that AZT would be the ‘wonder-drug’ provided hope for many infected individuals world-
wide.22 However, due to the unforeseen onset of resistance the prescription of AZT only 
succeeded, on average, in prolonging the life of infected individuals by 18 months.23, 24 This 
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meant that the search for a treatment against HIV, despite high expectations, had only just 
begun. 
 
Figure 3 Azidothymidine (AZT) 
In addition to AZT, six other NRTIs have been approved by the FDA for the treatment of HIV. 
These include lamivudine (Epivir®), emtricitabine (Emtriva®), zalcitabine (Hivid®), stavudine 
(Zerit®), didanosine (Videx®) and abacavir (Ziagen®) (Figure 4). These newer NRTIs often 
possess better long-term tolerability and safety. For example lamivudine, emtricitabine and 
tenofovir have none to almost no long-term adverse side effects.25 
 
Figure 4 Some commercially available NRTIs 
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1.3.2. Nucleotide Reverse Transcriptase Inhibitors (NtRTIs) 
Nucleotide reverse transcriptase inhibitors (NtRTIs) behave like NRTIs with regards to their 
mode of action. However, unlike NRTIs, they already contain one phosphonate group which 
cannot be cleaved by hydrolysis and, therefore, require only two phosphorylation steps to get to 
their active form.26 This is highly advantageous as the first phosphorylation is the rate 
determining step in vivo and so by already incorporating one phosphonate group the process of 
converting the prodrug to the active triphosphate form is expidited. The only NtRTI that has 
been approved for the treatment of HIV is tenofovir disoproxil fumarate (Viread®, Figure 5) 
which is an adenosine nucleotide analogue. It is also the most widely prescribed drug in the 
treatment of HIV and is used in combination with other ARVs in both treatment naïve and 
treatment experienced patients.18  
 
Figure 5 
1.3.3. Protease Inhibitors (PIs) 
Protease inhibitors are another class of therapeutic agents commonly used in HAART. HIV 
protease plays an important role in viral maturation as it is responsible for the generation of 
mature infectious HIV particles through the cleavage of viral Gag and GagPol precursor 
polypeptides into smaller proteins.15, 16 Currently there are nine protease inhibitors (PIs) 
approved by the FDA for clinical use. PIs mimic the naturally occurring substrate of the HIV 
protease enzyme and can be divided into two categories, peptidomimetic inhibitors and non-
peptidomimetic inhibitors, although the latter only refers to the PI tipravanir. The 
peptidomimetic PIs contain a hydroxyethylene core prohibiting cleavage of the PI by protease 
(Figure 6). As a result, competitive binding of the PI and subsequent failure to hydrolyse the 
drug results in deactivation of the enzyme. 
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Figure 6 A representation of the protease cleavage site on a naturally occurring protease substrate (top) and the 
blocked site on protease inhibitor Saquinavir (bottom) 
Saquinavir (Invirase®) was the first protease inhibitor approved by the FDA in 1995 (Figure 
7).16 Protease inhibitors that followed the approval of saquinavir were ritonavir (Norvir®) and 
indinavir (Crixivan®) in 1996. Ritonavir was poorly tolerated and was known to cause an 
elevation in cholesterol or triglycerides in the blood.25 Ritonavir is now commonly used in 
combination with other PIs as a booster. Saquinavir, ritonavir and indinavir are all first 
generation PIs. 
 
Figure 7 Some commercially available PIs 
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Lopinavir (Kaletra®), darunavir (Prezista®) and tipranavir (Aptivus®) are all second generation 
PIs. Like most second generation inhibitors these PIs were developed to combat issues of 
resistance associated with earlier PIs.16 Tipranavir is the only PI approved by the FDA that is 
non-peptidomimetic. Tipranavir is an important addition to the PI family as it has been shown 
to maintain efficacy against HIV strains that have resistance to other PIs.27 
 
1.4. Newer Classes of Anti-retrovirals 
1.4.1. Integrase Strand Transter Inhibitors (INSTIs).  
The newest class of antiretroviral drugs for the treatment of HIV infection are integrase 
inhibitors (Figure 8). These drugs target the integrase enzyme which catalyzes the insertion of 
the transcribed viral DNA in to the genome of the infected host cell. 
 
Figure 8 The first three FDA approved INSTIs 
Raltegravir (RAL, Isentress®) was the first integrase inhibitor approved for clinical use by the 
FDA in 2007.28 This drug functions by blocking the active site of integrase and inhibiting strand 
transfer, thereby preventing the incorporation of the viral DNA into the host cell’s genome.14, 29 
RAL, coadministered with an NNRTI or PI as a salvage therapy, is mostly given to treatment 
experienced patients where first line regimens have failed due to the onset of resistance and 
almost no treatment alternatives are available.29 Unfortunately, RAL has a low genetic barrier to 
resistance and as a result, single point mutations can confer high level resistance. After the 
discovery of the first INSTI, further studies into this field led to the identification of elvitegravir 
(EVG, Stribild®) as another first generation INSTI. Like RAL, EVG was shown to be an effective 
INSTI in clinical trials but, unfortunately, also suffered a moderate genetic barrier to 
resistance.30  
The moderate genetic barrier to resistance along with significant cross-resistance of first 
generation INSTIs led to the development of second generation INSTIs which would maintain 
efficacy in the presence of RAL and EVG resistant strains of the virus. The first of these to be 
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developed was dolutegravir (DTG, Tivicay®).31 DTG is advantageous in that it can overcome 
resistance issues experienced by first generation INSTIs.32 
1.4.2. Fusion Inhibitors 
Enfuvirtide (Fuzeon®, Figure 9) is the first and only drug to be approved by the FDA as a fusion 
inhibitor. Enfuvirtide acts by binding to the transmembrane glycoprotein gp41, blocking the 
fusion of the viral envelope with the host cell plasma membrane.33 It is a 36 amino acid 
synthetic peptide that stems from gp41.33 
 
Figure 9 
1.4.3. Entry Inhibitors 
CCR5 is the predominant chemokine receptor targeted in early infection of HIV and is 
responsible for aiding the entry of HIV into the host cell. The chemokine co-receptor has become 
the latest target for antiviral therapy and is unique in the sense that this target is found on the 
host cell and is not a component of HIV.34 Maraviroc (Selzentry®, Figure 10), which was 
approved for clinical use by the FDA in 2007, is the only small-molecule CCR5 chemokine 
receptor antagonist available on the market.34 This drug inhibits HIV-1 entry into the host cell 
by blocking the interaction between the HIV-1 viral envelope and the chemokine receptor CCR5. 
However, maraviroc has little to no activity against the CXCR4 co-receptor or viruses that 
possess dual tropism.25 Maraviroc is orally administered and only used for treatment 
experienced patients as a last resort.35 
 
Figure 10 FDA approved entry inhibitor Maraviroc 
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1.5. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
1.5.1. Allosteric Inhibition of HIV-1 Reverse Transcriptase 
Reverse transcriptase plays a crucial role in the transcription of viral RNA into double stranded 
viral DNA and, as a result, is an important target for HIV replication inhibition. Reverse 
transcriptase is an asymmetric heterodimeric enzyme consisting of two subunits, p66 (66 kDa) 
and p51 (51 kDa) (Figure 11). The p51 and p66 subunits consist of the same amino acid 
sequence but possess differing tertiary structure.36 The p66 unit comprises of the ribonuclease 
H (RNaseH) domain as well as four pol subdomains. The conformation of the p66 subunit is 
commonly likened to a right hand with three of the pol subdomains making up the fingers, palm 
and thumb. The palm domain contains the polymerase active site. The fingers subdomain 
holding down on the palm domain is the catalytic site. The fourth pol subdomain is called the 
connection domain, and lies between the RNaseH domain and the rest of the pol domain. The 
p66 domain has an open elongated conformation and plays a catalytic role in the enzyme. The 
p51 unit however, is more compact and seems to play a more structural role.36  
 
Figure 11 HIV-1 RT heterodimer (PDB structure 3v81). This image was prepared using Accelrys Discovery 
Studio 4.0. 
There are two sites in RT that are targeted for the inhibition of transcription. The first is the 
catalytic site or polymerase active site where transcription of viral RNA into dsDNA occurs. This 
site is targeted by NRTIs. However, about 10 Å away from this catalytic site is a small, 
hydrophobic, allosteric pocket which is targeted by non-nucleoside reverse transcriptase 
inhibitors (NNRTIs). This allosteric pocket, known as the non-nucleoside binding pocket 
(NNIBP) is an elastic pocket which only forms upon binding of an NNRTI molecule.37 This allows 
for vast structural diversity in the class of NNRTIs. This binding pocket is created by torsional 
rotation of the amino acids tyrosine 181 (Y181) and tyrosine 188 (Y188) from a “down” to an 
“up” position and the repositioning of the β-sheet containing amino acids tryptophan 229 
(W229) and phenylalanine 227 (F227).38 
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NNRTIs are small, hydrophobic molecules that are noncompetitve inhibitors, and are highly 
selective for HIV-1 RT. Furthermore, their size and hydrophobicity allows these drugs to cross 
the blood-brain barrier (BBB). Unlike NRTIs, which are prodrugs, NNRTIs do not require 
preliminary activation by the phosphorylation of cellular kinases. Furthermore, they have a 
lower toxicity profile than NRTIs as they do not affect the activity of other cellular 
polymerases.39  
 
1.5.2. First Generation NNRTIs 
Early NNRTIs, such as nevirapine (Viramune®) and delavirdine (Rescriptor®) (Figure 12) are 
classified as “first generation” NNRTIS due to the fact that they possess rigid butterfly-like 
structures. Although initially they significantly reduce viral levels in infected individuals, after 
prolonged treatment single-amino acid mutations confer resistance. The most common single 
point mutations to confer resistance are K103N and Y181C. This low genetic barrier to 
resistance can be attributed not only to the rigidity of these structures but also on the fact that 
the binding of these compounds depend on being able to form π-π interactions with amino acids 
Y181 and Y188, and these amino acids readily mutated to cysteine and leucine respectively. 
These mutations convert the aromatic tyrosine side chain to an aliphatic group, thereby, 
obliterating the important π-π interactions between the inhibitor and the tyrosine side chain.40  
 
Figure 12 FDA licensed NNRTIs 
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1.5.3. Second Generation NNRTIs 
Efavirenz (Sustiva®) is currently the most widely used component of first-line HAART. Although 
efavirenz has the rigidity associated with earlier NNRTIs, it is considered a second generation 
NNRTI. Efavirenz, unlike earlier NNRTIs, has a greatly improved resistance profile in 
comparison.41 This can be attributed to the fact that the cyclopropyl moiety introduced in 
efavirenz, as opposed to the pyrimidine ring present in nevirapine, results in fewer interactions 
with Y181 and Y188 (Figure 13). Furthermore, there is the introduction of a hydrogen bond 
with the carbonyl oxygen on the backbone of lysine 101.41 
 
Figure 13 Comparative Binding mode of Efavirenz with no notable interactions with Tyr188 and Tyr181 (left) and 
Nevirapine which is reliant on π-π interactions with the aromatic amino acid residues (right)  
 
Second generation inhibitors such as etravirine (Intelence®) and rilpivirine (Edurant®) (Figure 
14) are diarylpyrimidine (DAPY) NNRTIs and possess an element of conformational flexibility. 
Their considerable torsional flexibility allows for them to adopt a number of conformations 
enabling them to adapt to mutation induced changes in the allosteric pocket (Figure 15).37 As a 
result, these second generation NNRTIs possess a higher genetic barrier to resistance and are 
resistant to a number of common clinical mutations that render “first generation” NNRTIs 
ineffective, such as the common K103N mutation. In fact three or more mutations are often 
required to render these second generation inhibitors ineffective. Unfortunately, this same 
feature of conformational adaptability also confers higher toxicity on these drugs due to off-
target interactions. 
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Figure 14 FDA approved second generation NNRTIs 
 
Figure 15 The conformational flexibility of etravirine enables it to adopt multiple binding modes in the NNIBP 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 2: Introducing Our Strategy 
16 
 
Chapter 2: Introducing Our Strategy 
 
2.1. The emergence of drug resistance as a setback to controlling viral 
levels of infected individuals 
The biggest challenge to the success of clinically available NNRTIs in reducing the viral load 
effectively of infected individuals, is the onset of drug resistance. This issue is caused by the 
emergence of mutations immediately surrounding the NNIBP, which often directly leads to a 
decrease in the efficacy of a particular NNRTI.14  
As mentioned in the previous chapter, first generation NNRTIs nevirapine and delavirdine are 
highly susceptible to the emergence of a wide range of single point mutations. Second 
generation NNRTIs efavirenz, etravirine and rilpivirine have a higher barrier to resistance and 
often require the presence of two or more mutated amino acid residues in the region of the 
NNIBP before significant resistance is observed.42 The most common clinically relevant 
mutations that lead to the emergence of drug resistance are K103N, Y181C, Y188C/L, V106A/M, 
G180A/S and A98G.43 There are three mechanisms by which these mutations can confer 
resistance. These include reducing the Van der Waals and π-π stacking interactions between the 
inhibitor and the allosteric pocket, changing the hydrogen bonding character of the allosteric 
pocket and, finally, introducing steric clashes by altering the size of the amino acid residue side 
chains surrounding to the allosteric pocket.44  
The most prominent and clinically relevant mutation is K103N, where Lys103 is replaced by 
Asn103, and this causes broad-spectrum resistance to most NNRTIs. Researchers have 
suggested that the K103N mutation causes resistance by stabilizing the closed NNRTI binding 
region in the absence of an inhibitor. As a result, a higher energy barrier is created for the 
binding of an inhibitor to the NNIBP, thereby reducing the activity of many NNRTIs.45 Studies 
have shown that this occurs due to favourable hydrogen bonding interactions between the 
phenolic hydroxyl group of Tyr188 and the amide of Asn103.45 However, it is unclear whether 
the stabilization of the apo-enzyme is the only mechanism by which this mutation leads to 
resistance. This doubt has been brought on by the ability of newer second generation NNRTIs 
such as etravirine to maintain activity against this mutation.46 Other examples of less common 
mutations observed for amino acids surrounding the NNIBP include L100I, V106A and V108I. 
As a result of this ongoing problem of the emergence of drug resistance, there is a continuous 
need to develop new NNRTIs. Therefore, understanding how these mutations confer resistance 
is vital in order to design NNRTIs that are able to overcome these issues.46 
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2.2. Strategies employed in the design of novel NNRTIs to overcome 
resistance 
The mechanisms by which mutations confer resistance have been extensively studied. This has 
enabled researchers to design novel potential NNRTIs that overcome drug resistance. However, 
this success is often short-lived due to the inevitable re-emergence of resistance. There are two 
strategies often employed in the design of these novel NNRTIs. The first of which is for the 
inhibitor to possess an element of flexibility enabling it to adapt to conformational changes 
brought on by mutations in the NNIBP. Alternatively, one may set out to design novel inhibitors 
tailored for specific mutant strains.38 Second generation NNRTIs etravirine and rilpivirine are 
examples of this strategy having been employed successfully.37  
The second strategy is to target interactions between the inhibitor and highly conserved regions 
of the enzyme and minimize interactions to the more readily mutable amino acid residues.38 
These conserved residues which surround the binding site include Phe227, Trp229, Leu234 and 
Tyr318.47 Mutations of these amino acid residues, particularly Trp229 and Tyr318, often lead to 
a decrease in viral fitness, and are therefore detrimental to viral replication and are not 
favoured. 
Of these highly conserved residues, Trp229 is the most favoured residue for drug design. 
Trp229 forms part of the primer grip region (residues Phe227 to His235) of RT which sustains 
the primer terminus in the appropriate position for nucleophilic attack on incoming dNTPs.48 
Therefore, Trp229 is thought to be important for correct protein folding or for stabilizing the 
complex between RT and the template-primer. The effect of eight different mutations at 
position 229 on the enzymatic activity of RT and potential resistance to NNRTIs was studied by 
Pelemans et al.49 Their studies showed that the presence of these mutations at position 229 in 
all cases severely compromised that enzymatic activity of RT and compromised the replicative 
ability of the virus. Only one mutation showed any significant resistance to NNRTIs while 
maintaining viral fitness.49 Furthermore, any mutation of this amino acid residue in vitro or in 
vivo has not been observed under drug pressure, not even in combination with other 
mutations.49, 50 This method of targeting conserved residue Trp229 has found success in a 
number of potential NNRTIs.  
 
2.2.1. A promising NNRTI candidate, lersivirine 
This design approach to overcome resistance found success in drug candidate lersivirine 
(Figure 16), which was until recently undergoing phase IIB clinical trials. The design of 
lersivirine resulted from lead optimization of capravirine which progressed to phase IIB clinical 
trials. Although capravirine was very effective, it suffered from rapid in vivo clearance due to the 
fact that it was prone to oxidative metabolism.51 Lersivirine was designed to optimize the 
potency exhibited by capravirine and to maintain metabolic stability. In a 48 week double blind 
trial lersivirine was found to be as effective as efavirenz but was found to possess a better 
toxicological profile.52 The attractiveness of lersivirine is also based on its unique mode of 
binding to the allosteric pocket of RT and its impressive resistance profile.53  
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Figure 16 
Lersivirine possesses an “upper” dicyanophenyl ring which forms edge-to-face π-π interactions 
with immutable Trp229 and π-π stacking interactions with Tyr188, as opposed to the more 
commonly targeted Tyr181.53 Furthermore, this allows Tyr181 to adopt the energetically more 
favoured “down” orientation, as is found in the apo form of the enzyme.54 All licensed drugs 
force Tyr181 into the “up” position, incurring a slight energy penalty. In addition lersivirine 
features hydrogen bonding between its hydroxyl functionality and the backbone of amino acid 
Lys103 (Figure 17).  
This drug candidate was shown to be able to inhibit 60% of mutant strains of HIV. It maintained 
activity against 14 of 15 clinically significant single point mutations and against two double-
mutations, Y181C/Y188C and V106A/Y181C.53 Furthermore, the use of lersivirine in 
conjunction with other anti-HIV agents exhibits synergism.53 Unfortunately, due to reasons not 
disclosed the development of lersivirine was recently halted.  
 
 
Figure 17 A representation of the unique binding mode of lersivirine in the NNIBP showing π-π stacking interactions 
to Tyr188 and Trp229 and hydrogen bonding interactions to Lys103 and Pro236 
.  
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2.2.2. Other examples of attempts to overcome resistance by targeting conserved 
residues within the NNIBP 
Targeting conserved amino acid residues such as Trp229 has found considerable success in a 
number of other potential NNRTIs. Further examples of these include clinical candidates MK-
4965 and MK-1438 (Figure 18). Like lersivirine, these biaryl NNRTIs maintain an element of 
flexibility and form π-π stacking interactions with Trp229 and π-π stacking interactions with 
Tyr188. Both MK-4965 and MK-1439 have broad spectrum antiviral activity at subnanomolar 
concentrations against wild-type HIV-1 and in the presence of mutations such as K103N and 
Y181C.55, 56  
 
Figure 18 
Another interesting NNRTI candidate is indazole 1 (Figure 19). Although this compound also 
targets the conserved residue Trp229 and forms hydrogen bonding interactions with the 
backbone of the NNIBP, it possesses a more rigid structure. Despite this, 1 still exhibits activity 
at nanomolar concentrations against wild-type HIV-1 and also maintains potency in the 
presence of mutations K103N and Y181C.57 
 
Figure 19 A representation of the binding mode of indazole 1 showing π-π interactions with Trp229 and Tyr188 and 
hydrogen bonding interactions to Lys101. 
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This compound was designed through the use of molecular hybridization combining beneficial 
structural characteristics of efavirenz and capravirine (Scheme 1).57 This was achieved by 
superimposing crystal structures of efavirenz and capravirine in the binding pocket and 
creating a hybrid from the two ligands by transposing the 3,5-disubstituted phenyl moiety of 
capravirine onto the the indazole core (distinct but similar to the bicyclic template of efavirenz).  
 
Scheme 1 Alignment and superimposition of the crystal structures of capravirine (orange) and efavirenz (blue) led 
to the hybridization of the two NNRTIs to yield indazole 1. (Crystal structures taken from PDB structures 1EP4 and 
1FK9) 
 
 
2.3. Our Strategy 
Drawing inspiration from the successes discussed previously, we sought to design and 
synthesize novel NNRTIs that could maintain efficacy in the presence of resistance strains of the 
virus. We envisaged that we could achieve this by introducing elements of flexibility to our 
compounds and improving binding affinity to the mutated NNIBP by targeting conserved 
residues such as Trp229. The aim of this MSc project can be divided into three different 
research thrusts. Below, these will be introduced briefly, but discussed in greater detail in 
subsequent chapters. 
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2.3.1. Synthesis of a small triazole library 
The first of the three research thrusts focused on the synthesis of novel triazole-containing 
compounds 2 (Figure 20), the design of which was inspired by lersivirine. These small flexible 
biaryl compounds featured a bis-metasubstituted aryl ring to maintain π-π stacking interactions 
with Tyr188 and π-π edge-to-face interactions with Trp229. In addition, these compounds 
possess an appropriate substituent, such as a short alcohol chain on the triazole ring which 
would enable them to form hydrogen bonding interactions with the backbone of Lys103. For the 
construction of these triazole-containing compounds we would make use of the highly versatile 
click chemistry which could provide us with enough scope to synthesize a small library of 
compounds.  
 
Figure 20 
 
2.3.2. An indole based scaffold designed to target Trp229 and Lys101 
The second research thrust focused on the design and synthesis of a novel indole based 
compound 3 (Figure 21) which also features π-π interactions with Tyr188 and Trp229. In 
addition to these interactions we endeavour to extend to the entrance of the allosteric pocket 
with the appropriate functionality to introduce hydrogen bonding interactions with the 
backbone of Lys101. Other interactions include an ethyl chain to occupy the Val179 pocket, as 
well as a halogen at the 5-position shown to help improve potency of potential NNRTI 
candidates.57, 58 
 
Figure 21 
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2.3.3. An extension of previous work 
Finally the third research thrust is an extension of work done previously within our research 
group. Recently an indole based compound 4 (Figure 22) was synthesized in our laboratory and 
was found to be potent against HIV RT with an IC50 value of 1 nM. This compound was also 
found to maintain potency against the common and clinically problematic mutation K103N.59 
However, of concern was the fact that the compound appeared acid labile, and therefore in its 
current form would never be available in oral dosage form.  
Our strategy involves improving the stability of this compound by replacing the methoxy 
functionality with a suitable bioisostere, such as the aryl amine for compound 5. We wished to 
keep the π-π stacking interactions to Tyr181 as this was shown to be imperative in maintaining 
activity against RT.59 We also sought to maintain occupation of the Val179 pocket with an alkyl 
chain, as well as hydrogen bonding interactions to the backbone of Lys101. 
 
Figure 22 
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Chapter 3: Synthesis of a Small Triazole Library 
 
3.1. Establishing a Proof-of-Concept 
We had decided that lersivirine was a suitable starting point for the design of our novel triazole 
containing potential NNRTIs due to its unique and impressive resistance profile. In order to 
establish a proof-of-concept, our first target series of biaryl compounds would consist only of a 
disubstituted triazole ring. This is as far from the structure of lersivirine (which consists of a 
fully substituted pyrazole ring) as we dared go as these compounds would only possess the 
structural features that were deemed important in the binding mode of lersivirine (Figure 23). 
These included a bis-meta-substituted aryl ring maintaining π-π stacking interactions to 
conserved residue Trp229 and the less targeted Tyr188, as well as, an alcohol chain for 
maintaining hydrogen bonding interactions to Lys103. Furthermore, these compounds would 
possess an element of flexibility allowing for the rearrangement of the potential inhibitor within 
the binding pocket. For the linker atom we decided to replace the oxygen found in lersivirine 
with a carbon as this would not interfere with the conformation of our compounds and would 
also simplify the synthetic sequence. 
 
Figure 23 Binding mode of lersivirine showing π-π stacking interactions with Tyr188 and hydrogen bonding 
interactions with Lys103 (left) and proposed scaffold for our triazole compounds (right). 
 
The simplicity of this structure and the incorporation of the triazole ring would enable us to 
utilize the well-documented and established azide-alkyne Huisgen cycloaddition reaction 
(Scheme 2).60 This reaction would, due to its versatility, facilitate the synthesis of a small library 
of simple regiospecific compounds and allow for us to explore the effects of varying substituents 
on the aryl ring, as well as varying lengths of the alcohol chain situated on the triazole ring. 
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Scheme 2 Initial synthetic strategy leading to a series of disubstuted triazole compounds  
 
3.2. The use of triazole rings in drug design 
Heterocycles have been used extensively in the design and development of drug candidates, in 
fact it is estimated that approximately 80% of marketed drugs contain at least one 
heterocycle.61 Heterocycles are popularly used as bioisosteric replacements for a large number 
of functional groups to improve potency and selectivity of drug candidates. They are also often 
employed to improve the pharmacokinetic and toxicological profiles of drug candidates by 
improving their lipophilictiy, polarity and aqueous solubility.61  
The use of triazole rings, in particular, as the heterocycle of choice in drug discovery has grown 
steadily over the last couple of years.60 Although triazole rings do not occur in nature, they have 
been shown to exhibit several biological activities such anticancer, antimalarial, antiviral and 
anti-inflammatory activities.62 Triazole rings have become popular due to their ability to be 
employed as both hydrogen bond acceptor and donor, to be able to be involved in ring stacking 
interactions and, if not directly involved in any interactions, to act as a stable structural linking 
unit. Furthermore, triazole rings have been reported to be metabolically stable. In vivo they are 
not oxidized or reduced and cannot be cleaved hydrolytically.63 
With regards to NNRTIs, the presence of a triazole ring is not altogether uncommon. However, 
unlike the 1,2,3-triazole moiety employed in our compounds, triazole containing NNRTIs 
discovered in the literature seem to only consist of the 1,2,4-triazole moiety, examples of which 
include RDEA806 (Figure 24). This compound was found to exhibit potent activity against HIV 
RT and maintain efficacy in the presence of the mutation K103N.56, 64  
 
Figure 24 RDEA206, an example of the use of a triazole ring in NNRTIs 
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3.3. Introducing Click Chemistry 
The reactions for the synthesis of triazole rings such as the copper and ruthenium azide-alkyne 
catalyzed Huisgen cycloaddition reactions fall under the umbrella term click chemistry. The 
term click chemistry was first defined in 2001 by Sharpless et al. in a paper describing the 
synthesis of large molecules following nature’s method of joining smaller units together using a 
heteroatom linker.65 This is defined as a reaction that is versatile, makes use of readily available 
starting materials and reagents, provides good yields, is efficient and selective, can be carried 
out under mild and simple reaction conditions and requires minimal workup and purification.65 
Reactions that meet these criteria include the hetero-Diels Alder reaction, ring opening 
reactions of strained heterocycles such as epoxides and aziridines, “non-aldol” type carbonyl 
chemistry such as the formation of ureas and thioureas and the copper or ruthenium catalysed 
Huisgen 1,3-dipolar cycloaddition reactions.63, 65 
The Huisgen 1,3-dipolar cycloaddition of azides and alkynes is considered the “cream of the 
crop” of all click chemistry reactions. These reactions are popular due to the ease with which 
the azide and alkyne components can be introduced into the reaction and the stability that these 
components possess under standard synthetic conditions.65 Another attractive feature of this 
reaction is the tolerance of this reaction to the presence of a variety of functional groups, with 
the exception of Michael acceptors and strained olefins.66 The ease with which these reactions 
can be carried out simplifies synthesis and allows for faster and efficient lead discovery and 
optimization.67 
 
3.4. Synthesis of Azide Fragments for Triazole Ring Synthesis 
For the initial synthetic strategy we envisaged utilizing a variety of substituted benzylic azides 
with commercially available propargyl alcohol or 1-butyn-3-ol as the precursors for the azide-
alkyne Huisgen cylcoaddition reaction. The benzylic azides could be synthesized from available 
benzylic halides and alcohols. These included benzyl bromide 6, 1-(bromomethyl)-3,5-
bis(trifluoromethyl)benzene 8, 3-(bromomethyl)benzonitrile 10, (3,5-dichlorophenyl)methanol 
12 and (3,5-dimethylphenyl)-methanol 22.  
 
3.4.1. Nucleophilic substitution reactions with sodium azide 
The conversion of the benzyl halides to the corresponding benzyl azides could be carried out 
through the use of a simple and well documented substitution reaction with sodium azide. The 
respective benzyl halide along with 1.5 equivalents of sodium azide was taken up in a 4:1 
mixture of acetone and distilled water and was carried out at ambient temperature for 
approximately 18 hours.68 These reactions proceeded without incident and provided excellent 
yields as can be seen in Scheme 3 below. 
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Scheme 3  
However, the benzyl alcohol precursors (for example 12, Scheme 4) could of course not be 
converted to the azide by a simple nucleophilic substitution reaction. Therefore, we had to 
employ a different method. The most obvious route would be to convert the alcohol to a more 
suitable leaving group and only then carry out a nucleophilic substitution reaction with sodium 
azide. We envisaged that this could be achieved by simply converting the alcohol to 
methanesulfonate using methanesulfonyl chloride. 
 
Scheme 4  
This strategy was first attempted using 3,5-dichlorobenzyl alcohol 12 as the azide precursor. 
Precursor 12 was taken up in DCM with triethylamine as the base and methanesulfonyl chloride 
was added dropwise to this mixture at 0 °C.69 However, when we analysed the 1H NMR for the 
formed product the methyl signal associated with the methanesulfonate functionality was not 
observed. In fact the only observed signals corresponded to the starting material. As the isolated 
product could not be starting material due to the significant difference in the Rf value we came 
to the conclusion that dimerization had occurred. We envisaged that this was due to the fact 
that unreacted benzyl alcohol rapidly displaced methanesulfonate 13 as it was forming. Despite 
attempts to optimize this reaction (which included omitting the triethylamine) we were unable 
to prevent dimerization from occurring. As a result, an alternative strategy for the conversion of 
the benzyl alcohol to the respective azide had to be considered.  
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3.4.2. Employing a Modified Appel reaction for the synthesis of the desired azides from 
benzylic alcohols 
Having studied the literature we envisaged that an Appel reaction could be the solution to our 
azide installation difficulties. This reaction, as discovered by Professor Ralph Appel, readily 
converts an alcohol to an appropriate halide.70 In the case of converting an alcohol to a chloride, 
this is achieved through the use of triphenylphosphine and carbon tetrachloride as the chloride 
source. The mechanism for this reaction is presented in Scheme 5. The first step is the formation 
of the phosphonium chloride cation 15 and trichloromethanide 16. The trichloromethanide 
anion deprotonates the alcohol 17 while the cation is then responsible for the phosphorylation 
of the newly formed anion 18 to the alkoxyphosphonium salt 19. The driving force for this 
reaction is the formation of the strong P-O bond followed by the release of the relatively 
unreactive triphenylphosphine oxide.71 The reason we called this a modified Appel reaction is 
due to the fact that sodium azide was also added to the reaction mixture resulting in a 
substitution of the newly formed benzylic chloride 20 with the desired azide 21. The sodium 
azide was introduced into the reaction mixture prior to the addition of the chloride source. It 
was obvious that the presence of the charged azide ion in the reaction mixture meant that the 
less reactive alcohol was now unlikely to outcompete the azide in the displacement of the 
benzylic chloride and, as a result, dimerization would not to occur. 
 
Scheme 5 Proposed mechanism for a modified Appel reaction 
Therefore, to a solution of the benzyl alcohol and sodium azide in DMF was added 
triphenyphosphine. The reaction mixture was then heated to 90 °C under reflux before carbon 
tetrachloride was added. The modified Appel reaction was carried out at this temperature for 
approximately 18 hours.72 The yields for these reactions were moderate as shown in Scheme 6. 
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Scheme 6 
All spectroscopic data for the azides synthesized coincided with the data reported in literature. 
With the alkynes and benzyl azides in hand we could begin the synthesis of our triazole library. 
 
3.5. The CuI Catalyzed Huisgen Cycloaddition Reaction 
The CuI catalysed Huisgen cycloaddition reaction (CuAAC) is considered the most popular and 
versatile variant of Huisgen dipolar cycloaddition reactions. The advantages of the CuAAC 
reaction were first described in 2002 by the groups of Sharpless and Meldal independently. 73,74 
These reactions which occur between azides and terminal alkynes are highly regiospecific 
forming the 1,4-triazole product exclusively. Furthermore, these reactions can occur in a variety 
of solvents and tolerate a range of pH values and temperatures.75 
It is thought that the CuAAC reaction occurs in a stepwise manner (Scheme 7).75 The first step of 
the CuAAC reaction involves the complexation of a CuI dimer with the terminal alkyne to from 
an active Cu-acetylide species 25. This step can be carried out with either a Cu(I) salt such as 
copper iodide in the presence of a nitrogen containing base such as 2,6-lutidine or DIPEA, or 
with Cu(I) generated in situ from a Cu(II) salt such as CuSO4 in the presence of a reducing agent 
such as ascorbic acid or sodium ascorbate.73 Reactions using Cu(I) generated from a Cu(II) 
source, despite Cu(I) sensitivity to oxygen, are generally carried out in water/alcohol mixture 
which precludes the requirement for the presence of any base.75 The use of Cu(I) salts, however, 
can only be carried out under inert conditions and in organic solvents and so the presence of a 
base or the use of high temperatures is required for the formation of the active Cu-acetylide 
complex.76 In this instance the deprotonation of the terminal alkyne facilitates the insertion of 
the Cu1 into the terminal alkyne to form the active species 25. The second step involves the 
displacement of one of the ligands of the copper complex by coordination of the azide forming a 
copper acetylide-azide complex 26.75 The formation of this complex activates the alkyne, 
making it more susceptible to nucleophilic attack by the distal nitrogen of the azide. This 
generates a metallocycle intermediate which positions the azide for triazole ring formation, 
ultimately leading to the formation of a copper-triazole derivative. Next protonation of the 
copper-triazole derivative 27 occurs followed by dissociation of the triazole product 28 and 
regeneration of the copper catalyst.75 
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Scheme 7 Proposed mechanism for CuAAC reaction adapted from Hein et al.77 
 
For our purposes we chose a procedure which makes use of copper (I) iodide in acetonitrile and 
using DIPEA as the base. The use of DIPEA as a base in these reactions is thought to minimize 
the formation of unfavourable side products. Furthermore, the use of excess base has been 
shown to improve the yields of these reactions by possibly stabilizing the oxidation state of 
CuI.75  
 
  
24 
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28 
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3.5.1. Synthesis of the 1,4-triazole series of compounds 
For the synthesis of our first 1,4-triazole biaryl compound we made use of propargyl alcohol 
with benzyl azide 6 (Scheme 8). Both precursors were taken up in MeCN along with 2 
equivalents of DIPEA. A catalytic amount of CuI was then added and reaction was run at room 
temperature for 18 hours.78 
 
Scheme 8 
Interestingly, our initial attempt at the CuAAC reaction was unsuccessful, however, the reason 
for this was quickly revealed. These reactions require concentrated conditions to proceed and in 
our initial attempts the reaction mixture was simply too dilute. The copper iodide does not 
dissolve in the MeCN but remains suspended and, as a result, the reaction needs to be as 
concentrated as possible in order for the reaction to occur. With this in mind, the procedure 
mentioned above was attempted once more using significantly less solvent and under these 
conditions the reaction proceeded without further complications. Purification by column 
chromatography yielded 80% of 29 as a white solid.  
Analysis of the 1H NMR spectrum of 29 revealed that the CuAAC had been 
successful. Firstly the benzylic protons and the CH proton on the triazole 
ring were clearly accounted for. The protons at 6 appeared as a singlet at 
5.46 ppm integrating for 2H, and proton 5 appeared as a singlet at 
7.37 ppm integrating for 1H. The proton corresponding to the OH was also 
clearly observed as a broad triplet at 2.07 ppm. The methylene protons at 7 
were observed as a doublet at 4.71 ppm integrating for 2H. 
Confident that this synthetic strategy would work well with our other azide and alkyne 
precursors, we could continue synthesizing our small 1,4-triazole library. 
Table 1 shows the triazole compounds successfully synthesized using this method. These 
compounds were also fully characterized and the characteristic signals observed in the 1H NMR 
spectrum of 29 were also observed for the newly synthesized compounds. 
Interestingly, the yield obtained for the synthesis of compound 33 was relatively poor in 
comparison with the yields obtained for compounds 29 to 32. However, the reason for this was 
not investigated.  
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Table 1 
 
Compound R1 R2 R3 %Yield 
29 H H OH 80 
30 CF3 CF3 OH 92 
31 Me Me OH 98 
32 Me Me CH2OH 86 
33 H CN CH2OH 46 
 
3.5.2. Confirmation of regiochemistry 
Although literature clearly states that the CuAAC reaction exclusively synthesizes the 1,4-
triazole regioisomer, we deemed it important to confirm this by additional spectroscopic 
studies. To this end, the nuclear Overhauser effect (NOE) would mostly likely be effective as it 
establishes the spatial proximity between protons.79 By irradiating signals of interest and 
observing the through-space correlations to other signals the 3D structure of a small molecule 
can be confirmed. There are 2 options for NOE experiments, 1D and 2D NOE experiments can be 
carried out. We found that 1D NOE experiments were more sensitive and provided more 
information than the 2D NOE experiments. 
For the purpose of confirming regiochemistry we selected the 3,5-dimethyl triazole derivative 
32 with the longer alcohol chain. Using the 1H NMR spectrum of 32 as a reference (Figure 25), 
we irradiated at the chemical shifts corresponding to protons on the methylene linker 6, the 
proton on the triazole ring 5 and the methylene protons on the alcohol chain represented as 7 
and 8. If we had synthesized the desired 1,4-triazole ring we would expect to observe 
correlations between the protons 5 and 6, as well as between protons 5 and 7.  
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Figure 25 1H NMR spectrum of 32 
The blocks shown on the 1H NMR spectrum (Figure 25) correspond to the correlations observed 
between protons on the NOE spectrum. The blue blocks show the correlations observed when 
we irradiated at 5.44 ppm which corresponds to the methylene protons 6. Irradiation here 
showed clear correlations to the triazole proton 5 situated at 7.32 ppm, as well as the aromatic 
protons. However, no correlations were observed between protons 6 and those on the alcohol 
chain.  
The red blocks are associated with the correlations observed when we irradiated at 2.95 ppm 
which corresponds to proton 7 on the alcohol chain. Irradiation at this peak shows clear 
correlations between protons 7 and 8 as would be expected, as well as between protons 7 and 5. 
No correlations are observed between protons 7 and 6.  
If the undesired 1,5-regioiosmer (Figure 26) had been synthesized we would have expected to 
observe correlations between methylene protons 6 and 7 as the alcohol chain would occupy the 
5-position on the triazole ring as opposed to the 4-position. Consequentially we would not 
observe any correlations between the triazole proton, now proton 4 on the structure, and 
methylene protons 6. As our observations do not match those expected for the 1,5-regioisomer 
we could safely conclude that the CuAAC synthesis did provide us with the desired 1,4-triazole 
regioisomer.  
 
Irradiated 
signal 
Irradiated 
signal 
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Figure 26 
Having synthesized 5 different proof-of-concept 1,4-triazole compounds we could send them for 
biological evaluation. 
 
3.6. Efficacy results of the 1,4-triazole series 
Biological evaluation of our compounds was carried out by our collaborators at the National 
Institute for Communicable Diseases (NICD) in Johannesburg. Phenotypic and toxicity assays 
were carried out against wild-type HIV-1.80, 81 The results of these assays are shown in Table 2. 
Table 2 
 
Compound R1 R2 R3 CC50 (µM) IC50 (µM)  
29 H H OH >100 >83.5 
30 CF3 CF3 OH >53.4 >24.5 
31 Me Me OH >100 27.8 
32 Me Me CH2OH >100 >100 
33 H CN CH2OH >100 >83.5 
 
We had hoped that these compounds would show some activity against HIV RT due to the fact 
that despite their simplicity, they still featured what we considered to be the structural 
characteristics of lersivirine imperative for its impressive activity profile (Figure 23). Although 
we expected that the activity would be less than that of lersivirine due to the simplified nature 
of their structures we did not expect that the 1,4-disubstituted triazole compounds synthesized 
would show such poor to no activity. We considered attributing the lack of activity to the over-
simplification of these compounds and hypothesized that the triazole ring needed to be fully 
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substituted by introducing an alkyl chain, in particular an ethyl chain. This would bring the 
structure of our triazole compounds closer to the structure of lersivirine (Figure 27).  
 
Figure 27 
 
3.7. Attempts to introduce an ethyl chain onto the triazole ring 
As previously mentioned, CuI catalysed Huisgen cycloaddition reactions are explicitly used for 
the reaction of azides with terminal alkynes. As a result, we could not use this method to 
synthesize the desired tri-substituted triazole rings using an internal alkyne and benzyl azide.  
However, knowing how well these reactions worked in synthesizing the 1,4-triazole products 
we considered whether it would be possible to deporotonate the readily formed triazole ring at 
the 5-position and then introduce the desired ethyl chain onto the triazole ring using an 
appropriate alkyl halide. Only two papers were found that claimed to employ this method 
successfully. The papers by Ehlers et al. and Ohmatsu et al. reported a number of instances 
where they were able to lithiate a disubstituted 1,4-triazole ring using n-butyllithium and 
introduce an ethyl or methyl chain using ethyl or methyl iodide (Scheme 9). 82, 83  
 
Scheme 9 Example of reaction carried out by Ehlers et al.82 
Having decided to employ this methodology on our system, a first step required that we protect 
the alcohol on the ethyl chain. After careful consideration of the steps to follow, tert-
butyldimethylsilyl (TBDMS) chloride was chosen for this purpose as it could be installed and 
removed selectively and under fairly mild conditions. Protection of the alcohol chain was easily 
obtained by the treatment of 32 with TBDMS-Cl in the presence of imidazole (Scheme 10). 
Purification by column chromatography yielded 88% of 34 as a white solid. 
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The appearance of two singlets at 0.87 ppm and at 0.00 ppm integrating for 9H and 6H 
respectively in the 1H NMR spectrum for 34 indicated that the protection of the alcohol with 
TBDMS-Cl had been successful. 
 
Scheme 10 
With the protected triazole compound in hand we could now attempt to install an ethyl chain 
onto the triazole ring using the strategy employed by Ehlers et al. and Ohmatsu et al. 82, 83  n-
BuLi was added to 34 at -78 °C followed by the slow addition of iodoethane (Scheme 11). 
Unfortunately this reaction was not successful and produced numerous products, as determined 
by TLC. We therefore abandoned this methodology as a potential route, and thus returned to the 
possibilities available to us in the azide-alkyne cycloaddition reaction. 
 
Scheme 11 
 
3.8. The RuII Catalysed Huisgen Cycloaddition Reaction 
The ruthenium catalysed azide-alkyne cycloaddition (RuAAC) reaction was first introduced by 
the groups of Fokin and Jia in 2005.84 They discovered that the RuAAC reaction between 
terminal alkynes and azides selectively synthesises the 1,5-triazole regioisomer. Furthermore, 
the RuAAC reaction can overcome the limitations experienced by the CuAAC reaction and 
catalyse the cycloaddition of azides with internal alkynes.85 
Ruthenium catalysed cycloaddition reactions are sensitive to the nature of the ligands 
associated with the ruthenium metal centre. In other words, the activity and regioselectivity of 
RuAAC reactions are dependent on nature of ligands.84 In a paper by Boren et al. a number of 
ruthenium complexes were used as catalysts in a cycloaddition reaction between benzyl azide 
and phenyl acetylene to determine which ligands provided the most efficient and regioselective 
cycloaddition reaction.84 They discovered that the ruthenium catalysts Cp*RuCl(PPh3)2, 
Cp*RuCl(COD) and [Cp*RuCl]4 gave 100% conversion to the 1,5-regioisomer. However, the 
Cp*RuCl(COD) catalyst is more labile compared to ruthenium catalysts with phosphine ligands 
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and displaced more readily. This catalyst was also found to be particularly advantageous in 
reactions involving aryl azides and internal alkynes.85 We had access to Cp*RuCl(COD) and we 
decided to test if this would be the case for our own set of compounds.  
As the RuAAC reaction can occur with internal alkynes as well as terminal alkynes it is thought 
to be unlikely that ruthenium acetylides are involved in the catalytic cycle, unlike the formation 
of copper acetylide species in the CuAAC reaction. Ruthenium catalysis or cyclotrimerization 
using Cp*RuCl(COD) proceeds via a ruthenapentamethylcyclopentadiene intermediate.85 The 
first step in this catalytic cycle is the displacement of the spectator ligands by coordination of 
the alkyne and azide components to the ruthenium metal centre to yield the activated 
ruthenium complex 35 (Scheme 12). This is subsequently converted to the 
ruthenacyclopentadiene intermediate 36 via oxidative coupling of the azide and alkyne. This 
step is thought to control the regioselectivity of the reaction. The new C-N bond forms between 
the least sterically hindered and more electronegative carbon of the alkyne and the terminal 
nitrogen of the azide. This then undergoes reductive elimination, releasing the triazole product 
and regenerating the ruthenium catalyst.85 
 
Scheme 12 Proposed mechanism for RuAAC reaction adapted from Boren et al.85 
For our purposes the internal alkyne 3-hexyn-1-ol was commercially available. As this is an 
asymmetric alkyne there was the possibility of two regioisomers being formed when carrying 
out the RuAAC reaction. A study by Majireck and Weinreb reported that cycloaddition reactions 
with propargylic alcohols form exclusively the regioisomer where the alcohol chain is 
positioned at position 5 of the triazole ring, which in our case would be adjacent to the 
methylene linker (Scheme 13).86 However, in an attempt to force the cycloaddition of the benzyl 
azide with 3-hexyn-1-ol to generate rather the desired regioisomer where the alcohol chain 
35 
36 
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occupies the 4-position of the triazole ring we considered introducing more bulk on the alcohol. 
We thought to achieve this by introducing a large protecting group on alcohol. 
 
 
Scheme 13 
 
3.8.1. Synthesis of tert-butyl(hex-3-yn-1-yloxy)dimethylsilane (38)  
 
Scheme 14 
Protection of the alcohol was easily achieved by stirring a solution of 3-hexyn-1-ol with tert-
butyldimethylsilyl chloride and imidazole in DMF at room temperature for approximately 3 
hours. After a simple workup and purification by column chromatography the product was 
obtained in 69% yield as a colourless oil. 
Analysis of the 1H NMR spectrum clearly showed the presence of singlets at 0.88 ppm and 
0.05 ppm which integrated for 9H and 6H respectively. These singlets correspond to the tert-
butyl and dimethyl functionalities respectively. 
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3.8.2. Synthesis of fully substituted triazole series of compounds 
With the protected alcohol 38 in hand we could proceed with the ruthenium catalysed 
cycloaddition reaction (Scheme 15). Toluene was the solvent of choice due to its high boiling 
point in case a higher activation was necessary. To ensure that the reaction conditions were 
inert the toluene was degassed for 10 min with nitrogen. The alkyne 38 and benzyl azide 5 were 
then added after which a second degassing was carried out. Finally the ruthenium catalyst 
Cp*RuCl(COD) was added and the reaction was heated to 60 °C and left for 18 hours.  
 
Scheme 15 
We noticed when analysing the TLC that two products had formed. We expected that these 
products corresponded to the regioisomers represented in Scheme 15. As both products had 
very similar Rf values we decided to keep the products combined and carry out the deprotection 
on the combined material. In doing so we hoped that removing the protecting group would 
result in a better separation of the two products allowing for easier purification and 
characterisation.  
Table 3 
Compound R1 R2 
39A & 39B H H 
40A & 40B  Cl Cl 
41A & 41B H CN 
42A & 42B Me Me 
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3.8.3. Deprotection of fully substituted triazole compounds 
 
Scheme 16 
The combined products 39A and 39B were taken up in methanol and 3 equivalents of 6N HCl 
was added at 0 °C. The deprotection was carried out at room temperature for approximately 1 
hour and as hoped, separation of the alcohols 43A and 43B was then possible by conventional 
chromatography. 
 
Analysis of the 1H NMR spectrum of both products A 
and B revealed similarities between the two spectra 
that reinforced our hypothesis that two 
regioisomers had been formed. In both spectra 
signals were observed for protons 6, 7, 8 and 9, as 
well as for the methylene linker 10. However, the 
chemical shifts for these signals differed between 
the two spectra. The signals at chemical shifts 
corresponding to the aromatic region of the two compounds remained unchanged. 
 
3.8.4. Employing NOE experiments to distinguish between the two regioisomers 
In order to unambiguously assign compounds 43A and 43B as the 1,4- or 1,5-regiosiomers 
(with regards to the position of the alcohol chain on the triazole ring) we once again employed 
the use of 1H NOE. Here we focused on the possibility of correlations between the methylene 
linker and the two substituents on the triazole ring (Figure 28).  
 
Figure 28 
 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 3: Synthesis of a Small Triazole Library 
40 
 
For both compounds, we irradiated at the chemical shifts corresponding to the methylene linker 
in the hope that the correlations observed in the one spectrum would allow us to 
unambiguously assign the regiochemistry. This would provide us with a clear indication which 
substituent on the triazole ring is adjacent to the methylene linker for each regioisomer. For the 
product A, irradiation at 5.56 ppm revealed clear correlations to signals at 2.74 ppm, 3.64 ppm 
and 7.14 ppm represented by the blue blocks on the 1H NMR spectrum (Figure 29). The signal at 
7.14 ppm corresponds to the aromatic protons and so a correlation between these protons and 
those on the methylene linker is to be expected for both compounds and is unhelpful. However, 
the observation of the signals at 2.74 ppm and 3.64 ppm is somewhat more helpful. Both of 
these signals are triplets and integrate for 2H. Both signals, therefore, correspond to the ethyl 
alcohol chain on the triazole ring. From these observations it is clear that the first product A 
corresponds to regioisomer where the ethyl alcohol chain is situated at position 5 of the triazole 
ring and the ethyl chain is at the 4-position.  
For the second product B we would expect to see correlations between the protons on the 
methylene linker and the protons on the ethyl chain. We again irradiated at the signal 
corresponding to the protons of the methylene linker at 5.52 ppm. Here we saw clear 
correlations to signals at 1.00 ppm, 2.57 ppm and 7.20 ppm also represented by the blue blocks 
on the 1H NMR spectrum (Figure 30). Once again the signal at 7.14 ppm corresponds to the 
aromatic protons. The signal at 1.00 ppm is a triplet and integrates for 3H, whereas the signal at 
2.57 ppm is a quartet and integrates for 2H. These signals, therefore, correspond to the ethyl 
chain on the triazole ring. Again from these observations we were able to prove that the second 
product B was the regioisomer where the ethyl chain was now situated at the 5-position. 
Figure 29 
Irradiated 
signal 
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Along with these two fully substituted triazole compounds, a further 5 were successfully 
synthesized (Table 4) using the exact same synthetic method. As with 43A and 43B the yields 
for these reactions were poor, but enough product was obtained for characterization purposes 
and for testing. Unfortunately compound 46B proved to be an exception as although we 
suspected we had formed both regioisomers we were unable to isolate both products as there 
was too little of 46B to isolate. 
Table 4 
Compound R1 R2 
%Yield 
A 
%Yield 
B 
43 H H 22 9 
44 Cl Cl 37 12 
45 H CN 29 13 
46 Me Me 29 - 
 
  
Irradiated 
signal 
Figure 30 
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3.9. Efficacy results for fully substituted triazole compounds 
The set of 1,4- and 1,5-triazoles were sent to the National Institute for Communicable Diseases 
(NICD) for evaluation against wild type HIV in a whole cell assay and the results are presented 
in Table 5 below.  
Table 5 
 
# R1 R2 CC50 A (µM) IC50 A (µM) CC50 B (µM) IC50 B (µM) 
43 H H >100 >100 >100 >100 
44 Cl Cl >100 72.6 >100 45.2 
45 H CN >100 >100 >100 >100 
46 Me Me >100 >100 - - 
 
Once again these compounds were found to be inactive against HIV with the exception of 44A, 
and 44B which were found to be weakly effective. This was a surprising discovery due to the 
similarity between these compounds and lersivirine.  
At this point we hypothesized that the underlying issue with regards to these compounds is a 
structural one. A paper by Mowbray et al. describing the synthesis of a series of pyrazole 
compounds leading to the discovery of lersivirine showed that the presence of two ethyl chains 
on the pyrazole ring presented the best efficacy results.51 We termed these ethyl chains the 
upper and lower arms of lersivirine (Figure 31). 
 
Figure 31 
If we made the assumption that our 1,4-triazole compounds (compounds B) bind to the 
allosteric pocket in a similar manner to lersivirine, then the ethyl chain on our compounds 
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would occupy the position of the “lower” arm on the ring towards the back of the allosteric 
pocket (Figure 32, left). Unfortunately, due to the nature of the triazole ring we could not 
introduce a fourth substituent so that our structures could closely mimic the fully substituted 
pyrazole ring of lersivirine. We hypothesized that perhaps we had focussed on the wrong ethyl 
chain and, as a result, the ethyl chain should occupy the position of the “upper” arm of 
lersivirine (Figure 32, right), thereby, occupying the Val179 pocket. In order to achieve this we 
would need to revise the layout of our triazole scaffold as it is impossible to have the ethyl chain 
in the upper region using the benzylic azide precursors we had been using throughout the 
synthesis of our small triazole library. We would need to synthesize the less conventional 2N- 
substituted triazole regioisomer 47. The synthesis of 2N-substititued triazole rings can only 
occur between terminal and internal alkynes and unsubstituted azides such as sodium azide.87 
 
Figure 32 Comparison of the proposed binding modes of 46B and 47 with lersivirine 
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3.10. Synthesis of 2N-triazole regioisomers 47 
To obtain the desired 2N- triazole regioisomer (Scheme 17), the alkyne would have to be built 
onto the benzyl moiety as opposed to the azide as was done previously. From here we envisaged 
that we could form the 2N-triazole ring with sodium azide and then introduce an alcohol chain 
at the 2N position using 2-bromoethanol. For the purpose of being able to make a direct 
comparison with the triazole compounds synthesized previously we would utilize the 3,5-
dimethyl aryl moiety. 
 
Scheme 17 proposed route to the 2N-regioisomer 
 
3.10.1. Attempts to synthesize 1,3-dimethyl-5-(pent-2-yn-1-yl)benzene (48)  
In the synthesis of 48, our initial strategy was to quite simply use the alkynyl anion as the 
nucleophile, and react it with benzyl chloride (Scheme 18). To our surprise there was very little 
literature precedence for such a strategy, especially with regards to the usage of short chain 
alkynes. However, we decided to attempt this synthetic route regardless as all the starting 
materials were readily available. As a slight technical difficulty, 1-butyne has a low boiling point 
and so it was imperative that all reactions were carried out below 8 °C. 
Unfortunately, our first attempt to synthesize the alkyne 48 by carrying out a simple 
nucleophilic substitution reaction with 3,5-dimethylbenzyl chloride, n-BuLi and 1-butyne was 
unsuccessful. 
 
Scheme 18 
A survey of the literature revealed a slightly more complex procedure which involved a copper 
promoted coupling reaction between terminal alkynes and benzyl halides.88 The paper that 
reported this procedure focused largely on the coupling of benzyl halides with alkyl propiolates 
with the use of copper iodide, potassium carbonate and tetrabutylammonium iodide. However, 
they did report using the same reaction conditions for the coupling of benzyl chloride with 
hexyne. Unfortunately in our hands, this reaction did not proceed at all.  
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3.10.2. Synthesis of 1-(3,5-dimethylphenyl)pent-2-yn-1-one (53) 
 
Scheme 19 
Having been unsuccessful in our previous attempts, we now directed our attention to the fact 
that in stark contrast to the sparse amount of literature describing reactions involving alkylyl 
anion nucleophilic substitution onto benzyl chlorides, the literature describing the same 
substitution reaction onto acyl chlorides was far more abundant. Therefore, we considered this 
same strategy with the knowledge that we could to remove the ketone at a later stage in the 
synthesis. This procedure was reported by Verkruijsse et al.89 Here they report preparation of 
acetylenic ketones through an alkynylzinc chloride intermediate.  
However, we first had to synthesize 3,5-dimethylbenzoyl chloride 52 from 3,5-dimethylbenzoic 
acid 51 (Scheme 19). This reaction was proceeded without incident by heating the benzoic acid 
in excess of thionyl chloride under reflux at 80 °C for 18 hours. The thionyl chloride was 
removed and the resulting 3,5-dimethylbenzoyl chloride was taken crude to the next step.  
With the benzoyl chloride in hand we could carry out the procedure outlined by Verkruijsse et 
al. (Scheme 20).89  
 
Scheme 20 
The first step in this reaction sequence was to lithiate the alkyne (Step A). However, as 1-butyne 
is a gas at 8 °C great care had to be taken to ensure that the reaction was kept at a low 
temperature at all times. In order to ensure that we were, in fact, working with a sufficient 
amount of 1-butyne, we decided to first condense the butyne gas by releasing the gas into a 
round bottomed flask that was cooled to about -50 °C. We attempted to condense an excess 
amount of the butyne gas as we would control with stoichiometry of the reaction with n-BuLi. 
The formation of a clear liquid at the bottom of the flask indicated that we had successfully 
collected 1-butyne and could, therefore, proceed with the reaction. From here the 1-butyne was 
carefully diluted with cold THF. This was followed by the addition of n-BuLi, all the while 
ensuring that the addition of solvent and reagents was slow enough so as not to heat up the 1-
butyne. Once we had lithiated the alkyne we warmed the reaction to 0 °C before adding the zinc 
chloride, forming the alkynylzinc chloride intermediate (Step B). In order for the alkynylzinc 
chloride to react with the benzoyl chloride a catalytic amount of Pd[P(Ph)3]4 had to be added to 
the reaction mixture preceding the addition of the benzoyl chloride. This, according to 
Verkruijsse et al.89 would activate the carbonyl for attack by the alkynyl intermediate. 
Furthermore, they reported that without the presence of catalyst this reaction would not occur 
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but rather result in a number of side products.89 Finally 3,5-dimethylbenzoyl chloride could be 
added (Step C) resulting in the formation of the desired acetylenic ketone 53.  
By monitoring the reaction on TLC, it was observed that almost immediately after the addition 
of 3,5-dimethylbenzoyl chloride it had appeared that the reaction had gone to completion. As we 
were unsure of the stability of 53 we decided to take the product into the next reaction crude. 
 
3.10.3. Synthesis of (3,5-dimethylphenyl)(5-ethyl-2H-1,2,3-triazol-4-yl)methanone (54) 
With the alkyne 53 in hand, we could directly synthesize the 4,5 disubstituted triazole ring 54 
using sodium azide (Scheme 21). It is in this step that the importance of the carbonyl group 
adjacent to the alkyne is made clear. According to literature, cycloaddition reactions between 
internal alkynes and unsubstituted azides often require high temperatures and give low yields. 
However, the presence of an electron withdrawing group adjacent to the alkyne improves the 
reactivity of the alkyne.90 
 
Scheme 21 
The crude alkyne 53 was taken up in DMF with 1,2 equivalents of sodium azide and the reaction 
was carried out at room temperature for approximately 7 hours. The reaction mixture was then 
acidified and the product was purified by column chromatography to yield 54 as a yellow solid. 
Unfortunately, analysis of the 1H NMR spectrum did not reveal any additional additional signals 
in comparison to 53 as the NH signal was not observed. However this phenomenon seemed to 
be in accordance with literature. Fortuitously the correct number of carbons in the 13C NMR 
spectrum along with the significant difference in Rf value between compounds 53 and 54 
indicated that we had achieved the desired product 54. At this point we decided that we would 
only know for sure once we had attempted subsequent steps in the reaction synthesis. 
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3.10.4. Synthesis of (3,5-dimethylphenyl)(5-ethyl-2-(2-hydroxyethyl)-2H-1,2,3-triazol-4-
yl)methanone (42) 
 
Scheme 22 
Having synthesized the triazole ring 54, we were now in a position to introduce the final 
substituent required on our scaffold. The addition of the alcohol chain onto the triazole 
compound 54 was carried out using 2 equivalents of potassium carbonate and 1.5 equivalents 
of bromoethanol in DMF.91 The reaction was carried out at ambient temperature for 
approximately 18 hours. Purification using column chromatography yielded 68% of 55 as a 
yellow solid.  
We were able to establish the presence of the alkyl chain through 
analysis of the 1H NMR spectrum for 55. Two multiplets at 4.62 ppm 
and 4.17 ppm were observed, both of which integrated for 2H. These 
correspond with protons at positions 6 and 7 of the of the alkyl 
chain. The presence of the alcohol was also observed due to the 
presence of a small triplet at 2.83 ppm integrating for 1H. 
 
3.10.5. Attempts to reduce the benzylic ketone to the corresponding alkane 
Once the fully substituted triazole ring was in hand the next step was to remove the benzylic 
ketone functionality to relinquish the desired methylene linker. The reduction of a ketone 
located between a phenyl group and heteroaromatic ring to the corresponding alkane had been 
successfully executed on a different scaffold within our research group and, as a result, we 
thought to use the same synthetic strategy on our scaffold.59 The reduction was carried out 
employing trifluoracetic acid and a large excess of triethylsilane (Scheme 23). However, on our 
scaffold this reaction resulted in incredibly poor yields, making even characterization difficult.  
 
Scheme 23 
After searching through the literature, however, we were able to find a possible alternative 
strategy to optimize this reaction. The literature revealed that the above mentioned reduction 
proceeds via the corresponding secondary alcohol, which is then eliminated in the presence of 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 3: Synthesis of a Small Triazole Library 
48 
 
TFA to form a stabilized carbonium ion. The triethylsilane then acts as a hydride donor.92 
Considering the mechanism by which this reaction occurred we envisaged that perhaps we 
could optimize this reaction by first reducing the ketone to the alcohol and then carrying out the 
reduction of the alcohol using triethylsilane and TFA (Scheme 24).93 A possible complication 
that we considered was that after reducing the ketone to the secondary alcohol, we would have 
two hydroxyl functionalities on our scaffold 56. Although this problem could be readily solved 
by selectively protecting the primary alcohol, literature suggested that this precaution would 
not be necessary. A paper by Gevorgyan et al. suggested that reduction of a primary alcohol with 
triethylsilane would require the presence of a strong Lewis acid.94  
 
Scheme 24 
With this in mind we proceeded with the reduction of the ketone without taking the 
precautionary measure of first protecting the primary alcohol. To this end, sodium borohydride 
was added to 55 in ethanol at 0 °C after which the reaction was allowed to proceed at room 
temperature. The starting material was consumed within 2 hours. The crude product 56 
required no purification and was obtained in 89% yield as a white solid.  
 
Analysis of the 1H NMR spectrum of 56 confirmed that the reduction 
of the benzylic ketone to the alcohol had been successful. The 
benzylic proton 8 was identified at 5.87 ppm as a doublet integrating 
for 1H. 
 
Having disposed of the ketone functionality, reduction of the resulting secondary alcohol was 
carried out without taking the precautionary measure of first protecting the secondary alcohol. 
To this end 56 was stirred with trifluoroacetic acid and an excess of triethylsilane. The reaction 
was run for 2 hours at room temperature, worked up and purified by column chromatography 
to yield 47 in 63% yield as a white solid. 
Analysis of the 1H NMR spectrum for 47 revealed that the doublet 
observed for 56 was no longer present. However, a singlet at 
3.92 ppm integrating for 2H was now observed which corresponded 
to the protons 8 on the methylene linker of 47.   
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3.10.6. Confirmation of the structure of 2-(4-(3,5-dimethylbenzyl)-5-ethyl-2H-1,2,3-
triazol-2-yl)ethanol (47)  
Having arrived at our desired compound 47, an important consideration is the fact that there 
are indeed three possible regioisomers upon substitution of the triazole ring with the alcohol 
chain (Figure 33). The first of which is the desired 2N-triazole, however, the 1,4- or 1,5-triazole 
regioisomers were also possibilities. In order to confirm that the isolated product was the 
desired regioisomer we decided to conduct NOE experiments. The 1,5-regioisomer was thought 
to be unlikely due to the fact that this would be a sterically crowded system, especially given 
that the presence of the carbonyl in 55 would result in a preferred co-planar ring system.87 
According to literature the preferred regioisomer is, in all likelihood, the 2N-triazole 
regioisomer. 87 In terms of the 1,4-triazole regioisomer we would expect to see correlations 
between the ethyl chain and the alcohol chain. 
Figure 33 shows the 2N-, 1,5- and 1,4-triazole regioisomers respectively. The blue circles 
represent the correlations we would expect to observe when we look at the results of the NOE 
experiment. 
If we had indeed synthesized the desired 2N-regioisomer then we would expect to observe 
through-space correlations between the protons on the methylene linker and those on the ethyl 
chain. However, we would also expect no correlations between either the methylene linker 
protons or ethyl chain protons and the ethyl alcohol chain. 
 
Figure 33 Possible regioisomers 
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Analysis of the 1D NOE spectra revealed that interactions were indeed observed between the 
methylene linker and the ethyl chain as expected. Irradiation of the ethyl chain revealed 
through-space correlations to the methylene linker, however, no further coupling was observed 
(represented by the red blocks). Furthermore, irradiation of the methylene groups on the ethyl 
alcohol chain revealed no correlation to any other group on the triazole ring (represented by 
the blue blocks). We assume that this is due to the fact that at the 2N-position of the triazole ring 
the ethyl alcohol chain is too far away for any correlations to the rest of the molecule to be 
observed. We can, therefore, conclude that we did indeed synthesize the desired regioisomer. 
Satisfied that we had synthesized the desired 2N-regioisomer we sent 47 for biological 
evaluation. 
 
  
Figure 34 
Irradiated 
signals 
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3.11. Efficacy results of 2-(4-(3,5-dimethylbenzyl)-5-ethyl-2H-1,2,3-triazol-
2-yl)ethanol (47) 
Having arrived at our target compound 47, we could now evaluate this triazole scaffold system 
for efficacy against HIV. The graph below shows the activity results of compound 47 (Figure 
35). The similarity of the two curves indicated that the EC50 value was similar to the CC50 which, 
in essence, meant that the little activity we did see was not a result of HIV inhibition but rather 
reflected the toxicity of this compound at these concentrations. As a result, we could conclude 
that the new scaffold 47 was not active against HIV RT. 
 
Figure 35 
Altogether a library of 15 triazole containing compounds was successfully synthesized but, 
despite their structural similarity to lersivirine, possessed little to no activity against HIV. 
However, we were able to thoroughly explore the possibility of 1,2,3-triazole compounds as 
novel scaffolds by introducing all possible regioisomers of this moiety. By doing so we were able 
to conclude that the 1,2,3-triazole functionality is not a suitable scaffold for the synthesis of 
novel NNRTIs of this scaffold format.  
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4.1. Indole-based NNRTIs 
There have been a number of instances in literature where different research groups employed 
an indole scaffold, in the development of novel NNRTIs. In most cases the indole was shown to 
serve as an auspicious scaffold as many of these candidate NNRTIs were shown to possess 
excellent activity against HIV RT. In 1993 Williams et al. reported the development of 5-chloro-
3-(phenylsulfonyl)indole-2-carboxamide 57 (Figure 36) which was shown to be potent against 
HIV RT with an IC50 value of 3 nM and was also shown to exhibit significant activity against 
clinically important mutations such as K103N and Y181C.95 Following the development of 
NNRTI 57, a number of research groups developed novel NNRTIs with an indole core, which, 
like compound 58 resulted as a derivation of 57 in order to improve its resistance profile.96 
Recently however, researchers focused on the development of indole based NNRTIs with a 
phosphorous in place of the sulphur, such as compound 59, which displayed significantly 
improved activity against HIV-RT.97 IDX-899 60 was developed by Indenix Pharmaceuticals as a 
promising drug candidate with a high genetic barrier to resistance and with an IC50 value of 1.2 
nM against wild type RT.98 This NNRTI made it to phase IIB clinical trials but unfortunately, 
development was halted due to adverse effects.99 
 
Figure 36 Some examples of indole based scaffolds employed in the development of novel NNRTIs 
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4.2. Introducing a novel concept 
The strategy for the design of our novel indole compound 62 involved combining elements of 
these indole scaffolds 61 with that of an indazole containing NNRTI 1 (Figure 37). Thus in a 
molecular hybridization approach, we envisaged that we would be able to retain the beneficial 
indole scaffold 61, but shift the aryl functionality to the 4-position as is found on 1 thereby 
arriving at 62.  
 
Figure 37 Combining structural elements of two NNRTI scaffolds to create the indole template 62 
By doing so we would be able to achieve π-π stacking interactions with the conserved amino 
acid residue Trp229 (Figure 38), as well as Tyr188. Furthermore, by maintaining a suitable 
carbonyl containing functional group, such as an ester, at the 2-position of the indole we would 
be able to simultaneously achieve hydrogen bonding interactions with the backbone of Lys101 
at the entrance of the allosteric pocket. This concept is completely novel as no other NNRTIs 
within this category have accomplished interactions to both Tyr188 and Lys101. Additional 
features of our design would include an alkyl group at position 3 to occupy the Val179 pocket 
and a halogen at the 5-position. Both of these additional structural features have been shown to 
be imperative to the activity of a number of NNRTIs.58 As a proof-of-concept and as a starting 
point in our synthesis we decided that we would employ methyl groups on the aryl ring at 
position 4 as opposed to the nitrile groups used for compound 1, as this would simplify 
synthesis without altering the binding mode. 
  
Figure 38 Predicted binding mode of compound 62 in the NNIBP showing key interactions to Trp229, Tyr188 and 
Lys101 
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For the synthesis of compound 62 we originally considered functionalizing commercially 
available 4-hydroxy indole. However, as we would have to introduce the ester onto the 2-
position we strategized that perhaps a more practical strategy would be to construct the indole 
with the ester functionality already in place. Fortunately, having combed through the literature, 
the synthesis of a 4-hydroxy indole scaffold was well documented by a number of research 
groups in a number of applications.100, 101 They employed the Knoevenagel-Hemetsberger 
reaction sequence which would not only provide the indole with the hydroxyl functionality in 
the 4-position but also an ester at the 2-position. This synthetic method was therefore ideal for 
our purposes. 
The Knoevenagel-Hemetsberger reaction sequence (also known as the Hemetsberger-Knittel 
reaction sequence) is considered a critical workhorse process particularly in an industrial 
setting and is popular due to the simplicity by which the indolization reaction can occur.102 This 
process is divided into three consecutive steps (Scheme 25). Step 1 involves the synthesis of an 
alkyl azidoacetate 64 from an alkyl haloacetate 63 with sodium azide. This step is followed by a 
base-promoted Knoevenagel condensation reaction between the alkyl azidoacetate 64 and an 
aryl aldehyde 65 to form the intermediary α-azido-β-arylacrylate 66. Finally, step 3 involves 
formation of the indole 67 through thermolysis of the α-azido-β-arylacrylate 66.102 
 
 
Scheme 25 The three steps required for the Knoevenagel-Hemetsberger reaction sequence to form our desired 
functionalized indole system. 
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4.3. Synthesizing the precursors for the Knoevenagel-Hemetsberger 
reaction 
The two precursors required for the synthesis of our proof-of-concept indole 62 includes ethyl 
azidoacetate 64 as this would provide the desired ethyl ester functionality at position 2 of the 
indole and a 2-phenoxy benzaldehyde 69 which would provide us with the hydroxyl 
functionality at the desired 4-position of the indole (Figure 39). With regards to the 
benzaldehyde we decided, for the sake of simplicity, to introduce the 3,5-dimethyl aryl group 
onto the benzaldehyde at the very beginning of our synthetic strategy. Literature has shown 
that a variety of groups at this position, regardless of the size is well tolerated.101 As 2-
bromobenzaldehyde 70 and 3,5-dimethylphenol 71 were readily available we envisaged we 
could couple the two reagents using an Ullmann reaction. 
 
Figure 39 
4.3.1. Employing an Ullmann-type coupling reaction to form the biaryl aldehyde 
precursor 
The Ullmann coupling reaction was discovered by Fritz Ullmann and has the reputation of being 
the most practical and useful method for the synthesis of aryl C-N, C-C and C-O bonds, 
particularly in industry, although it has been mainly used for the synthesis of biaryl ethers.103 
However, the synthetic scope was relatively limited as these reactions suffered from the use of 
harsh conditions and high temperatures (125 °C - 250 °C) as well as the use of stoichiometric 
amounts of copper catalyst required to obtain satisfactory yields.103, 104  
It was only in 2001 that the introduction of an improved copper-ligand system arose as a 
solution to these drawbacks. This new method was discovered by the research groups of 
Taillefer and Buchwald, which led to a resurgence in the use of Ullmann-type reactions.104 This 
development enabled for the reactions to occur at milder conditions (90 °C - 110 °C) and 
allowed for the use of only catalytic amounts of copper.105 A study by Marcoux et al. showed that 
cesium carbonate seemed to be the base of choice for these reactions, as it substantially 
improved yields in comparison to other carbonate bases.106 Furthermore, the choice of copper 
catalyst appeared to be less essential to the success of the reaction.103, 106 
Ma et al. reported that CuI in the presence of the ligand N,N-dimethylglycine hydrochloride was 
an efficient system to catalyse Ullmann-type coupling reactions between aryl halides and 
phenols in good to moderate yields at 90 °C. 107 This was an extension of work done previously 
where this system was used successfully for Ullmann-type aryl amination reactions. The 
reaction was found to be tolerant of both electron-rich and electron-poor aryl halides, however, 
sterically hindered phenols give lower yields.107 Due to the fact that the reagents for this 
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strategy were readily available and inexpensive, we decided to employ this procedure for the 
coupling of 3,5-dimethylphenol to 2-bromobenzaldehyde.  
4.3.1.1. Synthesis of 2-(3,5-dimethylphenoxy)benzaldehyde (69) 
 
Scheme 26 
For our first attempt at synthesizing the benzaldehyde 69 we employed the procedure reported 
by Ma et al.107 This entailed using a small excess of phenol 71 (1.3 eq) in the presence of Cs2CO3, 
CuI and DMG in dioxane (Scheme 26). However, this reaction never seemed to go to completion 
and due to the similarity in Rf value between the product 69 and benzaldehyde 70 we were 
unable to isolate the pure product. As the starting material was likely to interfere with the 
subsequent condensation reaction we decided that we would attempt to optimize the reaction 
by first increasing the amount of 3,5-dimethylphenol introduced in the reaction. Therefore, we 
attempted to perform the coupling reaction with bromobenzaldehyde 70 in the presence of 4 
equivalents of phenol. Through monitoring the TLC we were able to observe that by increasing 
the amount of phenol we were able to push the reaction to complection. A base wash with NaOH 
was required to remove excess phenol, as this provided complications when attempting to 
purify the product using column chromatography. This reaction produced 69 as a yellow oil and 
gave moderate to high yields.  
In the 1H NMR spectrum the characteristic aldehyde signal 12 was observed 
as a singlet at 10.52 ppm. Two broad signals at 6.83 and 6.69 ppm 
integrated for 1H and 2H respectively corresponding to the 3,5-dimethyl 
aryl ring protons 8 and 10. Mass spectral analysis reported a mass of 
227.1076 amu which corresponds with the expected mass of 227.1072 amu. 
 
4.3.1.2. Synthesis of the second required precursor ethyl 2-azidoacetate (64) 
 
 
Scheme 27 
The synthesis of ethyl azidoacetate was carried out with ease using a nucleophilic substitution 
reaction. Ethyl chloroacetate 72 was taken up in DCM and water in the presence of 
tetrabutylammonium hydrogen sulphate as a phase transfer catalyst and sodium azide.  
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 The 1H NMR and 13C NMR data obtained coincided with the NMR data 
reported in literature.108, 109 The signal for the methylene protons at position 
1 integrates for 2H and is observed as a singlet at 3.86 ppm and the ethyl 
chain signals at 4.23 and 1.28 ppm integrate for 2H and 3H respectively. For the 13C NMR 
spectrum signals are observed at 168.3, 61.8, 50.2 and 14.0 ppm. Unfortunately, the sample 
decomposed when sent for MS analysis, which was not surprising for this azide. 
 
4.4. Initial attempts to synthesize the indole product. 
4.4.1. Employing the Knoevenagel condensation reaction to synthesize the acrylate 
precursor 
The Knoevenagel condensation reaction between the aryl aldehyde 69 and alkyl azidoacetate 
64 occurs through an azido alcohol intermediate 73 (Scheme 28). This intermediate then 
undergoes an elimination to yield the acrylate product 68.110 
 
Scheme 28 Knoevenagel condensation reaction 
Initially we attempted a procedure for the Knoevenagel condensation reaction reported by 
Coowar et al.100 Sodium ethoxide was synthesized in situ from sodium in ethanol, and a mixture 
of azido ethylacetate 64 and benzaldehyde 69 in EtOH and THF was added to the reaction 
mixture. Unfortunately, using this method we were unable to isolate any of the desired products 
and monitoring the reaction by TLC revealed that numerous products were forming. 
However, upon returning to the literature we discovered that this undesirable result could be 
explained. In a paper by Heaner et al., it was reported that low yields were not uncommon with 
the synthesis of α-azido-β-arylacrylate and that there are two principal reasons behind the poor 
results for this reaction.102 The first suggests that the ethyl azidoacetate is unstable and 
decomposes in the presence of base which, as a result, then interferes with the condensation 
process. Secondly the hydroxide by-product that had been eliminated after the condensation 
reaction can result in the hydrolysis of the ester group of the azido acetate 64, the azido alcohol 
intermediate 73, as well as the acrylate product 68.102 
It was reported that to overcome these complications and to maximize yields was to introduce a 
sacrificial electrophile, such ethyl trifluoroacetate 74, to the reaction (Scheme 29).102 The 
sacrificial electrophile which, by definition has to be highly electrophilic, is introduced in the 
condensation reaction to react with the hydroxide by-product before it is able to hydrolyse the 
ester functionality of the desired α-azido-β-arylacrylate product. The reaction between the 
hydroxide and the ethyl trifluoroacetate produces a weak unreactive base. Furthermore, the 
sacrificial electrophile does not interfere with the reaction process as it does not contain an 
acidic proton.102 
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Scheme 29 A schematic representing the role of the sacrificial electrophile 
 
4.4.1.1. Synthesis of (Z)-ethyl 2-azido-3-(2-(3,5-dimethylphenoxy)phenyl)acrylate (68) 
 
Scheme 30 
In our first attempt at the modified reaction we used 3 equivalents of the ethyl trifluoroacetate 
to 1 equivalent of the benzaldehyde 69, along with 4 equivalents of ethyl azidoacetate and 4 
equivalents of base. This reaction yielded product 68 (Scheme 30) but only at a disappointing 
43% yield. However, we found that if we increased the amount of the sacrificial electrophile to 
be equal to the equivalence of ethyl azidoacetate employed in the reaction we were able to 
improve the yields to above 60%. With the conditions of this experiment having been optimized 
we were able to continue with the reaction sequence. 
The stereochemistry of the acrylate product was of importance as both the E and Z isomers 
could potentially be synthesized. It was imperative that the Z configuration be attained as the E 
configuration would not allow for the cyclization to occur and form the desired indole. A study 
carried out by Heaner et al. discovered that only one isomer was observed in the 1H NMR 
spectra for all the acrylate products that they had synthesized.102 Using density functional 
theory calculations they discovered that the Z-isomer is the preferred configuration as it is more 
thermodynamically stable than the E-isomer. Further study showed that the Z configuration had 
all the atoms in one plane whereas the E configuration, due to the steric clash between the ester 
functionality and the aryl group on either side of the alkene, lead to a distorted and 
unfavourable non-planar structure.102 
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In accordance with literature the presence of only one vinyl 
proton in our 1H NMR was indicative of the fact that only the 
one stereoisomer was synthesized. The vinyl proton (*) was 
represented by a singlet at 7.35 ppm. Mass spectral analysis 
provided a mass of 360.1314 amu (M+Na) which coincided with 
the calculated mass of 360.1324 amu. 
 
4.4.2. Describing the Hemetseberger indolization reaction. 
The Hemetsberger indolization reaction is typically carried out at high temperatures in non-
polar, high boiling solvents such as xylene, mesitylene and toluene.102 The reaction is believed to 
proceed via the formation of an azirene intermediate 75 (Scheme 31) which is accompanied by 
the release of nitrogen gas. Cyclization then occurs to form intermediate 76 which then 
undergoes tautomerism forming the more stable 5-membered ring 77.111 Fortuitously, the 
phenoxy functionality is ortho to the reacting vinyl azide, and therefore blocks the possibility of 
obtaining two products which would certainly be a problem if this group were rather meta to 
the vinyl azide. 
 
Scheme 31 Proposed mechanism for the Hemetsberger reaction adapted from Heaner et al.102 
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4.4.2.1. Synthesis of ethyl 4-(3,5-dimethylphenoxy)-1H-indole-2-carboxylate (77) 
 
 
Scheme 32 
In our attempt at the Hemetsberger indolization reaction to form indole 77, the azido acrylate 
68 was taken up in toluene, and then added to a second volume of toluene refluxing at 130 °C. 
Monitoring the reaction by TLC revealed that after approximately 18 hours, the indole 77 had 
formed. 
The observation of a broad singlet at 8.94 ppm integrating for 1H, 
was indicative that the formation of the indole had occurred 
successfully. This singlet correlates to the N-H of the indole. 
Furthermore, a notable signal shift was observed for protons 3 
and 7. Spectral mass analysis provided a mass of 310.1444 amu 
which corresponds to the calculated mass of 310.1443 amu. 
 
 
4.5. Functionalizing the 3-position of the indole 
Having successfully synthesized the desired scaffold 77, we could now attempt to functionalize 
the 3-position of the indole. In this instance, we sought to functionalize this 3-position with an 
ethyl chain to occupy the Val179 pocket in the NNIBP. This has been shown to have an influence 
on the activity of a compound in wild-type HIV-1 as well as in mutant strains of the virus.58 We 
envisaged that the best method to achieve functionalization at this position would be to first 
acylate the indole, yielding 78 (Scheme 33), and subsequently reduce the carbonyl down to the 
corresponding alkyl chain resulting in indole 79. Although we did consider directly alkylating 
the indole product 77 using, for instance, a Grignard reagent as a base. However, we decided 
against this strategy as we were concerned about the formation of a mixture of products due to 
the alkylation occurring at other points on the indole scaffold such as at the N position on the 
indole. Fortunately, the selective acylation of indoles at the 3-position is prevalent in literature. 
The most common method employed to acylate this position of the indole is to carry out a 
Friedel-crafts acylation reaction.112 This would result in the ketone 79 which, as we had 
discovered in the previous chapter regarding the biaryl triazole containing species, could 
subsequently be reduced with TFA and triethylsilane to yield the alkyl chain.  
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Scheme 33 Two probable synthetic pathways to the synthesis of indole 79 
 
4.5.1. The Friedel-Crafts acylation reaction 
For the Friedel-Crafts reaction mechanism the acid chloride 80 and aluminium chloride forms a 
relatively stable acylium complex 81 which acts as an effective electrophilic reagent in the 
acylation process (Scheme 34).113 This occurs through a halogen exchange between the acid 
chloride and aluminium chloride. The oxonium cation of the acylium complex that is formed is 
widely accepted as the primary acylating agent.114 The π electrons of the indole then act as a 
nucleophile, attacking the acylium complex, in the process disrupting the aromaticity of the 
indole giving the cation intermediate 82. Subsequent elimination of the proton from the sp3 
carbon bearing the acyl group to from indole 78 then serves as the final step in the Friedel-
Crafts acylation reaction. 
 
Scheme 34 The mechanism for the Friedel-Crafts acylaton reaction 
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The Friedel-Crafts acylation of indoles takes place mainly at the 3-position, being the most 
nucleophilic site on the indole provided the nitrogen is not an anion.115 However, it is possible 
that direct attack of the indole nitrogen can occur, leading to side products, although this is 
usually in minor quantities.112 Normally protection and deprotection steps may circumvent this 
complication, however, the presence of the electron withdrawing ester functionality at the 2-
position means that this is not a necessity and, as a result, acylation at the 3-position can occur 
without competition from the NH site and at high yields.116 This observation is further justified 
by successful acylation of the 3-position of ethyl 2-indolecarboxylates carried out by our 
research group just recently.59, 117 As a result, we expected acylation of the 3-position of our 
indole system to be carried out without incident. 
 
4.5.1.1. Synthesis of ethyl-3-acetyl-4-(3,5-dimethylphenoxy)-1H-indole-2-carboxylate 
(78)  
 
 
Scheme 35 
Treatment of the indole 77 with aluminium chloride and acetyl chloride in a Friedel-Crafts 
acylation proceeded without incident and the reaction provided yields of 70% and higher of the 
acylated product 78, which could be rapidly purified by column chromatography.  
The presence of a singlet at 2.64 ppm in the 1H NMR spectrum 
was indicative of the fact that the introduction of the ketone 
onto the indole had been successful. This peak integrated for 3H 
correlating to the methyl peak 12. Furthemore, analysis of the 
13C NMR spectrum showed that the characteristic ketone 
(carbon 11) signal was observed at 198.09 ppm. 
 
4.5.2. Reduction of the ketone to the desired alkyl substituent 
With the required number of carbons attached at the 3-position of the indole 78, we could now 
proceed to defunctionalize the ketone, leading to the desired ethyl substituent. 
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4.5.2.1. Synthesis of ethyl-4-(3,5-dimethylphenoxy)-3-ethyl-1H-indole-2-carboxylate (79) 
 
Scheme 36 
This method of reducing the ketone to the alkane has been employed successfully in our 
previous section (Chapter 3), although in this particular case we found it unnecessary to first 
reduce the carbonyl to the alcohol. Treatment of ketone 78 with TFA and TMS resulted in the 
alkane 79 being produced in moderate yields. 
Analysis of the 1H NMR provided the evidence that the 
reduction of the ketone to the alkyl chain had been carried out 
successfully. The two methyl signals 10 and 12 overlap to give a 
complex signal at 1.40 ppm integrating for 6H. This, as well as 
the presence of two quartets at 4.41 and 2.89 ppm both 
integrating for 2H provided evidence for the presence of an 
ethyl chain on the indole scaffold. 
 
With the compound 79 successfully synthesized, we were now in a position to evaluate its 
efficacy against whole cell HIV, and to this end it was handed over to our collaborators at the 
NICD. However, it was completely inactive against HIV RT. Nevertheless we did not despair and 
instead hypothesized that perhaps the inactivity had to do with the lack of a halogen at the 5-
position of the indole. We made this hypothesis due to the fact that a halogen is always present 
on all indole based compounds synthesized both in our group and those in literature that have 
moderate to good activity against HIV (Figure 36). In fact, we discovered that there was an 
abundance of literature which supported this theory. 
 
4.6. Introducing a halogen at the 5-position in an attempt to improve 
activity 
Having studied the literature we were able to establish precedence that the presence of a 
halogen at the 5-position of the indole can increase the activity of a compound significantly.57, 58 
A paper by Jones et al. reported the synthesis of a series of indazole containing NNRTIs, also 
with a phenoxy functionality at the 4-position such as compound 1 mentioned previously. They 
reported the activities of their indazole compounds with and without a halogen at the 5-position 
(compounds 83, 84 and 1, Figure 40). They reported that by introducing a fluorine at the 5-
position of their indazole compound to give 1 they had managed to improve on the activity of 
the indazole compound by almost 7 fold. However, when they introduced a chlorine at this 
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position (84) the activity of these compounds decreased due to a steric clash caused by the 
large chlorine atom forcing the biaryl ether into a non-ideal configuration for binding.57 
 
Figure 40 The influence of introducing a halogen on some indazole NNRTIs57 
From these results and due to the similarity between our indole structure and their indazole 
structures, we decided that we would also attempt to introduce the smaller fluorine atom on 
our own indole based compounds at the 5-position. 
 
4.6.1. Our attempts to introduce a fluorine onto the indole scaffold 
Unfortunately there was little precedence for adding a halogen onto the 5-position of the indole 
and, as a result, we had to employ the methods reported by Jones et al. in the synthesis of their 
indazole series.57  
For the fluorination reaction Jones et al. reported the use of Selectfluor as the fluorinating agent 
(Figure 41).57 This reagent has become a popular source of electrophilic fluorine due to its 
stability and relatively low toxicity in contrast with fluorine gas which was originally used as a 
source of electrophilic fluorine.118  
 
Figure 41 Selectfluor 
For the fluorination of our indole 79 we envisaged that the electron donating phenolic 
functionality at the 4-position of the indole would promote fluorination at position 5, which is 
ortho to the phenoxy functionality. Furthermore, we hoped that selective fluorination at this 
position would be promoted due to fact that the 2 and 3-positions of the indole are occupied by 
the ester group and ethyl chain respectively. 
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4.6.1.1. Synthesis of ethyl-4-(3,5-dimethylphenoxy)-3-ethyl-5-fluoro-1H-indole-2-
carboxylate (85) 
 
 
Scheme 37 
For our first attempt at the fluorination reaction we added selectfluor to a solution of the indole 
79 suspended in acetonitrile. The reaction was only carried out for 2 hours due to the formation 
of a number of additional products. However, using column chromatography we were able to 
isolate what appeared to be the indole product 85. Unfortunately, at this point, we ran into 
some complications with regards to the purification of this compound as the Rf of the 
fluorinated indole 85 and the unfluorinated indole 79 were very similar. In an attempt to purify 
this compound we decided to carry out a Boc protection reaction. We envisaged that by 
protecting the indole with a Boc group we may achieve a better separation between indole 
products 85 and 79. Furthermore, we realized that by introducing a Boc protecting group onto 
the indole, we would be provided with an opportunity to run an NOE experiment in order to 
verify the fluorination position. 
4.6.1.2. Synthesis of 1-tert-butyl 2-ethyl-5-fluoro-1H-indole-1,2-dicarboxylate (86) 
 
Scheme 38 
We were able to carry out the Boc protection on the crude indole 85 in the presence of DMAP in 
THF. As we had hoped, purification of the protected indole 86 afforded a better separation 
between the fluorinated and non-fluorinated products. 
We were able to establish that the reaction had taken place by 
analysing the 1H NMR spectrum. The absence of the broad NH 
peak in the 1H NMR spectrum indicated that the protection 
reaction had been carried out successfully. This observation was 
further justified by the presence of the singlet at 1.68 ppm which 
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integrated for 9H corresponding to the methyls 15 belonging to the Boc group.  
4.7. Analysis of the NOE results to determine the position of the fluorine 
NOE experiments were carried out on our protected indole in the hope that we would be able to 
determine where the fluorine atom was situated by irradiating signals corresponding to the Boc 
tert-butyl groups, the indole aromatic protons and the protons on the upper aryl ring (Figure 
42). The rationale here was that if the fluorination had occurred at the desired position then 
ideally we would be able to observe correlations between the methyl protons on the protecting 
group and the protons on the aromatic ring but we would not observe any correlations between 
the upper aryl ring protons and the aromatic protons on the indole.  
 
Figure 42 
When we analysed the NOE results we did not observe any through-space correlations between 
the protons on the upper aryl ring and the protons on the indole which was expected should the 
fluorination have occurred at the correct position on the indole. However, when the signals of 
the Boc tert-butyl protons were irradiated no correlations to the aromatic protons were 
observed either which was odd. 
Indeed, instead of the expected correlations between these signals we were presented with 
some unusual and rather perplexing observations. On closer inspection of the NOE results we 
discovered correlations between the indole aromatic protons (6 and 7 supposedly) and the 
protons on the ethyl chain 11 and 12 (Figure 43). This observation seemed highly unlikely as we 
expected the ethyl chain to be far enough from the the aromatic protons for no correlations to 
be observed. In addition, one of the indole protons was clearly a singlet, and this did not 
correlate with our anticipated structure. 
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Figure 43 
At this point we decided that we would remove the Boc group to obtain a more polar sample 
which would be more likely to crystalize and be ameanable to X-ray analysis. 
 
4.8. Removal of the Boc protecting group and subsequent NMR analysis 
 
Scheme 39 
The Boc protecting group on compound 86 was readily removed in the presence of an excess of 
trifluoroacetic acid in DCM. Once the reaction had run to completion, as monitored by TLC, the 
solvent was removed in situ and the product 85 was recrystallized from diethyl ether to yield 
the product as a white solid in a moderate yield, but excellent purity, thereby providing an 
opportunity for careful NMR analysis.  
If the fluorination had occurred in the correct position then the only aromatic signals we would 
observe would coincide with the upper aryl ring and with the two vicinal protons free from 
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substitution on the indole aromatic ring (Figure 44). Furthermore, for the two vicinal protons 
we would expect to observe two signals each existing as a doublet both with similar, if not the 
same, J coupling values.  
  
Figure 44 
At first glance it appeared that all was in order as all the expected aromatic signals appeared to 
be present (Figure 45). The 1H NMR did reveal two aromatic signals belonging to the protons on 
the indole ring. The signal at 7.11 ppm presented as a doublet and the other at 7.05 ppm as a 
doublet of triplets which we thought could be attributed to some long range coupling to the 
indole NH. Furthermore, both of these aromatic signals integrated for 1H. However, on closer 
inspection we realized that the J coupling values of the two signals differed significantly which 
could not be possible. 
 
Figure 45 
We realized at this point that the only way we would be able to properly explain the anomalies 
observed in the NOE spectrum of 86 and in the 1H NMR spectrum of 85 would be to obtain a 
crystal structure of our compound. 
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4.9. A study of the crystal structure reveals the cause of the observed 
anomalies in previous characterisation analyses. 
Fortunately, after some experimentation we were able to recrystallize 85 and obtain crystals of 
sufficient quality for X-ray analysis. The crystal structure we obtained was astounding as we had 
not predicted the observed results. To our astonishment the crystal structure showed that 
although the fluorine was situated at the desired position on the indole, the ethyl chain was not. 
Instead of at the 3-position as has always been the case when working with indoles in the past, 
the ethyl chain had been introduced onto the 7-position of the indole (Figure 46). 
 
Figure 46 The crystal structure obtained of compound 85. This image was prepared using XSeed v2.05. 
 
Although these results we obtained were unexpected, we were able to rationalize this 
phenomenon. Firstly, unlike previous indole compounds synthesized within our group, our 
indole scaffold possessed the phenoxy functionality situated at the 4-position of the indole 
which would be ortho/para directing on the aromatic ring. We had already established that 
without the phenoxy functionality at the 4-position, acylation does occur at the 3-position, even 
with the presence of the ester at the 2-position.117 Therefore, we hypothesized that the presence 
of the phenoxy group is enough to alter the most nucleophilic site on the indole from the usual 
3-position, to the observed 7-position. 
In addition to explaining the anomalies observed in the NOE and NMR experiments, this 
phenomenon could explain why the indole 79 that we had sent for biological evaluation 
previously had been found to be inactive against whole cell HIV-1. We considered the possibility 
that the presence of the ethyl chain at the 7-position (87) led to steric clashes with the allosteric 
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pocket due to the presence of Tyr318 and other amino acid residues crowding that region 
(Figure 47). 
 
Figure 47 
At this point, we took a measure of comfort in the fact that there could be a plausible 
explanation to the lack of activity of our compound. In order to establish whether our theory 
was founded, we decided to send our indole product 77, without the ethyl chain situated at the 
3-position, for biological evaluation (Figure 48). Fortunately, the obtained crystal structure 
assured us that at least the ester and phenoxy funtionalities were situated in the desired 
positions on the indole. We envisaged that this scaffold would serve as a suitable proof-of-
concept to indicate whether our aim to target both Trp229 and Lys101 was possible. To this end 
we sent this compound for biological evaluation. However, to our dismay the results obtained 
from the assays carried out on this compound indicated that it was also completely inactive 
against whole cell HIV. Even without the necessary halogen at the 5-position we would have 
expected the compound to have had some activity against HIV! 
 
Figure 48 
Unfortunately, these results seemed to imply that it may not be possible to achieve interactions 
with both Trp229 and Tyr188, as well as the backbone of Lys101 using a relatively rigid scaffold 
like the indole.  
In order test this theory we decided to synthesize the corresponding indole analogue without 
the ester at the 2-position.  
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4.10. Attempts to remove the ester functionality at position 2 using a 
quinoline/copper mediated decarboxylation reaction 
To remove the ester functionality from the 2-position we would need to carry out a 
decarboxylation reaction. However, this would require that the ester first be converted to the 
carboxylic acid. Fortuitously, there were a large number of examples in literature where a 
decarboxylation reaction was successfully carried out on the 2-position of an indole with 
varying substituents on differing positions on the indole. These procedures often entailed 
heating the indole under reflux in a high boiling point solvent such as quinoline and in the 
presence of a copper source such as copper powder or copper oxide.100, 119.  
 
4.10.1. Synthesis of 4-(3,5-dimethylphenoxy)-1H-indole-2-carboxylic acid (88) 
 
Figure 49 
In order to carry out the decarboxylation reaction, the ester had to be hydrolysed to the 
carboxylic acid given that very little literature precedence existed for direct decarboxylation 
form the ester. The hydrolysis of the indole ester was carried out with ease using an excess of 
potassium hydroxide in ethanol. Once all the starting material had been consumed the product 
was isolated without the need for further purification resulting in 95% of yellow solid as the 
product. 
The disappearance of the protons corresponding to the ethyl chain 
of the ethyl ester was indicative that the hydrolysis had been 
successful. Mass spectral analysis confirmed absence of the ethyl 
ester reporting a mass of 282.1122 amu corresponding to the 
expected mass of 282.1130 amu. 
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4.10.2. Synthesis of 4-(3,5-dimethylphenoxy)-1H-indole (89) 
 
 
Figure 50 
Having successfully hydrolysed the ester to the acid we could continue with the 
quinoline/copper mediated decarboxylation reaction. The indole was dissolved in quinoline 
with a catalytic amount of copper oxide and was heated to 200 °C. Unfortunately, the 
decarboxylation reaction afforded a very poor yield of only 6%. However, this was nevertheless 
enough product to send for biological evaluation. Our strategy at this point was to first evaluate 
the efficacy of 89 and if found to show promise in its HIV inhibition, then we would return to 
optimize this reaction. 
Analysis of the 1H NMR spectrum revealed that the carboxylic acid had 
been successfully removed. This conclusion was made due to the 
observation of a new complex signal in the aromatic region of the 
spectrum which integrates for 1H. This signal corresponds to proton 2 of 
the indole. Unfortunately, the yield was so poor that we were unable to 
get further characterization data. 
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4.11. Efficacy results for the unfunctionalized 4-phenoxyl indole (89) 
 
Having arrived at the 4-phenoxy indole scaffold 89 we could evaluate whether the presence of 
the ester at the 2-position of the indole was in fact detrimental to the activity of our desired 
compound. Compound 89 was handed to our collaborators at the NICD for biological 
evaluation.80, 81 However, even without the ester, our 4-phenoxy indole scaffold was completely 
inactive against whole cell HIV. Although results gave an average IC50 value of 3.41 µM and an 
average CC50 value of 7.86 µM.  
 
Table 6 Activity results for compound 89 
Although our indole scaffold 89 was still missing some of the desired substituents such as an 
ethyl chain at position 3 and a halogen at position 5, both of which were considered to be 
imperative for activity against HIV RT, the lack of activity of 89 was surprising. This is especially 
the case when one considers that without the ester present our scaffold (89) was becoming 
increasingly similar to the structure of indazole compound 1 (Figure 51).57 At this point we had 
decided not to pursue this scaffold, as the scaffold was now moving away from the novelty we 
had hoped to achieve by targeting the region of Trp229 and Lys101 simultaneously. 
 
Figure 51 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 5: The Design and Synthesis of a 3-Aminoindole-Based Scaffold as an Extension of a 
Lead Compound 
73 
 
Chapter 5: The Design and Synthesis of a 3-Aminoindole-Based 
Scaffold as an Extension of a Lead Compound 
 
5.1. The rationale behind our design 
Recently in our research group, a particularly potent methoxy-indole based compound 4 was 
synthesized (Figure 52).59 Not only was this compound potent against HIV RT with an IC50 value 
of 1 nM but was also found to maintain potency against problematic resistant strains of the 
virus, in particular the troublesome K103N mutation.59  
 
Figure 52 Representative schematic of 4 in the binding pocket showing π-π stacking interactions with Tyr188 and 
hydrogen bonding interactions to the backbone of Lys101. 
Unfortunately, problems with the stability of this compound ensured that 4, as it was, could not 
advance to drug candidate level. It was identified that the cause of the instability was the 
methoxy functionality occupying the Val179 pocket. In an acidic environment the methoxy 
functional group could be activated through protonation converting it into a good leaving group. 
The protonated methoxy functionality is subsequently eliminated to form the reactive 
electrophile 92 (Scheme 40). In vivo this reactive species 92 is vulnerable to nucleophilic attack 
by water which would afford the hydroxyl product 93. Furthermore since 93 is actually a 
precursor in the synthetic route to obtaining 4, its HIV activity has already been established and 
it is a very poor inhibitor.59 Therefore, inadvertent conversion of 4 to 93 in vivo is a serious 
problem. 
 
Scheme 40 
In order to combat this issue of instability we envisaged a strategy to replace the methoxy with 
a suitable and much more stable bioisostere. It was imperative that the choice of bioisostere 
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would be well accommodated within the Val179 pocket so as not to alter the binding orientation 
of the compound in the NNIBP. Furthermore, we wished to maintain the presence of the phenyl 
group at the 3-position of the indole as the π-π stacking interactions with Tyr181 were 
discovered to be essential for the activity of the compound.117 
To this end an amine-based compound 5 was envisaged which appeared to mimic 4 in terms of 
pharmocaphoric features, but did not possess a labile leaving group (Scheme 41). Molecular 
modelling studies were undertaken using Accelrys Discovery Studio software, with CDocker as 
the main docking tool, in order to compare the predicted binding mode of a 5 against the lead 
compound 4.120 We proposed that by replacing the methoxy with an aryl amine we would 
remove the potential for elimination to occur as the reactive species formed in the case of 1 
could not exist for the amino compound 5. The modelling results suggested that our proposed 
compound 5 bound to the NNIBP in a manner very similar to that of the lead compound 4 
(Figure 53). The ethylamine functionality was well accommodated in the Val179 pocket and 
hydrogen bonding interactions were maintained to the backbone of Lys101 as were the π-π 
stacking interactions with Tyr181 and the proposed inhibitor 5.  
 
Scheme 41 
 
Figure 53 Overlay of target compound 5 (orange) and lead compound 4 (green) (left) and schematic representing 
the binding mode of compound 5 in the binding site (right). 
These results were further supported by the CDocker energy scores calculated (Table 7). Both 
of these energy scores represent the receptor-ligand interaction energy with the CDocker 
Energy score taking into account the internal ligand strain energy. By comparing the scores 
between compounds 4 and 5, we found that the energy values were very close. This further 
supported the theory that compound 5 bound to the NNIBP in a similar fashion to the lead 
compound 4. 
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Table 7 
Compound 
  
CDocker Energy 
(kcal/mol) 
-52.059 -55.5512 
CDocker Interaction Energy 
(kcal/mol) 
-49.4207 -56.8945 
 
The promising docking results along with the proposed enhanced stability of the 3-amino indole 
derivative 5 was certainly encouraging. However, despite these promising results, we were 
nevertheless wary of a possible problem with respect to the required binding orientation of the 
nitrogen compound 5. The energetically favoured orientation of the nitrogen attached to an 
aromatic ring system is to adopt an sp2 hybridised trigonal planar arrangement to facilitate p-
orbital overlap with the adjacent aromatic ring (Figure 54). However, modelling studies show 
that the required binding configuration of the compound is such that this conjugation can only 
occur partially, if at all, as the p-orbital of the nitrogen appears to be out of plane with either of 
the adjacent aromatic systems. 
 
Figure 54 The binding configuration of compound 4 (left) compared to a more preferable configuration with the 
nitrogen in the same plane as the adjacent phenyl ring (right). 
With this concern in mind we embarked upon a search to see if there was indeed precedence for 
this binding configuration. Indeed a search of the protein data bank (PDB) revealed compounds 
which similarly possessed nitrogens with only partial sp2 character. Therefore, we considered it 
worth the risk to synthesize this compound and investigate its activity in comparison to the lead 
compound.  
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5.2. The paper behind our initial synthetic strategy 
Having identified the desired target molecule 5, we now embarked upon developing a synthetic 
strategy. To our surprise, the preparation of similar compounds had already been published. A 
paper by Hiremath et al. was discovered which described the preparation of 3-amino indole 96 
as a precursor in the synthesis of antibacterial agents such as indolobenzodiazepinone 
derivative 97. 121 The synthetic procedure (Scheme 42) involved a copper catalysed coupling 
between brominated indole 94 and an aniline to afford indole precursors 95 and 96 in 
moderate yields.121  
 
Scheme 42 
Compound 96 which is similar in structure to our target compound could be synthesized either 
by directly coupling the brominated indole 94 with substituted aniline, N-methyl-p-toluidine or 
by alkylating indole compound 95, itself having been obtained by coupling 94 with p-toluidine. 
This conveniently discovered methodology certainly seemed suitable for our purposes and we 
decided to make use of the latter option, as we envisaged that the less sterically demanding 
aniline could potentially be more reactive in the coupling reaction. Furthermore, this route 
would allow us to finally alkylate the nitrogen with either methyl or ethyl substituents, 
providing more scope for potential NNRTI derivatives (Scheme 43). To this end we envisaged 
that commercially available ethyl 5-chloro-indole-2-carboxylate 98 could be brominated 
exclusively at the 3-position to afford 99, which would be amenable to the coupling reaction 
with aniline yielding 100. Subsequently alkylation could provide the methyl and ethyl 
derivatives 5 and 101 respectively. 
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Scheme 43 Initial synthetic strategy 
With our synthetic strategy in hand we could initiate attempts to synthesize our target 
compound 5. 
 
5.2.1. Synthesis of ethyl 3-bromo-5-chloro-1H-indole-2-carboxylate (99) 
 
Scheme 44 
The first step in our synthetic strategy involved the bromination of ethyl 5-chloro-1H-2-
carboxylate 98 to afford compound 99. Fortunately, there is an abundance of procedures in the 
literature for the selective bromination of ethyl indole-2-carboxylates at the 3-position. This 
was easily attained using n-bromosuccinimide and afforded high yields. 
Analysis of the 1H NMR revealed only three aromatic signals 
corresponding to protons 4, 6 and 7. The singlet corresponding to 
proton 3 was not observed. Furthermore, analysis of the mass 
spectrum confirmed that the bromination had occurred as the 
results revealed a mass of 301.9591 amu which coincided with the 
calculated mass of 301.9583 amu. 
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5.2.2. Ullmann-type coupling in an attempt to obtain amine 100 
 
Scheme 45 
Having successfully synthesized the brominated indole 99 we hastened to attempt the coupling 
reaction using the conditions laid out by Hiremath et al. This entailed heating under reflux a 
mixture of 100, aniline, potassium carbonate and cupric oxide in pyridine.121 However, in our 
hands this reaction would not proceed. Therefore, we attempted to repeat the exact reaction as 
carried out by the authors (Scheme 46) employing p-toluidine. Despite several attempts at this 
strategy, the coupling product 102 still proved to be unobtainable.  
 
Scheme 46 
 
5.3. The search for an alternative aryl amination strategy 
Failing in this attempt we decided to abandon this method and consider alternative procedures. 
Remarkably, after reviewing the literature, we discovered that there was very little precedence 
for the amination of indole halides at the 3-position and only a few other viable procedures 
were identified. 
 
5.3.1. Attempting a Buchwald-Hartwig Reaction procedure. 
Amongst the few procedures we had identified as being a probable alternative for the synthesis 
of our amino indole compound was a more conventional Buchwald-Hartwig type reaction 
method.122 In this instance the brominated indole 103 was coupled with a substituted aniline, 
such as N-methylaniline or diphenylamine, in the presence of Pd(dba)2, tri-tert-butylphosphine 
and sodium tert-butoxide leading to the 3-amino indole 104 (Scheme 47).  
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Scheme 47 
This methodology certainly looked promising for the synthesis of our target compound 4, but 
unfortunately we did not have the specific tri-tert-butyl phosphine ligand on hand. Therefore, 
we substituted this with conventional triphenylphosphine. We hoped that even without the 
correct ligand we would be able to produce some product even if in not in the high yields 
reported in the paper.122  
Our initial attempts at this reaction involved trying to couple 99 to N-ethylaniline (Scheme 48) 
to afford the desired compound 5. Although we had argued previously that aniline may be more 
reactive, we were tempted to give the reaction a chance due to the fact that in the paper more 
sterically crowded amines such diphenylamine were employed successfully. However, when 
this reaction failed we attempted it again using aniline in an attempt to form compound 100. 
Unfortunately, even in this instance, the reaction afforded complex mixtures from which any 
product was impossible to isolate. 
 
Scheme 48 
At this point, we considered that perhaps the unprotected indole nitrogen was impeding the 
reaction by acting as a completing nucleophile or, as a second possibility, rendering the C-Br 
bond too stable by virtue of electron donation. To test this hypothesis we introduced a Boc 
protecting group onto 99. This was readily achieved affording compound 105 in good yield 
(Scheme 49). However, upon attempting the amination to form compound 106 we found that 
the Boc group made no difference to the end result, as the reaction continued to produce a 
complex mixture of products. 
 
Scheme 49 
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5.3.2. A final attempt to obtain compound 4 employing a coupling reaction procedure. 
As a final resort we turned to a procedure described by Barraja et al. Here, they made use of the 
respective amine as the solvent and carried out the reaction under phase transfer catalysis 
conditions to achieve displacement of the bromine on position 3 of the indole. For example, 
under these conditions they converted compound 107 to 108, albeit in a modest yield (Scheme 
50).123 
 
Scheme 50 
According to Barraja et al. the presence of a protecting group on the indole nitrogen reduced the 
ability for nucleophilic substitution to occur, therefore, we decided to keep the indole nitrogen 
unprotected. Furthermore, although we expected that our ester could be hydrolysed in the 
presence of KOH we did not consider this to be a problem as we could easily re-esterify at a later 
stage. 
With these considerations in mind we attempted the reaction by heating 99 in aniline, in the 
presence of KOH and dibenzo-18-crown-6 as the phase transfer catalyst (Scheme 51). However, 
as was becoming the trend with this scaffold, the reaction did not proceed at all and none of the 
desired product was obtained. 
 
Scheme 51 
 
5.4. Changing direction in our synthetic strategy 
At this point we decided to abandon this strategy of trying to aminate the brominated indole 
and began to consider the fact that we may have been approaching the synthesis of our target 
compound the wrong way around. We considered that perhaps it would be simpler to first 
install the amine at the 3-position, to form 109 (Scheme 52) and then build onto the scaffold by 
introducing the phenyl 100 and alkyl groups 5 individually. 
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Scheme 52 
A major consideration was that, having searched the literature, we realized that the entire 
indole scaffold would need to be constructed in order to achieve the desired substitution 
pattern for 109. Fortunately, we could employ methodology described by Romagnoli et al., and 
this would require only two steps to get to the desired indole scaffold 109.124 The first step in 
the reaction sequence involves the formation of N-ethoxycarbonylaniline 111 from 2-
aminobenzonitrile 110 treated with ethyl chloroformate, followed by a condensation reaction 
with bromoethanone 112 and cyclization to form the indole 113 (Scheme 53).124  
 
Scheme 53 
For our reaction sequence we needed a somewhat different substitution as we would ultimately 
require an ester at the 2-position (Scheme 54). In order to achieve this, it was decided that we 
could carry out the condensation reaction with ethyl chloroacetate instead of bromoethanone. 
Furthermore, we could employ commercially available 2-amino-5-chlorobenzonitrile 114 as 
our starting material as we envisaged that the presence of the halogen at this position would not 
cause conflict with subsequent steps in the synthesis of compounds 115 and 116, and would 
directly deliver the chloro at the 5-position of the indole.  
 
Scheme 54 Our synthetic strategy based on the methodology described by Romagnoli et al.124 
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5.4.1. Synthesis of ethyl (4-chloro-2-cyanophenyl)carbamate (115) 
 
Scheme 55 
Following the reaction sequence carried out by Romagnoli et al. the first step of this synthetic 
strategy involved the formation of carbamate 115 (Scheme 55). This was readily achieved by 
heating 5-chloro-2-aminobenzonitrile under reflux in the presence of ethyl chloroformate for 18 
hours. For this reaction no purification was required and the crude product was obtained in 
high yields. 
Analysis of the 1H NMR spectrum revealed a clear quartet integrating 
for 2H and a triplet integrating for 3H at 4.29 ppm and at 1.37 ppm 
respectively. These signals are indicative of the successful introduction 
of the carbamate on compound 115. Furthermore, a broad singlet 
integrating for 1H at 7.13 ppm corresponds to the expected N-H. Mass 
spectral analysis revealed a mass of 225.0426 amu which coincides with the expected mass of 
225.0431 amu. 
 
5.4.2. Synthesis of diethyl 3-amino-5-chloro-1H-indole-1,2-dicarboxylate (116) 
 
Scheme 56 
The subsequent condensation between carbamate 115 and ethyl chloroacetate, followed by 
intramolecular cyclization in the presence of NaH in DMF at ambient temperature proceeded 
with ease and resulted in the formation of indole 116 in good yields.  
The presence of two multiplets at 4.30 ppm and at 1.31 ppm, 
integrating for 4H and 6H respectively, coincides with the two ethyl 
groups on the carbamate and ester functionalities. A broad singlet 
at 5.07 ppm which integrates for 2H is indicative of the presence of 
the amine at the three position of the indole. 
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5.5. Functionalizing the Amine 
With the desired 3-amino indole 116 in hand we enthusiastically began our attempts to 
functionalize the amine. We had decided that we would first attempt to introduce the phenyl 
group onto the amine prior to the alkyl chain by employing a Buchwald-Hartwig type of 
methodology. We envisaged that if we attempted to introduce the larger phenyl group 
subsequent to the alkyl chain we could run into some complications based on steric effects.  
 
5.5.1. Synthesis of diethyl 5-chloro-3-(phenylamino)-1H-indole-1,2-dicarboxylate (117) 
The Buchwald-Hartwig method we decided upon involved heating under reflux a mixture of 
116 and an excess of bromobenzene in the presence of potassium phosphate, Pd(dba)2 and 2-
dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (Xphos) in toluene for 48 hours at 130 °C 
(Scheme 57).125  
 
Scheme 57 
This reaction we found was inexplicably inconsistent. Our initial attempts afforded product 117 
in low to moderate yields ranging between 20% and 40% despite various attempts at 
optimizing the reaction conditions. Interestingly, when we attempted to carry out the reaction 
at higher concentrations in an effort to optimize our yields we found that the carbamate group 
was removed. Although this result was not desired at this point due complications that the free 
indole nitrogen might provide with subsequent steps in the synthesis, it did provide us with a 
possible means to remove the carbamate at a later stage. Despite the inconsistencies 
experienced with this reaction we were able to moderately improve the yields at higher 
concentrations and produce enough product 117 to continue on with the synthesis. 
The signals in the aromatic region integrate for 8H which coincides 
with the presence of the protons on the phenyl ring as well as on the 
aryl part of the indole. Furthermore, a broad singlet belonging to the 
amine proton 11, integrating for 1H was observed at 7.71 ppm. 
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5.5.2. Synthesis of diethyl 5-chloro-3-(ethyl(phenyl)amino)-1H-indole-1,2-dicarboxylate 
(118) 
Having synthesized compound 117 we could move on to the second last step in our synthetic 
strategy which entailed introducing the ethyl chain onto the amine. As before we envisaged that 
we could simply deprotonate the amine with a suitable strong base and then introduce the ethyl 
chain using an alkyl halide. Our initial attempt entailed heating 117 in the presence of K2CO3 
(Table 8). However, this reaction was unsuccessful and the full amount of starting material was 
recovered. We then considered attempting alkylation of the amine using a stronger base such as 
NaH. In this instance, we observed the formation of a product which we were able to isolate only 
in a very poor yield of 7%. Analysis of the 1H NMR suggested that this could be the desired 
product 118 due to the fact that 6 proton signals comprising of 3 quartets integrating for 2H 
and 3 triplets integrating for 3H were observed which indicated that three ethyl chains were 
present on the structure. However, as the yield was so poor, which could impede our progress, 
we decided to attempt to optimize the reaction conditions. Initially we changed the solvent from 
DMF to THF, however, in this environment no reaction occurred.  
Table 8 
 
Attempt Base Solvent Temperature Yield 
1126 K2CO3 DMF 80 °C  - 
2127 NaH DMF rt 7% 
3 NaH THF rt - 
 
At this point, we decided that while we attempted to improve upon the yields of this reaction we 
would take the little material we had managed to isolate and advance to the next step in the 
synthesis as it was the final step. This step entailed the removal of the carbamate group from 
the indole nitrogen. 
 
5.5.3. An attempted deprotection to afford our target compound (5) 
In the paper by Romagnoli et al. the carbamate was removed by alkaline hydrolysis in the 
presence of NaOH in aqueous ethanol.124 On our scaffold these conditions would inevitably 
result in the hydrolysis of the ester functionality at the 2-position in addition to the removal of 
the carbamate. In order to reduce the number of steps by keeping the ester intact and avoid 
losing the precious little product we had, we sought an alternative strategy. We knew that a Boc 
group could be removed in the presence of an excess amount of K3PO4 and we knew that the 
carbamate could be removed in the same manner due to the accidental discovery made when 
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attempting to introduce the phenyl group in a too concentrated solution as mentioned 
previously. Unfortunately when we attempted to remove the carbamate under these conditions 
no reaction occurred and we struggled to retrieve the starting material 118. 
 
 
Scheme 58 
 
5.5.4. A last attempt to optimize the alkylation reaction 
While we were still struggling to improve the yields of the alkylation reaction using sodium 
hydride we had, fortunately, come across another procedure for the reaction which employed 
potassium tert-butoxide in DMF.128 When we carried out the alkylation using the alternative 
base, we noticed the distinct formation of a second product in addition to the product we had 
isolated using sodium hydride previously. We were intrigued by this second product as it had 
stained similarly to the first product on TLC. Having toyed with the idea that the carbamate, 
somehow, had been removed during the reaction we endeavoured to isolate both products 
which were subsequently purified using column chromatography and afforded in equally low 
yields of about 10%.  
Surprisingly, the 1H NMR spectra of the two products revealed a number of similarities. The 
most prominent being the fact that for both spectra, 6 signals indicating the presence of three 
ethyl chains, was observed.  
In the chemical shift region corresponding to the methylene protons of the three ethyl chains 
we can see the similarity quite clearly between the two products. For each spectrum three 
distinct quartets are observed each integrating for 2H. 
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Figure 55 Expanded region of 1H NMRs of products 1 (left) and 2 (right) showing signals corresponding to the three 
methylene groups 
However, when we looked at the chemical shift region showcasing the signals belonging to the 
methyl protons a more distinctive difference between the two spectra was observed. For the 
newly formed product the methyl signals overlap slightly whereas the methyl signals for the 
first product we isolated don’t overlap at all. This observation was important as it suggested 
that the original product we had isolated may have been the wrong product. This was based on 
the fact that for the starting product 117 a similar overlap for the methyl signals was observed. 
We could not imagine that introducing the ethyl chain onto the amine would affect the chemical 
shifts of the carbamate and ester signals so drastically, if at all. 
 
  
Figure 56 Expanded region of 1H NMRs of products 1 (left) and 2 (right) showing signals corresponding to the three 
methyl groups 
It was at this point that we hypothesized that during the alkylation step the carbamate had, in 
fact, been cleaved by the potassium tert-butoxide and had been replaced with the ethyl group. 
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As a result, we had formed a doubly alkylated product 119 in addition to the desired product 
118 (Scheme 59). We feared that in the case of sodium hydride, the stronger base lead to the 
formation of only the doubly alkylated product, which would explain why the deprotection 
reaction hadn’t worked.  
 
Scheme 59 
5.6. Identifying the two products 
In order to test our hypothesis and ascertain which product was which, we decided to compare 
the 13C NMR spectra. We could not compare the 1H NMR spectra of the two products as the 
spectra would, of course, be very similar. However, the 13C NMR would provide us with the 
answer as the spectrum for the desired compound 118 would have an extra carbon when 
compared with the doubly alkylated product 119. 
Figure 57 shows the 13C spectrum for the first product we isolated, whereupon we suspected 
alkylation had occurred at the amine as well on onto the indole nitrogen. If this had occurred, 
we would expect observe only 19 signals of which 7 would represent quaternary carbon 
centres. Analysis of the 13C spectrum revealed that the number of carbon signals observed 
coincides with what was expected for the doubly alkylated product 119.  
 
 
Figure 57 13C spectrum of products 1 (left) and 2 (right) 
The 13C spectrum for the second product isolated which we now anticipated to be the desired 
product 118. In this instance we had expected to observe one additional signal downfield 
corresponding to the carbonyl of the carbamate. As expected 20 carbon signals are observed of 
which 8 correspond to quaternary carbons with the additional carbonyl signal situated at 
150 ppm (Figure 57). 
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5.6.1. Another attempt at the deprotection to yield ethyl 5-chloro-3-
(ethyl(phenyl)amino)-1H-indole-2-carboxylate (5) 
Having now successfully isolated and identified the correct product we could once again 
attempt the deprotection of the carbamate using the same conditions we had employed for the 
incorrect product. 
 
Scheme 60 
For the deprotection reaction, the indole 118 and potassium phosphate were taken up in 
ethanol and heated to 70 °C for 3 hours. Subsequently purification by column chromatography 
afforded the desired product 5 in quantitative yield. 
 
Analysis of the 1H NMR of 5 revealed that the deprotection 
reaction had proceeded successfully due to the presence of a 
singlet at 9.16 ppm integrating for 1H which was indicative of the 
unprotected indole nitrogen 1. Furthermore, only two methylene 
signals, both integrating for 2H at 4.26 ppm and at 3.81 ppm, as 
well as two methyl signals at 1.23 ppm and 1.16 ppm integrating 
altogether for 6H were observed. Analysis of the 13C NMR 
spectrum further justified our observations that the reaction had 
been successful. Finally mass spectral analysis confirmed that 5 had a mass of 343.1200 amu 
which was in accordance with the calculated mass of 343.1213 amu. 
 
5.7. Efficacy results. 
Having finally arrived at our target compound 5, we could now assess the compounds efficacy 
against HIV and compare it to the efficacy of the lead compound. 
Figure 58 reveals the activity results for compound 5. Although compound 5 showed some 
activity against HIV RT with an IC50 value of 1.2 µM and a CC50 value of 22.8 µM it was, 
disappointingly, nowhere near as active as the lead compound with an IC50 value of 1 nM. 
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Figure 58 
In an attempt to explain the poor activity of our target compound, we considered two 
possibilities. The first pertained to the problem observed with regards to the binding 
configuration of our compound as described earlier in the chapter. Upon binding to the 
allosteric pocket, the aromatic amine is forced out of plane with the adjacent aryl ring, 5B 
(Scheme 61). The danger presented here is that without the favourable p-orbital overlap 
between the nitrogen and the adjacent aromatic systems, 5A, the nitrogen may revert to an sp3 
hybridization state. This occurrence would not only change the geometry of the nitrogen from 
trigonal planar to trigonal pyramidal but would also result in the nitrogen becoming basic. 
Although the change in geometry may still be well accommodated in the Val179 pocket, the 
basicity of the nitrogen would mean that in vivo at a pH of 7.4 the nitrogen would become 
protonated 120 and, as a result, no longer have as much of an affinity for the hydrophobic 
binding pocket. In addition, by forcing the compound into a less favourable position would 
result in a large energy penalty which, in essence, means that the molecule upon binding no 
longer can occupy a lowest energy configuration. 
 
Scheme 61 
The second possibility to explain the lack of activity of our compound relates to the electron rich 
nitrogen centre which, we hypothesized, could reduce the hydrogen bonding potential of the 
indole N-H.  
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We resolved to investigate whether the amine at the 3-position could have an effect on the 
indole N-H. To do this we first decided to compare the 1H NMR spectra of our target compound 
5 with compound 4 and, in particular, focus on the position of the indole N-H signal. If the 
nature of the functional group at the 3-position of the indole had any effect on the N-H we would 
expect a fairly obvious difference between the chemical shifts of the N-H peaks for both 
compounds. However, upon examination of both spectra we did not observe any significant 
difference in chemical shift between the indole N-H signal for both compounds. The small 
difference in chemical shift we reasoned could, more likely, be attributed to the fact that the 
position of the interchangeable N-H proton signal could vary depending on the concentration of 
the sample, as a result, this approach proved to be not entirely reliable.  
A second strategy to investigate if the amine had any effect on the hydrogen bonding character 
of the indole N-H was to carry out some density functional theory (DFT) calculations in order to 
determine the partial charges on the indole N-H proton for both compounds. Again, if the 
presence of the amine at the 3-position had any direct effect on the bonding character of the 
indole N-H we would expect that the positive partial charge on the N-H proton would be greater 
than for the N-H proton on the methoxy-indole scaffold.  
Table 9 displays the results of the DFT calculations carried out in both water and in a vacuum. 
Unfortunately, in either environment, there was no distinctive difference between the partial 
charges calculated for the N-H proton on compounds 4 and 5. These observations, along with 
the observed similarity between the chemical shifts of the N-H proton for both compounds 
suggest that the hypothesis that the electron rich amine reduces the hydrogen bonding 
character of the indole is possibly incorrect. 
Table 9 
Compound 
  
Calc. Mulliken Charge (H2O) 0.383 0.384 
Calc. Mulliken Charge (Vacuum) 0.381 0.383 
 
Having ruled out this possibility, it would appear that the orbital problem as the primary 
suspect to explain the low activity of our target compound.  
Although this compound had such poor activity it was worth investigating in an attempt to 
overcome the issue of instability with regards to the methoxy-indole compound. 
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Chapter 6: Conclusion 
 
In this project we set out to investigate the potential of novel scaffolds as NNRTIs. To this end 
we strategized the design and synthesis of three different scaffolds.  
The first of these involved a library of small, flexible triazole containing NNRTIS whose design 
was based on the promising drug candidate lersivirine. To this end we managed to synthesis a 
library of 15 compounds using three different forms of Click chemistry to obtain three different 
triazole regioisomers. Unfortunately, all of these showed little or no activity against whole cell 
HIV-1 despite their structural similarity to lersivirine. As a result, we concluded that the triazole 
ring was perhaps an unsuitable core scaffold for the design of NNRTIs. 
The second strategy involved the design and synthesis of a completely novel concept. Using an 
indole as our scaffold we sought to functionalize the 2 and 4-positions with appropriate 
functional groups in order to achieve π-π interactions with Trp229 and Tyr188 respectively, as 
well as hydrogen bonding interactions with the backbone of Lys101. To this end we were able 
to synthesis the indole scaffold. However, when attempts were made to functionalize the 3-
position with an alkyl chain we ran into problems as we were unaware of the electronic effects 
that would cause the alkyl chain to be introduced at the 7-position of the indole as opposed to 
the desired 3-position. At this point we had decided to evaluate the scaffold for efficacy against 
HIV as a proof-of-concept before attempting to solve the problem of putting on the alkyl group. 
However, we found that the basic scaffold had no activity against HIV. We were concerned that 
perhaps our aspirations to achieve the interactions to both regions of the NNIBP were not 
possible and as a result, we decided to remove the ester functionality in order to test this 
theory. We were able to successfully remove the ester by first albeit with low yields however, 
upon testing we found that even without the ester our compound had no activity against whole 
cell HIV-1. This was a somewhat baffling result and warrants further attention in a follow-up 
project. 
The third and final part of this project involved improving on the stability of a lead compound 
by replacing the problematic methoxy functionality with a suitable bioisostere. With the aid of 
molecular modelling we were able to design a 3-aminoindole derivative of the lead compound. 
We were able to successfully synthesize our desired 3-aminoindole target however, despite 
promising docking results this compound was found to have an IC50 value of only 1.2 µM, which 
was significantly less potent that the 1 nM IC50 value of the lead compound.  
Overall, we were successful in synthesizing all target scaffolds but ascertained that in their 
current forms they were not to be pursued. 
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Chapter 7: Future Work 
 
7.1. A revision of our 4-hydroxyindole target 
Despite having had no success in targeting both Trp229 and Lys101 simultaneously using the 4-
hydroxyindole scaffold discussed in chapter 4, we reasoned that it would still be worthwhile to 
pursue other scaffold options based on the 4-hydroxyindazole compound 1, synthesized by 
Jones et al.57 Once again using this compound as a starting point we envisaged that a hybrid of 
the indazole compound 1 with benzimidazolone compound such as compound 121 could create 
a novel compound with the desired efficacy to both wild-type and drug resistance HIV-1 
(Scheme 62). The discovery of benzimidazolone compound 121 as a potent NNRTI was first 
reported by Barreca et al. in 2007.129 Using this core in NNRTI drug design is not novel and this 
particular compound was found to have a low toxicity and activity profile comparable to 
efavirenz.129, 130  
Therefore, in a similar molecular hybridization approach as for our 4-hydroxyindole compound 
we envisaged we could introduce the aryl functionality of 1 to the 4-position of an imidazolone 
scaffold to afford compound 122 (Scheme 62). Once again, with the aryl functionality at this 
position we would be able to achieve π-π stacking interactions with conserved residue Trp229 
and Tyr188. Ideally the linker atom between the aryl functionality and the imidazolone core will 
be an oxygen however, we imagined that we could explore other options such as a carbon or 
sulphur atom as the linker atom. Additional features would include the introduction of an alkyl 
group at position 3, and a halogen at position 5. Furthermore, the presence of the carbonyl at 
the 2-position is advantageous as it renders the N-H proton to be more acidic and, therefore a 
better hydrogen bond donor. 
 
Scheme 62 
7.2. Exploring a variety of bioisosteres to improve the stability of a lead 
compound 
For future work on this project it remains imperative that we maintain our focus on improving 
the stability of the potent indole compound 4, due to its promising activity against wild type 
HIV-1 and mutant strains of the virus. Fortunately, we had not yet completely explored the 
scope of possible bioisosteres we could introduce to replace the acid labile methoxy 
functionality at the 3-position of the indole. Therefore, it was evident to us that this would be a 
good point to start in terms of future work.  
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To this end we proposed that the simplest option would entail replacing the problematic 
methoxy functionality of the lead compound 4 with an ethyl chain 123 (Figure 59). Not only 
would this ethyl chain occupy the same space in the Val179 pocket as the methoxy group but it 
would completely remove the possibility that elimination could occur at this position.  
 
Figure 59 
If we are able to synthesize the ethyl chain derivative and it is shown to have promising activity 
against whole cell HIV-1 then we would have to take into consideration that we would produce 
a racemic mixture of products. As a result, we would have to explore options to separate out the 
two diastereomers in order to test them separately (Scheme 63). 
 
Scheme 63 
 
We envisaged that we would be able to synthesize the ethyl derivative by first acylating ethyl 5-
chloro-indole-2-carboxylate 98 with benzoyl chloride to yield the acylated product 124. We 
knew that we could selectively acylate the 3-position on this particular scaffold as this was the 
same first step employed in the synthesis of lead compound 4. Subsequently we could carry out 
a Wittig reaction with methylmagnesium bromide on a Boc protected indole 125 and then 
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reduce the resulting alkene 126 to the desired ethyl chain derivative 127. This would be 
followed by removal of the Boc group to yield the desired product 123 (Scheme 64). 
 
Scheme 64 Proposed synthetic strategy for the synthesis of compound 2 
 
7.3. Getting creative and introducing an oxetane ring. 
Another strategy that we are particularly keen to explore involves replacing the methoxy 
functionality of the lead compound 4 with an oxetane ring 128 (Figure 60). The oxetane ring is 
of particular interest due to its ability to be chemically robust in both basic and acidic 
environments.131 Furthermore, by introducing the oxetane ring at this position we eliminate the 
problem of forming a racemic mixture of products whilst maintaining a similar pharmacophore 
to our lead compound. If we were to be successful in our endeavour to synthesize the oxetane 
compound 128 we would be breaking into new ground as no oxetane rings have been reported 
in the literature with regards to NNRTIs. 
 
Figure 60
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Chapter 8: Experimental 
 
8.1. General Procedures. 
8.1.1. Purification of Reagents and Solvents 
The chemicals used in the following experiments were purchased from Merck or Sigma Aldrich. 
Solvents used for chromatographic purposes were distilled by means of conventional 
distillation procedures. Solvents used for reaction purposes were dried over the appropriate 
drying agents and then distilled under nitrogen gas. Tetrahydrofuran was distilled from sodium 
metal, using benzophenone as an indicator. Dichloromethane, dichloroethane, 
dimethylformamide and acetonitrile were distilled from calcium hydride. Ethanol was distilled 
from magnesium turnings and iodine. Diethyl ether and dioxane were purchased with a ≥98% 
purity grade from Sigma Aldrich and then dried on activated 3Å molecular sieves. 
 
8.1.2. Chromatography  
Thin layer chromatography was performed using Merck silica gel 60 F254 coated on aluminium 
sheets. Visualization was performed with a UV lamp, using iodine on silica, or by spraying with a 
Cerium Ammonium Molybdate (CAM) or p-anisaldehyde or ninhydrin (NIN) or potassium 
permanganate (KMnO4) solution followed by heating. Column chromatography was performed 
on Merck silica gel 60 (particle size 0.040-0.063 mm) using one of or combinations of hexane, 
EtOAc, or MeOH as the mobile phase. 
 
8.1.3. Spectroscopic and physical data  
NMR spectra (1H, 13C) were recorded on a 300 MHz Varian VNMRS (75 MHz for 13C), a 400 MHz 
Varian Unity Inova (101 MHz for 13C), or a 600 MHz Varian Unity Inova (150 MHz for 13C). 
Chemical shifts (δ) are reported in ppm and J-values are given in Hz. Chemical shifts were 
recorded using the residual solvent peak or external reference. All spectra were obtained at 
25 °C unless otherwise reported. Spectroscopic data were processed using MestReNova v6.0.2.  
Mass spectrometry was performed on a Waters SYNAPT G2. Infrared spectra were recorded on 
a Thermo Nicolet Nexus 470 by means of Attenuated Total Reflectance (ATR) mode. Melting 
points were obtained using a Gallenkamp Melting Point Apparatus and are uncorrected. 
 
8.1.4. Other general procedures  
All reactions were performed under a positive pressure of 5.0 grade N2 or Ar unless water was 
used as a solvent. The glassware was flame-dried while under vacuum or oven dried overnight 
before being purged with N2 gas. Condensers were pre-dried at 120 °C for a minimum of two 
hours. Standard Schlenk techniques were employed when necessary. Solvents were removed 
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using a rotary evaporator followed by the removal of trace amounts of solvent using a high 
vacuum pump at ca. 0.08 mm Hg. 
 
8.2. Experimental Procedures Pertaining to Chapter 3 
8.2.1. Synthesis of (azidomethyl)benzene (7) 
 
Sodium azide (570 mg, 8.78 mmol) was added to a solution of benzylbromide 
(0.70 mL, 5.9 mmol) in a mixture of acetone (6 mL) and water (4 mL). The reaction 
was left to carried out for 18 h at room temperature, after which the reaction mixture 
was taken up in ethyl acetate and washed with water. The organic layer was isolated 
and dried over magnesium sulphate and then concentrated in vacuo to yield a crude 
yellow oil. The crude material was then purified on silica by column chromatography 
(2% EtOAc/Hexane) to yield a colourless oil (697 mg, 5.24 mmol, 90%). (Rf = 0.53, 
10% EtOAc/Hexane)  
The spectroscopic data for this product correlated with the literature.132 
1H NMR (400 MHz, Chloroform-d) δ 7.47 - 7.40 (m, 3H, ArH), 7.39 - 7.33 (m, 2H, ArH), 4.36 (s, 
2H, CH2) 
 
8.2.2. Synthesis of 1-(azidomethyl)-3,5-bis(trifluoromethyl)benzene (9) 
 
 The same procedure used for the synthesis of compound 7 was utilized for 
the synthesis of 9. The following equivalents were used: 3,5-
bis(trifluoromethyl)benzyl bromide (0.30 mL, 1.7 mmol), sodium azide 
(161 mg, 2.48 mmol), acetone (8 mL) and water (2 mL). This reaction 
yielded a colourless oil (532  mg, 1.98 mmol, quant.). (Rf = 0.66, 
20% EtOAc/Hexane). 
The spectroscopic data for this product correlated with the literature.133 
1H NMR (300 MHz, CDCl3) δ 7.86 (s, 1H), 7.79 (s, 2H), 4.55 (s, 2H, CH2). 
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8.2.3. Syntheis of 3-(azidomethyl)benzonitrile (11) 
The same procedure used for the synthesis of compound 7 was utilized for the 
synthesis of 11 but using DMF (10 mL) as the solvent. The following equivalents 
were used: 3-(bromomethyl)benzonitrile (1.0 g, 5.1 mmol) and sodium azide 
(3.32 g, 51.0 mmol). This reaction yielded a yellow oil (728 mg, 4.60 mmol, 90%). 
(Rf = 0.33, 20% EtOAc/Hexane)  
The spectroscopic data for this product correlated with the literature.134 
1H NMR (400 MHz, CDCl3) δ 7.59 (dd, J = 6.5, 1.5 Hz, 2H. ArH), 7.54 (dt, J = 7.8, 1.4 Hz, 1H, ArH), 
7.50 - 7.46 (m, 1H, ArH), 4.39 (s, 2H, CH2).  
 
8.2.4. Synthesis of 1-(azidomethyl)-3,5-dichlorobenzene (14) 
 
3,5-Dichlorobenzyl alcohol (300 mg, 1.71 mmol), sodium azide (141 mg, 
2.17 mmol) and triphenylphosphine (446 mg, 1.71 mmol) were suspended in 
DMF (10 mL) and the reaction mixture was heated to 90 °C under reflux. 
Carbon tetrachloride (4 mL) was then added and the reaction was allowed to 
carried out for 5 h. The reaction mixture was then cooled to room temperature 
and taken up in diethyl ether. The organic layer was washed with cold water. The organic layer 
was separated and dried over magnesium sulphate. The solvent was then removed in vacuo. 
The resulting crude oil was purified by silica gel chromatography (2% EtOAc/Hex) to yield a 
yellow oil (218 mg, 1.08 mmol, 68%). (Rf = 0.45, 2% EtOAc/Hexane) 
The spectroscopic data for this product correlated with the literature.135 
1H NMR (400 MHz, CDCl3) δ 7.33 (s, 1H, ArH), 7.21 (d, J = 0.7 Hz, 2H, ArH), 4.32 (s, 2H, CH2). 
 
8.2.5. Synthesis of 1-(azidomethyl)-3,5-dimethylbenzene (23) 
 The same procedure used for the synthesis of compound 14 was utilized for the 
synthesis of 23. The following equivalents were used: 3,5-methylbenzyl alcohol 
(500 mg, 3.67 mmol), sodium azide (287 mg, 4.41 mmol) and triphenylphosphine 
(960 mg, 3.67 mmol). This reaction yielded a colourless oil (327 mg, 2.03 mmol, 
55%). (Rf = 0.68, 20% EtOAc/Hexane) 
The spectroscopic data for this product correlated with the literature.135 
1H NMR (400 MHz, CDCl3) δ 7.01 (s, 1H, ArH), 6.96 (s, 2H, ArH), 4.28 (s, 2H, CH2), 2.36 (s, 6H, 
CH3).  
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8.2.6. Synthesis of (1-benzyl-1H-1,2,3-triazol-4-yl)methanol (29) 
 Copper iodide (46 mg, 0.24 mmol) was added to a solution of 7 (500 mg, 
3.76 mmol), propargyl alcohol (0.139 mL, 2.35 mmol) and DIPEA (0.90 mL, 
4.9 mmol) in acetonitrile (2.5 mL). The reaction mixture was carried out at 
room temperature for 5 h after which the mixture was diluted with ethyl 
acetate and quenched with water. The organic and aqueous layers were 
separated and the organic layer was dried over magnesium sulphate and then 
concentrated in vacuo yielding a pink solid. The crude material was purified 
on a silica gel column (1% MeOH/EtOAc) to yield a white solid (354 mg, 
1.87 mmol 80%). (Rf = 0.36, 1% MeOH/EtOAc) 
Mp 85-87 °C. 1H NMR (300 MHz, CDCl3) δ 7.37 (s, 1H, NCHC), 7.33 - 7.29 (m, 3H, ArH), 7.23 -
7.20 (m, 2H, ArH), 5.46 (s, 2H, CH2), 4.71 (d, J = 5.9 Hz, 2H, CH2), 2.07 (t, J = 6.0 Hz, 1H, OH). 
13C NMR (75 MHz, CDCl3) δ 148.28 (CHCN), 134.51 (ArC), 129.10 (ArC), 128.75 (ArC), 128.11 
(ArC), 121.81 (NCHC), 56.14 (CH2), 54.16 (CH2). HRMS-TOF MS ES+: m/z [M+H]+ calcd for 
C10H12N3O: 190.0980; found: 19.0973. 
 
8.2.7. Synthesis of 1-(azidomethyl)-3,5-bis(trifluoromethyl)benzene (30) 
The same procedure used for the synthesis of compound 29 was utilized 
for the synthesis of 30. The following equivalents were used: 9 (405 mg, 
1.53 mmol), propargyl alcohol (60 µL, 0.96 mmol), DIPEA (0.35 mL, 
2.0 mmol), CuI (18 mg, 0.10 mmol) and MeCN (2 mL). The reaction 
yielded a white solid (284 mg, 0.880 mmol, 92%). (Rf = 0.52, 3% 
MeOH/EtOAc) 
Mp 127-129 °C. 1H NMR (300 MHz, CDCl3) δ 7.82 (s, 1H, NCHC), 7.67 (s, 
2H, ArH), 7.49 (s, 1H, ArH), 5.59 (s, 2H, CH2), 4.76 (s, 2H, CH2), 1.98 (s, 1H, OH). 13C NMR (75 
MHz, DMSO) δ 149.02 (CHCN), 139.91 (ArC), 131.04 (q, J = 32.9 Hz CF3), 129.51 (ArC), 125.40 
(CCN), 123.70 (ArC), 122.53 (ArC), 55.46 (CH2), 51.81(CH2). HRMS-TOF MS ES+: m/z [M+H]+ 
calcd for C12H10N3OF6: 326.0728; found: 326.0737. 
 
8.2.8. Synthesis of (1-(3.5-dimethylbenzyl)-1H-1,2,3-triazol-4-yl)methanol (31) 
 
The same procedure used for the synthesis of compound 29 was utilized for 
the synthesis of 31. The following equivalents were used: 23 (122 mg, 
0.757mmol), propargyl alcohol (30 µL, 0.47 mmol), DIPEA (0.20 mL, 
0.99 mmol), CuI (10 mg, 0.047 mmol) and MeCN (2 mL). The reaction 
yielded a white solid (100 mg, 0.460 mmol, 98%). (Rf = 0.60, 
3% MeOH/EtOAc) 
Mp 101-103 °C 1H NMR (300 MHz, CDCl3) δ 7.46 (s, 1H, NCHC), 7.02 (s, 1H, 
ArH), 6.92 (s, 2H, ArH), 5.46 (s, 2H, CH2), 4.81 (d, J = 5.8 Hz, 2H, CH2), 2.33 (d, J = 0.6 Hz, 6H, CH3). 
13C NMR (75 MHz, CDCl3) δ 138.86 (NCHC), 134.29 (ArC), 130.43 (ArC), 125.98 (ArC), 121.46 
(ArC), 56.79 (CH2), 54.22 (CH2), 21.20 (CH3). HRMS-TOF MS ES+: m/z [M+H]+ calcd for 
C12H16N3O: 218.1293; found: 218.1295 
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8.2.9. Synthesis of 2-(1-(3.5-dimethylbenzyl)-1H-1,2,3-triazol-4-yl)ethanol (32) 
 
The same procedure used for the synthesis of compound 29 was utilized 
for the synthesis of 32 but using but-3-yn-1-ol as the alkyne. The 
following equivalents were used: 23 (130 mg, 0.807 mmol), but-3-yn-1-ol 
(40 µL, 0.50 mmol), DIPEA (0.20 mL, 1.1 mmol), CuI (10 mg, 0.050 mmol) 
and MeCN (2 mL). The reaction yielded a white solid (100 mg, 
0.432 mmol, 86%). (Rf = 0.75, 3% MeOH/EtOAc). 
1H NMR (300 MHz, CDCl3) δ 7.32 (s, 1H, NCHC), 7.02 (s, 1H, ArH), 6.93 (d, 
J = 5.6 Hz, 2H, ArH), 5.44 (s, 2H, CH2), 3.97 (q, J = 6.0 Hz, 2H, CH2), 3.00 - 2.89 (m, 2H, CH2), 2.58 
(t, J = 6.1 Hz, 1H, OH), 2.33 (t, J = 1.7 Hz, 6H, CH3). 
8.2.10. Synthesis of 3-((4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl)methyl)benzonitrile 
(33) 
 The same procedure used for the synthesis of compound 29 was utilized for 
the synthesis of 33. The following equivalents were used: 11 (247 mg, 
1.86 mmol), but-3-yn-1-ol (70 µL, 0.98 mmol), DIPEA (0.40 mL, 2.1 mmol), 
CuI (19 mg, 0.098 mmol) and MeCN (2 mL). The reaction yielded a white 
solid (102 mg, 0.45 mmol, 46%). (Rf = 0.21, 2% MeOH/EtOAc). 
Mp 129-131 °C. 1H NMR (300 MHz, DMSO) δ 7.70 - 7.65 (m, 1H, ArH), 
7.59 - 7.55 (m, 1H, ArH), 7.54 - 7.50 (m, 2H, ArH), 7.40 (s, 1H, NCC), 5.57 (s, 
2H, CH2), 3.98 (q, J = 5.9 Hz, 2H. CH2), 3.02 - 2.93 (m, 2H, CH2), 2.42 (t, J = 5.9 Hz, 1H, 
OH).13C NMR (75 MHz, DMSO) δ 148.01 (CCN), 140.88 (ArC), 135.96 (ArC), 134.97 (ArC), 
134.65 (ArC), 133.13 (ArC), 125.89 (NCHC), 121.52 (CCN), 114.72 (ArC), 63.33 (CH2), 54.74 
(CH2), 32.22 (CH2). HRMS-TOF MS ES+: m/z [M+H]+ calcd for C12H13N4O: 229.1089; 
found: 229.1092 
 
8.2.12. Synthesis of tert-butyl(hex-3-yn-1-yloxy)dimethylsilane (38) 
Imidazole (1.53 g, 22.4 mmol) was added to a solution of 3-hexyn-1-ol 
(1.1 mL, 10 mmol) in DMF (10 mL) at 0 °C. Once all the imidazole had 
been fully dissolved, tert-butyldimethylsilyl chloride (1.84 g, 
12.2 mmol) was added to the reaction mixture and the reaction was 
allowed to warm to room temperature. The reaction was carried out 
for 3 h. EtOAc was added to the reaction mixture and the organic phase was washed with brine. 
The organic phase was separated and dried over MgSO4, after which the solvent was removed in 
vacuo. The residue was purified by silica gel column chromatography (5% EtOAC/Hexane) to 
afford the product as a colourless oil (1.48 g, 6.97 mmol, 69%). (Rf = 0.56, 5% EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3) δ 3.62 (t, J = 7.2 Hz, 2H, CH2), 2.35 - 2.23 (m, 2H, CH2), 2.16 - 2.01 (m, 
2H, CH2), 1.04 (t, J = 7.5 Hz, 3H, CH3), 0.88 - 0.78 (m, 9H, CH3), 0.04 - -0.04 (m, 6H, CH3). 13C NMR 
(75 MHz, CDCl3) δ 82.88 (CCC), 76.35 (CCC), 62.54 (CH2), 26.03 (CH3), 23.30 (SiCC), 18.48 (CH2), 
14.34 (CH3), 12.53 (CH2), -5.15 (CH3). HRMS-TOF MS ES+: m/z [M+H]+ calcd for C12H25OSi: 
213.1675; found: 213.1662 
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8.2.13. Synthesis of 2-(1-benzyl-4-ethyl-1H-1,2,3-triazol-5-yl)ethanol (43A) and 2-(1-
benzyl-5-ethyl-1H-1,2,3-triazol-4-yl)ethanol (43B) 
Toluene (5 mL) was thoroughly degassed for approximately 15 minutes before the ruthenium 
catalyst Cp*RuCl(COD) (17 mg, 0.045 mmol) was added and the solvent was degassed again. 
This was followed by the addition of the alkyne 38 (478 mg, 2.25 mmol) and finally the benzyl 
azide 7 (300 mg, 2.25 mmol). After a final degassing of the reaction was heated to 60˚C and was 
allowed to carried out for 18 h. The reaction was allowed to cool to room temperature before 
being concentrated under reduced pressure. The material was then taken to the next step crude. 
To a solution of the crude protected triazole products in MeOH (5 mL), was added 6N HCl 
(0.60 mL, 3.6 mmol) and the reaction was allowed to stir at room temperature for 1.5 h. The 
reaction mixture was then concentrated in vacuo, taken up in EtOAc and washed with distilled 
water. The crude products were purified and isolated using column chromatography on silica 
gel (60% EtOAc/Hexane). 
43A was isolated as a white solid (61 mg, 0.26 mmol, 22%). (Rf = 0.40, 2% MeOH/EtOAc). 
Mp 96-98 °C. 1H NMR (300 MHz, CDCl3) δ 7.37 - 7.32 (m, 3H, ArH), 
7.21 - 7.17 (m, 2H, ArH), 5.61 (s, 2H, CH2), 3.64 (dd, J = 11.8, 6.4 Hz, 
2H, CH2), 2.80 (t, J = 6.5 Hz, 2H, CH2), 2.69 (q, J = 7.6 Hz, 2H, CH2), 1.65 
(t, J = 5.4 Hz, 1H, OH), 1.32 (t, J = 7.6 Hz, 3H, CH3). 13C NMR (101 MHz, 
CDCl3) δ 147.52 (CCN), 135.70 (ArC), 130.41 (CCN), 129.14 (ArC), 128.40 
(ArC), 127.32 (ArC), 61.20 (CH2OH), 52.29 (CH2), 26.24 (CH2), 18.70 (CH2), 
14.17 (CH3). HRMS-TOF MS ES+: m/z [M+H]+ calcd for C13H18N3O: 
232.1450; found: 232.1447 
 
 
43B was isolated as a white solid (25.0 mg, 0.11 mmol, 9%). (Rf = 0.26, 2% MeOH/EtOAc).  
 
Mp 75-77 °C. 1H NMR (300 MHz, CDCl3) δ 7.35 (dd, J = 6.9, 5.1 Hz, 3H, ArH), 
7.23 - 7.17 (m, 2H, ArH), 5.52 (s, 2H, CH2), 4.02 (q, J = 6.0 Hz, 2H, CH2), 3.02 (t, 
J = 6.3 Hz, 1H, OH), 2.87 (t, J = 5.8 Hz, 2H, CH2), 2.57 (q, J = 7.6 Hz, 2H, CH2), 
1.00 (t, J = 7.6 Hz, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 142.78 (CCN), , 
135.16 (ArC), 128.96 (ArC), 128.30 (ArC), 128.11 (CCN), 127.11 (ArC), 61.60 
(CH2OH), 51.95 (CH2), 27.98 (CH2), 15.94 (CH2), 13.18 (CH3). HRMS-TOF MS 
ES+: m/z [M+H]+ calcd for C13H18N3O: 232.1450; found: 232.1662 
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8.2.14. Synthesis of 2-(1-(3,5-dichlorobenzyl)-4-ethyl-1H-1,2,3-triazol-5-yl)ethanol (44A) 
and 2-(1-(3,5-dichlorobenzyl)-5-ethyl-1H-1,2,3-triazol-4-yl)ethanol (44B) 
The same procedure used for the synthesis of compounds of 43A and 43B was utilized for the 
synthesis of 44A and 44B. The following equivalents were used: 14 (309 mg, 1.53 mmol), 38 
(325 mg, 1.53 mmol), Cp*RuCl(COD) (12 mg, 0.031 mmol) and toluene (5 mL), then 6N HCl 
(0.20 mL, 1.3 mmol) and MeOH (5 mL). 
 The reaction yielded a yellow solid (46 mg, 0.15 mmol, 37%). (Rf = 0.28, 2% MeOH/EtOAc). 
Mp 153-155 °C. 1H NMR (300 MHz, CDCl3) δ 7.22 (t, J = 1.8 Hz, 1H, ArH), 
6.97 (d, J = 1.8 Hz, 2H, ArH), 5.47 (s, 2H, CH2), 3.69 (t, J = 6.1 Hz, 2H, CH2), 
2.69 (t, J = 6.1 Hz, 2H, CH2), 2.57 (q, J = 7.6 Hz, 2H, CH2), 1.22 (t, J = 7.6 Hz, 
3H, CH3). 13C NMR (75 MHz, CDCl3) δ 147.23 (CCN), 138.79 (ArC), 135.62 
(ArC), 130.66 (CCN), 128.51 (ArC), 125.68 (ArC), 61.23 (CH2OH), 50.85 
(CH2), 25.85 (CH2), 18.48 (CH2), 13.90 (CH3). HRMS-TOF MS ES+: m/z 
[M+H]+ calcd for C13H16N3OCl2: 300.0670; found: 300.0669 
 
The reaction yielded a yellow solid (15 mg, 0.050 mmol, 12%). (Rf = 0.21, 2% MeOH/EtOAc). 
Mp 112-114 °C. 1H NMR (300 MHz, CDCl3) δ 7.34 (t, J = 1.8 Hz, 1H, 
ArH), 7.08 (d, J = 1.8 Hz, 2H, ArH), 5.44 (s, 2H, CH2), 4.02 (t, J = 5.7 Hz, 
2H, CH2), 2.89 (t, J = 5.9 Hz, 2H, CH2), 2.60 (q, J = 7.6 Hz, 2H, CH2), 2.48 (s, 
1H, OH), 1.07 (t, J = 7.6 Hz, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 143.00 
(CCN), 138.40 (ArC), 135.74 (ArC), 135.23 (CCN), 128.71 (ArC), 125.58 
(ArC), 61.55 (CH2OH), 50.64 (CH2), 27.93 (CH2), 15.98 (CH2), 13.37 
(CH3). HRMS-TOF MS ES+: m/z [M+H]+ calcd for C13H16N3OCl2: 
300.0670; found: 300.0676 
 
 
8.2.15. Synthesis of 3-((4-ethyl-5-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl)methyl)-
benzonitrile (45A) and 3-((5-ethyl-4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-
yl)methyl)benzonitrile (45B) 
The same procedure used for the synthesis of compounds of 43A and 43B was utilized for the 
synthesis of 45A and 45B. The following equivalents were used: 11 (351 mg, 2.22 mmol), 38 
(470 mg, 2.22 mmol), Cp*RuCl(COD) (42 mg, 0.11 mmol) and toluene (5 mL), then 6N HCl 
(0.30 mL, 1.8 mmol) and MeOH (5 mL).  
The reaction yielded a white solid (43 mg, 0.17 mmol, 29%). (Rf = 0.36, 2% MeOH/EtOAc). 
Mp 137-139 °C. 1H NMR (300 MHz, CDCl3) δ 7.65 - 7.59 (m, 1H, ArH), 7.53 - 
7.40 (m, 3H, ArH), 5.66 (s, 2H, CH2), 3.78 (t, J = 6.0 Hz, 2H, CH2), 2.78 (t, J = 
6.0 Hz, 2H, CH2), 2.66 (q, J = 7.6 Hz, 2H, CH2), 2.19 (s, 1H, OH), 1.30 (t, J = 7.6 
Hz, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 147.16 (CCN), 137.17 (ArC), 
131.89 (ArC), 131.80 (ArC), 130.87 (CCN), 130.73 (ArC), 129.83 (ArC), 
118.21 (CN), 113.04 (ArC), 61.13 (CH2OH), 51.06 (CH2), 25.91 (CH2), 18.46 
(CH2), 13.91 (CH3). HRMS-TOF MS ES+: m/z [M+H]+ calcd for C14H17N4O: 
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257.1402; found: 257.1398 
 
The reaction yielded a white solid (19 mg, 0.074 mmol, 13%). (Rf = 0.22, 2% MeOH/EtOAc). 
Mp 85-87 °C. 1H NMR (300 MHz, CDCl3) δ 7.67 - 7.62 (m, 1H, ArH), 7.46 
(ddd, J = 10.1, 9.2, 4.6 Hz, 3H, ArH), 5.53 (s, 2H, CH2), 4.01 (t, J = 5.9 Hz, 2H, 
CH2), 2.88 (t, J = 6.0 Hz, 2H, CH2), 2.58 (t, J = 7.6 Hz, 2H, CH2), 1.04 (t, J = 7.6 
Hz, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 143.08 (CCN), 136.83 (ArC), 
135.28 (CCN), 132.10 (ArC), 131.51 (ArC), 130.53 (ArC), 129.98 (ArC), 
118.11 (CN), 113.24 (ArC), 61.54 (CH2OH), 50.83 (CH2), 27.96 (CH2), 15.96 
(CH2), 13.40 (CH3). HRMS-TOF MS ES+: m/z [M+H]+ calcd for C14H17N4O: 
257.1402; found: 257.1401 
 
8.2.16. Synthesis of 2-(1-(3,5-dimethylbenzyl)-4-ethyl-1H-1,2,3-triazol-5-yl)ethanol 
(46A) and 2-(1-(3,5-dimethylbenzyl)-5-ethyl-1H-1,2,3-triazol-4-yl)ethanol (46B) 
The same procedure used for the synthesis of compounds of 43A and 43B was utilized for the 
synthesis of 46A and 46B. The following equivalents were used: 23 (200 mg, 1.24 mmol), 38 
(264 mg, 1.24 mmol), Cp*RuCl(COD) (9.4 mg, 0.025 mmol) and toluene (5 mL), then 6N HCl 
(0.10 mL, 0.79 mmol) and MeOH (5 mL).  
The reaction yielded a white solid (43 mg, 0.17 mmol, 29%). (Rf = 0.50, 2% MeOH/EtOAc). 
Mp 151-153 °C. 1H NMR (300 MHz, CDCl3) δ 6.94 (s, 1H, ArH), 6.80 (s, 2H, 
ArH), 5.50 (s, 2H, CH2), 3.65 (d, J = 5.8 Hz, 2H, CH2), 2.79 (t, J = 6.3 Hz, 2H, 
CH2), 2.67 (q, J = 7.4 Hz, 2H, CH2), 2.28 (s, 6H, CH3), 1.83 (s, 1H, OH), 1.31 (dd, 
J = 8.1, 7.1 Hz, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 138.56 (ArC), 135.34 
(ArC), 129.84 (ArC), 124.89 (ArC), 61.14 (CH2OH), 52.06 (CH2), 26.00 (CH2), 
21.22 (CH3), 18.54 (CH2), 14.03 (CH3). HRMS-TOF MS ES+: m/z [M+H]+ 
calcd for C15H22N3O: 260.1763; found: 260.1765 
 
Unfortunately we were unable to isolate the desired 1,4-regioisomer 46B. 
 
8.2.17. Synthesis of (3,5-dimethylphenyl)(5-ethyl-2H-1,2,3-triazole-4-yl)methanone (54) 
3,5-dimethylbenzoic acid (300 mg, 2.00 mmol) was dissolved in thionyl chloride (1.2 mL, 
16 mmol) and the reaction was heated to 80 °C under reflux. The reaction was carried out for 18 
h, allowed to cool down and the thionyl chloride was then aziotroped off with an excess of 
toluene. The crude product was taken to the next step without further purification. 
An unknown amount of 1-butyne gas was condensed in a 3-necked r.bf. at -50 °C, after which 
THF (5 mL) was added dropwise. This was followed by the slow addition of n-BuLi (1.2 mL, 
1.7 mmol) at -50 °C. The reaction mixture was warmed to -20 °C before ZnCl2 (228 mg, 
1.67 mmol) in THF (5 mL) was added slowly. The reaction mixture was then warmed to 0 °C 
and allowed to stir for approximately 10min before the addition of Pd[P(Ph)3]4 (4.00 mg, 
3.34 µmol). The reaction was then warmed to 15 °C and the crude 3,5-dimethylbenzoyl chloride 
was added dropwise. After approximately 5 minutes the reaction had appeared to carried out to 
completion. The reaction mixture was diluted with diethyl ether and added to a saturated 
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solution of sodium bicarbonate. Liquid ammonia was then added and the reaction was shaken 
up vigorously. The phases were separated and the aqueous layer was washed once more with 
diethyl ether. The organic phases were then combined and dried over MgSO4. The organic 
solvent was removed in vacuo and the remaining brown crude material was again taken to the 
next step without purification. 
 
The crude alkyne (292 mg, 1.57 mmol) was taken up in DMF (5 mL). Sodium 
azide (122 mg, 1.88 mmol) was then added to the reaction mixture and the 
reaction was left to carried out for 7 h at room temperature. The reaction 
mixture was then poured onto ice and acidified with a 6N HCl solution until a 
pH of 2 or 3 was achieved. The product was then extracted with EtOAc and 
washed with distilled water and brine. The organic solvent was dried over 
MgSO4 and concentrated in vacuo. The crude product was purified by silica gel chromatography 
(20% EtOAc/Hexane) to yield the triazole product as an orange solid (245 mg, 1.07 mmol, 
quant.). (Rf = 0.11, 20% EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3) δ 7.82 (s, 2H, ArH), 7.23 (s, 1H, ArH), 3.10 (q, J = 7.5 Hz, 2H, CH2), 
2.38 (s, 6H, CH3), 1.34 (t, J = 7.5 Hz, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 182.88 (CO), 150.32 
(CCN), 150.24 (CCN), 137.98 (ArC), 137.42 (ArC), 134.79 (ArC), 128.04 (ArC), 21.29 (CH3), 18.62 
(CH2), 12.76 (CH3). 
 
8.2.18. Synthesis of (3,5-dimethylphenyl)(5-ethyl-2-(2-hydroxyethyl)-2H-1,2,3-triazol-4-
yl)methanone (55) 
2-bromoethanol (100 µL, 1.61 mmol) was added to a mixture of 54 
(245 mg, 1.07 mmol) and K2CO3 (295 mg, 2.14 mmol) in DMF (5 mL) 
at -8 °C. The reaction was allowed to warm to room temperature and 
was left to carried out for 18 h. Once completed the reaction mixture 
was quenched with distilled water and extracted with EtOAc. The 
organic layer was washed with brine and dried over MgSO4 and then 
concentrated in vacuo. The crude material was purified by silica gel 
column chromatography (20% EtOAc/Hexane - 60% EtOAc/Hexane) to yield the product as a 
yellow solid (197 mg, 0.72 mmol, 68%). (Rf = 0.30, 40% EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3) δ 7.74 (dd, J = 1.4, 0.8 Hz, 2H, ArH), 7.25 (d, J = 0.7 Hz, 1H, ArH), 4.66 
- 4.58 (m, 2H, CH2), 4.23 - 4.12 (m, 2H, CH2), 3.04 (q, J = 7.5 Hz, 2H, CH2), 2.83 (t, J = 6.5 Hz, 1H, 
OH), 2.41 (d, J = 0.6 Hz, 6H, CH3), 1.33 (t, J = 7.5 Hz, 3H, CH3). HRMS-TOF MS ES+: m/z [M+H]+ 
calcd for C15H20N3O2: 274.1556; found: 274.1555 
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8.2.19. Synthesis of 2-(4-((3,5-dimethylpheynyl)(hydroxyl)methyl)-5-ethyl-2H-1,2,3-
triazol-2-yl)ethanol (56) 
Triazole 55 (197 mg, 0.721 mmol) was dissolved in EtOH (5 mL). 
Sodium borohydride (109 mg, 2.88 mmol) was then added to the 
reaction mixture at 0 °C and the reaction was allowed to warm to 
room temperature and carried out for 4 h. The reaction mixture was 
then quenched with H2O and extracted twice with EtOAc. The organic 
layers were washed with brine and then dried over MgSO4 before 
being concentrated in vacuo to yield the product as a white solid (177 mg, 0.648 mmol, 89%). 
No further purification was required. (Rf = 0.10, 40% EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3) δ 6.99 (s, 2H, ArH), 6.93 (s, 1H, ArH), 5.87 (d, J = 4.6 Hz, 1H, CHOH), 
4.52 - 4.43 (m, 2H, CH2), 4.07 (dd, J = 9.9, 6.1 Hz, 2H, CH2), 3.06 (d, J = 6.4 Hz, 1H, OH), 2.63 (d, J = 
4.8 Hz, 1H, OH), 2.51 (q, J = 7.6 Hz, 2H, CH2), 2.30 (d, J = 0.5 Hz, 6H, CH3), 1.12 (t, J = 7.6 Hz, 3H, 
CH3). 13C NMR (75 MHz, CDCl3) δ 141.49 (NCC), 138.17 (ArC), 130.30 (ArC), 129.65 (ArC), 
124.21 (ArC), 69.18 (CHOH), 61.07 (CH2), 56.38 (CH2), 21.33 (CH3), 18.34 (CH2), 13.17 (CH3). 
 
8.2.20. Synthesis of 2-(4-(3,5-dimethylbenzyl)-5-ethyl-2H-1,2,3-triazol-2-yl)ethanol (47) 
Triflouroacetic acid (1 mL) was added to a suspension of 56 (177 mg, 
0.648 mmol) in triethylsilane (1.2 mL, 7.2 mmol). The reaction was 
carried out for two h at room temperature, after which the reaction 
mixture was quenched with sodium bicarbonate solution and 
extracted twice with EtOAc. The organic layer was washed with brine, 
dried over MgSO4, concentrated in vacuo and then purified by silica 
gel chromatography (20% EtOAc/Hexane - 60% EtOAc/Hexane) to yield the product as a white 
solid (105 mg, 405 µmol, 63%). (Rf = 0.42, 70% EtOAc/Hexane). 
Mp 63-65 °C. 1H NMR (300 MHz, CDCl3) δ 6.86 (s, 1H, ArH), 6.82 (d, J = 0.6 Hz, 2H, ArH), 4.51 - 
4.45 (m, 2H, CH2), 4.12 - 4.04 (m, 2H, CH2), 3.92 (s, 2H, CH2), 3.24 (d, J = 6.5 Hz, 1H, OH), 2.56 (q, J 
= 7.6 Hz, 2H, CH2), 2.29 (d, J = 0.5 Hz, 6H, CH3), 1.18 (t, J = 7.6 Hz, 3H, CH3). 13C NMR (75 MHz, 
CDCl3) δ 147.41 (CCN), 144.17 (CCN), 138.48 (ArC), 138.03 (ArC), 128.04 (ArC), 126.25 (ArC), 
61.18 (CH2), 56.09 (CH2), 30.79 (CH2), 21.26 (CH3), 18.11 (CH2), 13.24 (CH3). HRMS-TOF MS 
ES+: m/z [M+H]+ calcd for C15H22N3O: 260.1763; found: 260.1769 
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8.3. Experimental Procedures Pertaining to Chapter 4 
8.3.1. Synthesis of 2-(3,5-dimethylphenoxy)benzaldehyde (69) 
 Dioxane (20 mL) was added to a Schlenk tube and degassed for approximately 
10 min. To this was added 2-bromobenzaldehyde (3.2 mL, 27 mmol), 3,5-
dimethylphenol (13.2 g, 108 mmol), N,N-dimethylglycine hydrochloride (1.13g, 
8.10 mmol), cesium carbonate (13.2 g, 40.5 mmol) and copper iodide (516 mg, 
2.71 mmol). The reaction mixture was heated to 97 ˚C and carried out for 43 h. 
The reaction mixture was then cooled to room temperature and then diluted 
with EtOAc and washed with a cold 1 N NaOH solution. The NaOH solution was removed and the 
organic layer was washed with brine. The organic phase was removed in vacuo and the residue 
was purified on silica gel by column chromatography (3% EtOAc/Hexane - 10% EtOAc/Hexane) 
to yield a yellow oil (4.10 g, 18.1 mmol, 67%). (Rf = 0.52, 20% EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3) δ 10.53 (s, 1H, CHO), 7.96 (dd, J = 7.8, 1.4 Hz, 1H, ArH), 7.53 (ddd, J = 
9.8, 8.2, 1.8 Hz, 1H, ArH), 7.23 - 7.15 (m, 1H, ArH), 6.93 (d, J = 8.4 Hz, 1H, ArH), 6.85 (s, 1H, ArH), 
6.71 (s, 2H, ArH), 2.34 (d, J = 0.5 Hz, 6H, CH3). 13C NMR (75 MHz, CDCl3) δ 189.46 (CHO), 
160.22 (ArC), 156.37(ArC), 140.00 (ArC), 135.71 (ArC), 128.26 (ArC), 126.83 (ArC), 126.03 
(ArC), 123.09 (ArC), 118.64 (ArC), 117.04 (ArC), 21.31 (CH3). HRMS-TOF MS ES+: m/z [M+H]+ 
calcd for C15H15O2: 227.1072; found: 227.1076 
 
8.3.2. Synthesis of ethyl azidoacetate (64) 
Ethyl chloroacetate (0.90 mL, 8.2 mmol) and tetrabutylammonium 
hydrogensulfate (277 mg, 0.816 mmol) were added to sodium azide (1.06 g, 
16.3 mmol) suspended in a 1:1 mixture of dichloromethane (10 mL) and 
distilled water (10 mL). The reaction mixture was carried out for 18 h at room temperature. The 
aqueous layer was separated from the organic layer and washed with dichloromethane. The 
organic layers were combined and dried over MgSO4. The solvent was removed in vacuo and no 
further purification was required. This reaction yielded a brown oil (929 mg, 7.20 mmol, 89%). 
(Rf = 0.47, 20% EtOAc/Hexane). 
The spectroscopic data for this product correlated well with the literature.136 
1H NMR (300 MHz, CDCl3) δ 4.23 (q, 2H, CH2), 3.86 (s, 2H, CH2), 1.28 (t, 3H, CH3). 13C NMR 
(75 MHz, CDCl3) δ 168.25 (CO), 61.75 (CH2), 50.24 (CH2), 14.00 (CH3). 
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8.3.3. Synthesis of (Z)-ethyl 2-azido-3-(2-(3,5-dimethylphenoxy)phenyl)acrylate (68) 
Sodium (364 mg, 15.8 mmol) was added to stirring ethanol 
(10 mL). Once all the sodium had dissolved, ethyl azidoacetate 
(2.28 g, 17.7 mmol) and ethyl trifluoroacetate (2.1 mL, 
15 mmol) in a 1:2 mixture of EtOH (2 mL) and THF (4 mL) were 
added slowly dropwise at -8 ˚C. After which, benzaldehyde 69 
(1.00 g, 4.42 mmol) in EtOH (2 mL) and THF (4 mL) was added 
dropwise at -8 ˚C. The reaction was allowed to carried out for 18 
h at room temperature. The solvent was then removed in vacuo. The resulting residue was 
quenched with saturated ammonium chloride solution and extracted with EtOAc. The organic 
solvent was dried over MgSO4, conventrated in vacuo, and purified on silica gel by column 
chromatography (5% EtOAc/Hexane) to yield a yellow solid (969 mg, 2.87 mmol, 65%). (Rf = 
0.61, 20% EtOAc/Hexane). 
1H NMR (400 MHz, CDCl3) δ 8.32 - 8.26 (m, 1H, ArH), 7.35 (s, 1H, CHCN), 7.29 - 7.22 (m, 1H, 
ArH), 7.13 (t, J = 7.5 Hz, 1H, ArH), 6.84 (t, J = 8.2 Hz, 1H, ArH), 6.76 (s, 1H, ArH), 6.61 (s, 2H, ArH), 
4.33 (q, J = 7.1 Hz, 2H, CH2), 2.29 (s, 6H, CH3), 1.35 (dd, J = 7.5, 6.7 Hz, 3H, CH3). 13C NMR 
(101 MHz, CDCl3) δ 163.79 (CO), 157.29 (ArC), 155.98 (ArC), 139.94 (ArC), 130.76 (ArC), 
130.85 (ArC), 126.35 (ArC), 125.51 (ArC), 124.82 (CCN3), 123.15 (CCHC), 119.06 (ArC), 118.56 
(ArC), 116.88 (ArC), 62.41 (CH2), 21.52 (CH3), 14.38 (CH3). HRMS-TOF MS ES+: m/z [M+Na]+ 
calcd for C19H19N3O3Na: 360.1324; found: 360.1314 
 
8.3.4. Synthesis of ethyl 4-(3,5-dimethylphenoxy)-1H-indole-2-carboxylate (77) 
 68 (1.52 g, 4.51 mmol) was dissolved in toluene (10 mL) and 
added slowly dropwise to toluene (30 mL) stirred at 130 ˚C under 
reflux. The reaction was allowed to carried out for 18 h, after 
which the reaction was cooled to room temperature. The toluene 
was removed in vacuo and the residue was purified on silica gel 
by column chromatography (5% EtOAc/Hexane) to yield the 
product as a yellow solid (965 mg, 3.12 mmol, 69%). (Rf = 0.40, 
20% EtOAc/Hexane). 
Mp 135-137 °C. 1H NMR (300 MHz, CDCl3) δ 8.94 (s, 1H, NH), 7.25 (ddd, J = 9.6, 6.1, 5.2 Hz, 2H, 
ArH), 7.18 (dt, J = 8.3, 1.0 Hz, 1H, ArH), 6.78 (d, J = 0.7 Hz, 1H, ArH), 6.71 (d, J = 0.6 Hz, 2H, ArH), 
6.63 (dd, J = 7.4, 1.0 Hz, 1H, ArH), 4.46 - 4.36 (m, 2H, CH2), 2.30 (d, J = 0.6 Hz, 6H, CH3), 1.47 - 
1.36 (m, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 162.01 (CO), 157.38 (ArC), 151.95 (ArC), 139.72 
(ArC), 138.81 (ArC), 127.22 (ArC), 126.32 (ArC), 125.24 (ArC), 120.86 (ArC), 116.62 (ArC), 
108.64 (ArC), 107.16 (ArC), 106.42 (ArC), 61.25 (CH2), 21.54 (CH3), 14.59 (CH3). HRMS-TOF MS 
ES+: m/z [M+H]+ calcd for C19H20NO3: 310.1443; found: 310.1444 
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8.3.5. Synthesis of 4-(3,5-dimethylphenoxy)-1H-indole-2-carboxylic acid (88) 
KOH (126 mg, 2.25 mmol) was added to a mixture of 77 (231 mg, 
0.75 mmol) in EtOH (10 mL) and the reaction was allowed to stir at 
room temperature for 24 h. The solvent was then removed in vacuo 
and the residue was taken up in DCM and washed with water. The 
aqueous layer was then acidified with HCl and extracted with EtOAc. 
The organic layer was then washed with brine and dried over 
MgSO4. The organic layer was then once again concentrated in vacuo 
to afford 88 as a yellow solid (201 mg, 0.72 mmol, 95%). 
1H NMR (300 MHz, DMSO) δ 11.94 (s, 1H, NH), 7.27 - 7.16 (m, 2H, ArH), 6.81 (d, J = 2.2 Hz, 1H, 
ArH), 6.77 (s, 1H, ArH), 6.64 (s, 2H, ArH), 6.57 (dd, J = 6.5, 1.9 Hz, 1H, ArH), 2.23 (s, 6H, CH3). 
HRMS-TOF MS ES+: m/z [M+H]+ calcd for C17H16NO3: 282.1130; found: 282.1122 
8.5.6. Synthesis of 4-(3,5-dimethylphenoxy)-1H-indole (89) 
 
A catalytic amount of cupric oxide (5.00 mg, 0.063 mmol) was added to a 
solution of 88 (200 mg, 0.63 mmol) in quinoline (6 mL) and the reaction 
mixture was heated to 200 °C. The reaction was allowed to carried out for 
18 h after which the reaction was cooled and diluted with EtOAc. The 
organic phase was washed with dilute HCl solution, washed with water 
and finally with brine. The organic phase was then dried over MgSO4 and 
concentrated in vacuo. 
1H NMR (300 MHz, CDCl3) δ 8.22 (s, 1H, NH), 7.23 - 7.11 (m, 3H, ArH), 6.75 (dd, J = 1.4, 0.7 Hz, 
1H, ArH), 6.72 (d, J = 0.6 Hz, 2H, ArH), 6.52 (ddd, J = 3.1, 2.1, 0.9 Hz, 1H, ArH), 2.30 (d, J = 0.6 Hz, 
5H, CH3). 13C NMR (101 MHz, CDCl3) δ 157.98 (ArC), 150.30 (ArC), 139.53 (ArC), 138.15 (ArC), 
124.70 (ArC), 123.69 (ArC), 122.84 (ArC), 120.82 (ArC), 116.29 (ArC), 108.89 (ArC), 106.83 
(ArC), 100.44 (ArC), 21.55 (CH3). 
 
8.4. Experimental Procedures Pertaining to Chapter 5 
8.4.1. Synthesis of ethyl 3-bromo-5-chloro-1H-indole-2-carboxylate (99) 
 
n-Bromosuccinamide (191 mg, 1.07 mmol) was added to ethyl 5-
chloro-2-indolecarboxylate (200 mg, 0.89 mmol) in THF (20 mL) at 
0 °C. The reaction was carried out for 18 h after which the reaction 
mixture was quenched with water. The aqueous layer was then 
washed with EtOAc and the organic phase was then separated and 
dried over MgSO4 and concentrated in vacuo. The crude residue was purified by silica gel 
column chromatography (5% - 40% EtOAc/Hexane) to yield the product as a yellow powder 
(214 mg, 0.705 mmol, 79%).(Rf = 0.31, 20% EtOAc/Hexane). 
Mp 192-194 °C. 1H NMR (300 MHz, DMSO) δ 12.47 (s, 1H, NH), 7.58 - 7.55 (m, 1H, ArH), 7.53 
(d, J = 0.6 Hz, 1H, ArH), 7.40 (dd, J = 8.8, 2.1 Hz, 1H, ArH), 4.41 (q, J = 7.1 Hz, 2H, CH2), 1.40 (t, J = 
7.1 Hz, 3H, CH3). 13C NMR (75 MHz, DMSO) δ 165.06 (CO), 139.47 (ArC), 133.00 (ArC), 131.46 
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(ArC), 131.08 (ArC), 130.65 (ArC), 124.28 (ArC), 120.23 (ArC), 100.18 (ArCBr), 66.29 (CH2), 
19.43 (CH3). HRMS-TOF MS ES+: m/z [M+H]+ calcd for C11H10NO2ClBr: 301.9583; found: 
301.9591 
8.4.2. Synthesis of ethyl (4-chloro-2-cyanophenyl)carbamate (115) 
2-amino-5-chlorobenzonitrile (1.00 g, 6.55 mmol) was suspended in 
ethyl chloroformate (3.1 mL, 33 mmol) and heated to 93 °C. The reaction 
was carried out for 18 h, cooled to room temperature and then worked 
up with a saturated solution of sodium bicarbonate and EtOAc. No 
further purification was required. The reaction yielded an orange solid 
(1.25 g, 5.56 mmol, 85%). (Rf = 0.30, 20% EtOAc/Hexane). 
Mp 136-138 °C. 1H NMR (300 MHz, CDCl3) δ 8.29 - 8.22 (m, 1H, ArH), 7.59 - 7.52 (m, 2H, ArH), 
7.13 (s, 1H, NH), 4.29 (q, J = 7.1 Hz, 2H, CH2), 1.36 (t, J = 7.1 Hz, 3H, CH3). 13C NMR 
(75 MHz, CDCl3) δ 152.68 (CO), 139.68 (ArC), 134.47 (ArC), 131.44 (ArC), 128.14 (ArC), 120.59 
(ArC), 117.64 (CCN), 115.11 (ArC), 62.27 (CH2), 14.37 (CH3). HRMS-TOF MS ES+: m/z [M+H]+ 
calcd for C10H10N2O2Cl: 225.0431; found: 225.0426 
 
8.4.3. Synthesis of diethyl 3-amino-5-chloro-1H-indole-1,2-dicarboxylate (116) 
Sodium hydride (107 mg, 4.45 mmol) was added to a stirring solution 
of ethyl (4-chloro-2-cyanophenyl)carbamate (500 mg, 2.23 mmol) 
at °C. The reaction was then allowed to stir for 1 hour before ethyl 
chloroacetate (0.24 mL, 2.2 mmol) was added dropwise at 0 °C. The 
reaction was allowed to warm to room temperature. After 18 h the 
reaction mixture was quenched with distilled water and then 
extracted twice with dichloromethane. The organic layer was washed with brine and dried over 
MgSO4 before being concentrated in vacuo. The crude residue was purified by silica gel column 
chromatography (5% - 40% EtOAc/Hexane) to yield the product as a colourless oil (1.11g, 
3.57 mmol, 82%).(Rf = 0.20, 20% EtOAc/Hexane). 
Mp 75-78 °C. 1H NMR (300 MHz, CDCl3) δ 7.90 (dd, J = 8.9, 0.5 Hz, 1H, ArH), 7.42 (dd, J = 2.1, 
0.5 Hz, 1H, ArH), 7.33 (dd, J = 8.9, 2.1 Hz, 1H, ArH), 5.07 (s, 2H, NH2), 4.30 (m, J = 10.3, 7.1 Hz, 4H, 
CH2), 1.35 - 1.28 (m, 6H, CH3). 13C NMR (75 MHz, CDCl3) δ 162.55 (CO), 151.83 (CO), 140.31 
(ArC), 136.64 (ArC), 129.09 (ArC), 128.33 (ArC), 123.24 (ArC), 118.65 (ArC), 116.74 (ArC), 
108.34 (ArC), 63.42 (CH2), 60.49 (CH2), 14.50 (CH3), 14.24 (CH3). HRMS-TOF MS ES+: m/z 
[M+H]+ calcd for C14H16N2O4Cl: 311.0799; found: 311.0802 
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8.4.4. Synthesis of diethyl 5-chloro-3-(phenylamino)-1H-indole-1,2-dicarboxylate (117) 
Diethyl 3-amino-5-chloro-1H-indole-1,2-dicarboxylate (533 mg, 
1.38 mmol) was taken up in toluene (5 mL) and degassed. 
Bromobenzene (0.22 mL, 2.1 mmol) was then added followed by the 
addition of Pd(dba)2 (790 µg, 0.138 mmol), Xphos (132 mg, 
0.276 mmol) and K3PO4 (586 mg, 2.76 mmol). The reaction mixture 
was then added to 130 °C. As the reaction mixture heated up it 
changed colour from yellow to red, indicative of a ligand exchange 
occurring with the palladium catalyst. The reaction was carried out 
for 2 days. The reaction mixture was allowed to cool to room 
temperature, carried out through celite and then concentrated in vacuo. The residue was then 
purified by silica gel column chromatography (5% - 20% EtOAc/Hexane) to yield the product as 
a yellow solid (239 mg, 0.618 mmol, 32%). (Rf = 0.32, 20% EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3) δ 8.05 (dd, J = 9.0, 0.5 Hz, 1H, ArH), 7.72 (s, 1H, NH), 7.40 (ddd, J = 
7.6, 6.5, 1.8 Hz, 2H, ArH), 7.36 - 7.29 (m, 2H, ArH), 7.21 (dd, J = 2.1, 0.5 Hz, 1H, ArH), 7.07 - 7.01 
(m, 2H, ArH), 4.42 (m, J = 22.1, 7.1 Hz, 4H, CH2), 1.49 - 1.34 (m, 6H, CH3). 13C NMR 
(75 MHz, CDCl3) δ 162.53 (CO), 141.41 (CO), 136.04 (ArC), 135.30 (ArC), 130.08 (ArC), 129.23 
(ArC), 128.50 (ArC), 128.36 (ArC), 128.00 (ArC), 123.34 (ArC), 123.16 (ArC), 122.15 (ArC), 
120.43 (ArC), 116.25 (ArC), 63.78 (CH2), 61.05 (CH2), 14.33 (CH3), 14.24 (CH3). 
 
8.4.5. Synthesis of diethyl 5-chloro-3-(ethyl(phenyl)amino)-1H-indole-1,2-dicarboxylate 
(118) 
Sodium tert-butoxide (82 mg, 0.85 mmol) was added to 117 (200 mg, 
0.568 mmol) in DMF (3 mL) at 0 °C. Ethyl iodide (90 µL, 1.1 mmol) 
was added to the reaction mixture which was then allowed to warm 
to room temperature. The reaction was left to carried out for 18 h 
and then diluted with EtOAc and quenched with water. The organic 
phase was separated, dried over MgSO4 and concentrated in vacuo. 
The residue was then purified on silica using column 
chromatography (5% EtOAc/Hexane) to yield the product as a yellow 
oil (25 mg, 0.60 mmol, 11%). (Rf = 0.61, 20% EtOAc/Hexane). 
 
1H NMR (300 MHz, CDCl3) δ 7.50 (dd, J = 2.0, 0.6 Hz, 1H, ArH), 7.40 
(dd, J = 8.9, 0.5 Hz, 1H, ArH), 7.35 - 7.30 (m, 1H, ArH), 7.18 - 7.10 (m, 2H, ArH), 6.72 - 6.64 (m, 
1H, ArH), 6.60 - 6.53 (m, 2H, ArH), 4.61 (q, J = 7.1 Hz, 2H, CH2), 4.18 (q, J = 7.1 Hz, 2H, CH2), 3.77 
(q, J = 7.1 Hz, 2H, CH2), 1.45 (td, J = 7.1, 4.4 Hz, 3H, CH3), 1.29 - 1.21 (m, 3H, CH3), 1.09 (t, J = 7.1 
Hz, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 161.17 (CO), 148.77 (CO), 148.65 (ArC), 135.00 (ArC), 
128.84 (ArC), 128.04 (ArC), 126.48 (ArC), 126.07 (ArC), 125.99 (ArC), 124.74 (ArC), 119.83 
(ArC), 116.43 (ArC), 112.35 (ArC), 111.53 (ArC), 60.70 (CH2), 46.72 (CH2), 40.23 (CH2), 15.75 
(CH3), 13.86 (CH3), 13.34 (CH3). 
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8.4.6. Synthesis of ethyl 5-chloro-3-(ethyl(phenyl)amino)-1H-indole-2-carboxylate (5) 
A mixture of 118 (25 mg, 0.060 mmol) and K3PO4 (26 mg, 
0.12 mmol) in EtOH (1 mL) was heated to 70 °C and allowed to 
carried out for 3.5 h. The reaction was then cooled to room 
temperature and filtered over celite. The filtrate was then 
concentrated in vacuo and purified by silica gel column 
chromatography (5% EtOAc/Hexane - 20% EtOAc/Hexane) to yield 
the product as a yellow powder (22 mg, 0.64 mmol, quant.). (Rf = 
0.31, 20% EtOAc/Hexane). 
Mp 162-164 °C. 1H NMR (400 MHz, CDCl3) δ 9.16 (s, 1H, NH), 7.48 - 7.22 (m, 3H, ArH), 7.14 (dd, 
J = 8.0, 7.4 Hz, 2H, ArH), 6.70 (dd, J = 7.2, 6.6 Hz, 1H, ArH), 6.62 (d, J = 8.6 Hz, 2H, ArH), 4.26 (dt, J 
= 14.0, 7.0 Hz, 2H, CH2), 3.80 (q, J = 7.1 Hz, 2H, CH2), 1.25 - 1.19 (m, 3H, CH3), 1.16 (q, J = 6.8 Hz, 
3H, CH3). 13C NMR (75 MHz, CDCl3) δ 161.33 (CO), 148.67 (ArC), 133.60 (ArC), 129.09 (ArC), 
127.91 (ArC), 127.46 (ArC), 126.83 (ArC), 126.78 (ArC), 124.08 (ArC), 120.24 (ArC), 117.18 
(ArC), 113.60 (ArC), 113.15 (ArC), 61.38 (CH2), 46.74 (CH2), 14.23 (CH3), 13.40 (CH3). HRMS-
TOF MS ES+: m/z [M+H]+ calcd for C19H20N2O2Cl: 343.1213; found: 343.1200 
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